

t a b l e s

s t a t i s t i c a l



# Cancer in Queensland

## 1982-2007

Incidence, Mortality, Survival  
and Prevalence



# **CANCER IN QUEENSLAND**

**1982 to 2007**

**Incidence, Mortality, Survival and Prevalence**

**Statistical Tables**

**Queensland Cancer Registry**

**Cancer Council Queensland**

**May 2010**

## **Acknowledgements**

This report has been made possible through the co-operation of staff of hospitals, pathology laboratories and nursing homes throughout Queensland. The work of all people concerned is appreciated and grateful thanks are extended to them for their continued support in notifying cancer cases.

Thanks are due also to the Registrar of Births, Deaths and Marriages and to the members of the medical profession who provided additional information to improve the accuracy of Registry data.

We acknowledge and thank the Queensland Cancer Control Analysis Team at Queensland Health, and the Viertel Centre for Research in Cancer Control at Cancer Council Queensland for their advice and support.

Finally, acknowledgement is made of the work of the members of staff of the Queensland Cancer Registry. The Registry staff work tirelessly to ensure the quality of the data is of the highest standard. This publication would not have been possible without their support and dedication.

**Published by Cancer Council Queensland, May 2010**  
**© The State of Queensland, Queensland Health, 2010**

**Queensland Cancer Registry**  
**Cancer Council Queensland**  
**Locked Bag No 1450**  
**Spring Hill Q 4004**

**Telephone** (07) 3634 5333  
**Facsimile** (07) 3259 8590  
**E-mail** [qcr@cancerqld.org.au](mailto:qcr@cancerqld.org.au)  
**Websites** [www.cancerqld.org.au](http://www.cancerqld.org.au) or [www.health.qld.gov.au/hic](http://www.health.qld.gov.au/hic)

**ISSN: 1323 - 8760**

<b>Contents</b>	<b>Page</b>
Acknowledgements	2
Members of the Queensland Cancer Registry	4
Introduction	5
Establishment of the Cancer Registry	5
Aims of the Registry	5
Notification and Sources of Data	5
Classification and Coding	5
Coverage of the Registry	6
Structure of this Report	6
Publication of Reports	7
Abbreviations	7

## **Tables**

1a. Leading 20 Cancer Sites for 2007 (Counts), Incidence, Males, 1982-2007	8
1b. Leading 20 Cancer Sites for 2007 (Counts), Mortality, Males, 1982-2007	8
1c. Leading 20 Cancer Sites for 2007 (Counts), Incidence, Females, 1982-2007	9
1d. Leading 20 Cancer Sites for 2007 (Counts), Mortality, Females, 1982-2007	9
2. Cancer Incidence and Mortality (Counts) by Site and Sex, Queensland, 1982 - 2007	10-16
3. Cancer Incidence and Mortality (Age Standardised Rates (World)/100,000) by Site and Sex, Queensland, 1982 – 2007	17-23
4. Cancer Incidence and Mortality (Age Standardised Rates (Australia 2001)/100,000) by Site and Sex, Queensland, 1982 – 2007	24-30
5. Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007	31-45
6. Limited Duration (5 year and 25 year) Cancer Prevalence by Site, Sex and Age Group, Queensland, 2007	46-50
7. Relative Survival by Site, Sex and Year after diagnosis, Queensland, 2007	51-54

## **Appendices**

Appendix 1: Guidelines for Release of Information, Queensland Cancer Registry	55-56
Appendix 2: Queensland Cancer Registry Notification Form	57
Appendix 3: Cancer Reporting Definitions and Calculation of Statistics	58-60
Appendix 4: Age Distribution of Standard Populations	61
Appendix 5: Indices of Data Quality	62-63

## **Members of the Queensland Cancer Registry during this period**

Dr Joanne Aitken  
Kerrie Dennison  
Marilla Fraser  
Georgina Novak

Director  
Registrar  
Assistant Registrar  
Coding Educator

Anthony Armstrong  
Brooke Daniels  
Mark Foster  
Nikkitia Golobic  
Belinda Gritsch  
Pauline Kuhn  
Lachlan Manahan  
Kim Neri (Melanoma Clinical Coder)  
Sharee Newman  
Caroline Reimers  
Jessica Smith  
Kathy Temperton  
Kira Ward

## INTRODUCTION

### Establishment of the Cancer Registry

The Queensland Cancer Registry operates under the *Public Health Act 2005*, to receive information on cancer in Queensland. The Cancer Registry is a population-based registry and maintains a Register of all cases of cancer diagnosed in Queensland since the beginning of 1982. It was established in response to the need for state-wide information on cancer expressed by community and state organisations.

Cancer Council Queensland manages the processing operations of the Registry for Queensland Health (since October 2000).

### Aims of the Registry

The main aim of the Queensland Cancer Registry is to collect data to describe the nature and extent of cancer in Queensland. This can be combined with related data to assist in the control and prevention of cancer. To this end, Queensland Cancer Registry data is available for use:

- in research projects on the causes, treatment and prevention of cancer,
- in the planning and assessment of cancer treatment and prevention services,
- in monitoring survival times of cancer patients, and
- for the education of health professionals and members of the general public.

### Notification and Sources of Data

Notification of cancer is a statutory requirement for all public and private hospitals, nursing homes and pathology services. Notifications are received for all persons with cancer separated from public and private hospitals and nursing homes. Queensland pathology laboratories provide copies of pathology reports for cancer specimens. Data on all persons who die of cancer or cancer patients who die of other diseases are abstracted from the mortality files of the Registrar of Births, Deaths and Marriages and linked to hospital and pathology data.

### Classification and Coding

The Queensland Cancer Registry codes the site and the histology of the cancers to the International Classification of Diseases for Oncology, 3<sup>rd</sup> edition (ICD-O-3). Prior to July 2004, the primary site of cancer was coded to the International Classification of Diseases for Oncology, 2<sup>nd</sup> edition (ICD-O-2).

The change to ICD-O-3 was in response to an Australasian Association of Cancer Registries (AACR) recommendation. At present, cancer registries in Australia use this specialist oncology classification. Hospitals code patient separation records using International Classification of Diseases, 10<sup>th</sup> Revision, Australian Modification (ICD-10-AM). The Australian Bureau of Statistics codes deaths from 1999 using ICD-10. The variety of classifications employed and a desire to publish categories that are comparable with other states has meant that for the purposes of this publication ICD-O-3 codes have been mapped to the equivalent ICD-10-AM structure.

All sub-descriptions of cancer sites and morphologies are included on an electronic reference file that is readily accessible to coders on-line. This means that:

- a greater degree of detail may be recorded by coders,
- the search process has improved,
- the inclusion of the additional coded detail makes it easier to code with certainty,
- it may assist future conversions by having more detail available.

In addition, the Registry links sites and morphologies through the use of morphology families based on those published by the International Agency for Research on Cancer (IARC Technical Report No. 19). This means we are able to validate our code combinations more thoroughly and investigate any that appear unusual or unlikely.

## Coverage of the Registry

All primary cancers (ICD-O-3 rubrics C00-C80) with either a malignant, uncertain or in-situ behaviour are registered, excluding basal or squamous cell carcinoma of skin (C44, M805-M811). Basal and squamous cell carcinomas of skin are not registered by the Queensland Cancer Registry (nor most other registries) as many are treated in doctors' surgeries using destructive techniques which preclude histological confirmation.

Benign brain tumours are also registered.

## Structure of this Report

The information contained in this publication is intended to give a summary of cancer statistics in Queensland from the inception of the Register (1982 to 2007) and a brief outline of the Queensland Cancer Registry. Incidence and mortality data have been aggregated for the earlier years of 1982-1986, 1987-1991 and 1992-1996 with the average being displayed in the tables. The data presented in this report only include invasive primary cancers (behaviour = 3, site C000-C809) other than basal and squamous cell carcinomas of skin (C44, M805-M811).

The annual report publications prior to 2004 were based on the ICD-O-2 topography and morphology codes. Due to the change in coding systems to ICD-O-3, the data in this report will not be comparable to publications prior to 2004.

The main coding changes from ICD-O-2 to ICD-O-3, which have changed in behaviour and therefore impact on the Incidence and Mortality counts and rates are:

- Myeloproliferative Disorders and Myelodysplastic Syndromes. These have changed from an uncertain behaviour to an invasive cancer, and are now included in the report.
- Ovarian tumours of borderline malignancy and pilocytic astrocytoma cancers of the brain, have changed from an invasive cancer to an uncertain behaviour. These are no longer included.
- In addition, the morphology codes for lymphoma and leukaemias have changed significantly. Although the malignant status of these neoplasms has not altered, many of the morphology codes have been merged together and new codes have been added.

As in previous reports, in an effort to publish data that is comparable with historical and other data sources, ICD-O-3 codes have been mapped to the equivalent ICD-10-AM structure.

This means that the following cancer types: mesothelioma, Kaposi sarcoma, lymphoma and other neoplasms of haematopoietic and reticuloendothelial systems, are tabulated as separate categories and excluded from the organ in which these diseases were diagnosed. The remaining sites retain their ICD-O-3 site code. Some are grouped for the purposes of preserving comparability with previous reports or where the numbers are very small.

M905	Mesothelioma
M914	Kaposi Sarcoma
M959,M967-M972	Non-Hodgkin Lymphoma
M965-M966	Hodgkin Lymphoma
M974 - M976	Other Neoplasms Of Lymphatic & Haematopoietic Tissue
M973	Myeloma / Plasma Cell Tumours
M980	Unspecified Leukaemia
M994	Other Specified Leukaemia
M982 - M983	Lymphoid Leukaemia
M984 - M993	Myeloid Leukaemia
M998	Myelodysplastic Diseases
C44, M872-M879	Melanoma
M995 – M996	Chronic Myeloproliferative Diseases

Details of cancer reporting definitions and calculation of statistics are included in Appendix 4. More detailed statistics are available on request. See Appendix 1 for details.

## Publication of Reports

It should be noted that despite intensive efforts to ensure the completeness of incidence and mortality data before publication, the rates for a given time period change by a small percentage over time. The Registry may continue to receive notifications for cases already counted in incidence and the diagnosis date or diagnosis may be amended as a result of this later notification. Reports for previously uncounted cases diagnosed in a particular year may continue to arrive at the Registry for some years after the incidence for that year has been published. The database is therefore continually being updated and the quality of data improved across the entire period of cancer reporting.

The incidence and mortality data reported in this publication are the 1982 to 2007 statistics as they stood in April 2010. Future publications and requests for data may not exactly correspond to the figures in this report as they will reflect subsequent revisions to the data.

## Abbreviations

ASR	Age Standardised Rate. See Appendix 4 - Cancer reporting definitions and calculation of statistics.
Cum Rate	Cumulative Rate. See Appendix 4 - Cancer reporting definitions and calculation of statistics.
Cum Risk	Cumulative Risk. See Appendix 4 - Cancer reporting definitions and calculation of statistics.
n.a.	not applicable
ICD-O-3	International Classification of Diseases, Oncology, 3 <sup>rd</sup> Edition
95% CI	95% Confidence Interval

**Table 1a. Leading 20 Cancer Sites for 2007 (Counts), Incidence, Males, Queensland, 1982 - 2007**

ICD-O3/SITE	1982-1986	1987-1991	1992-1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>														
C61 PROSTATE GLAND	737.2	1022.2	1801.2	1631	1730	1791	1884	1972	2245	2674	2993	2945	3308	3680
C44, M872-M879 MELANOMA	514.8	750.0	955.6	1241	1230	1146	1299	1354	1464	1421	1307	1560	1454	1558
C33,C34 TRACHEA AND BRONCHUS & LUNG	808.6	890.6	950.8	1058	1026	1082	1048	1085	1060	1060	1134	1158	1283	1216
C18 COLON	413.2	537.0	612.6	718	694	725	826	870	788	798	884	893	933	995
C19,C20 RECTOSIGMOID JUNCTION AND RECTUM	208.4	263.6	378.0	413	405	424	469	483	476	471	557	530	552	558
M959,M967-M972 NON-HODGKIN LYMPHOMA	138.8	182.6	242.2	291	293	308	327	329	344	361	364	392	415	414
C64-C66,C68 KIDNEY AND OTHER RENAL TRACT	126.6	154.6	222.4	254	261	287	308	268	261	294	300	346	397	395
C67 BLADDER	286.6	331.2	408.4	479	511	466	523	534	509	523	528	533	543	364
C26, C39,C76,C77,C80 OTHER & ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE	185.4	218.8	269.4	272	301	288	278	266	296	274	302	312	319	351
C25 PANCREAS	100.6	116.4	140.0	171	161	171	191	191	173	165	203	188	235	255
C16 STOMACH	178.6	187.0	198.8	200	199	237	221	206	212	229	233	217	241	198
C15 OESOPHAGUS	54.0	80.6	110.2	108	114	157	143	135	142	142	143	149	166	173
C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM	80.2	96.6	115.2	149	130	132	140	140	141	143	167	169	172	170
C22 LIVER & INTRAHEPATIC BILE DUCTS	25.8	42.4	62.4	66	80	67	98	107	89	97	99	129	141	159
M882-M883 LYMPHOID LEUKAEMIA	81.4	85.0	119.8	115	164	171	154	135	158	155	160	146	166	157
C00 LIP	102.2	155.0	204.6	229	271	137	122	148	187	161	141	153	190	140
M998 MYELODYSPLASTIC DISEASES	3.8	11.2	26.2	47	61	78	96	134	118	138	131	118	128	134
M973 MYELOMA/PLASMA CELL TUMOURS	52.6	63.4	76.2	103	132	105	119	119	109	116	106	120	134	132
M984-M993 MYELOID LEUKAEMIA	74.6	87.0	108.4	115	109	113	117	92	123	127	108	102	101	125
C62 TESTIS	59.0	61.4	94.0	92	107	111	85	105	132	116	114	132	138	116

**Table 1b. Leading 20 Cancer Sites for 2007 (Counts), Mortality, Males, Queensland, 1982 - 2007**

ICD-O3/SITE	1982-1986	1987-1991	1992-1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>														
C33,C34 TRACHEA AND BRONCHUS & LUNG	663.2	734.6	808.2	827	851	883	873	875	898	877	955	939	1005	1034
C61 PROSTATE GLAND	230.8	324.6	452.0	433	460	439	510	505	502	525	569	526	556	600
C18 COLON	191.8	238.4	246.4	306	282	310	296	310	321	271	306	323	332	306
C25 PANCREAS	90.6	101.0	129.2	131	148	141	144	176	161	175	183	163	177	244
C19,C20 RECTOSIGMOID JUNCTION AND RECTUM	92.2	123.2	160.6	160	173	172	187	179	143	182	164	199	182	210
C26, C39,C76,C77,C80 OTHER & ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE	148.6	167.0	200.2	211	226	189	206	184	218	183	201	216	215	209
C44, M872-M879 MELANOMA	68.4	92.4	120.2	118	137	142	142	149	134	182	189	184	145	196
C16 STOMACH	139.6	134.6	142.8	165	142	157	160	149	172	157	157	150	147	151
C67 BLADDER	67.2	77.6	96.6	103	98	118	106	115	124	114	111	116	125	131
C15 OESOPHAGUS	45.8	61.6	87.2	73	96	88	99	104	109	113	123	106	125	130
C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM	62.8	73.8	83.2	122	111	108	116	95	114	117	126	127	142	125
C64-C66,C68 KIDNEY AND OTHER RENAL TRACT	53.6	65.2	84.6	86	80	100	97	99	91	101	100	101	106	122
M905 MESOTHELIOMA	17.8	30.2	44.4	54	60	69	71	77	72	98	83	75	84	111
M959,M967-M972 NON-HODGKIN LYMPHOMA	20.0	20.0	46.4	48	50	57	63	82	81	80	67	88	105	106
M984-M993 MYELOID LEUKAEMIA	67.6	85.8	110.2	139	131	128	145	111	132	132	131	103	123	101
M973 MYELOMA/PLASMA CELL TUMOURS	54.6	61.6	72.8	72	89	78	74	62	75	71	78	59	68	91
M998 MYELODYSPLASTIC DISEASES	27.6	45.6	43.0	53	65	68	65	69	69	60	70	67	57	70
M982-M983 LYMPHOID LEUKAEMIA	2.4	3.6	6.8	16	17	12	25	37	46	36	48	54	47	55
M984-M993 MYELOID LEUKAEMIA	28.0	31.0	46.0	49	50	53	33	49	49	49	41	50	46	42
C32 LARYNX	23.0	30.0	26.6	31	25	31	28	35	33	41	45	36	34	39

**Table 1c. Leading 20 Cancer Sites for 2007 (Counts), Incidence, Females, Queensland, 1982 - 2007**

ICD-O3/SITE	1982-1986	1987-1991	1992-1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>														
C50 BREAST	912.2	1209.8	1556.8	1825	1930	2034	2124	2209	2228	2208	2290	2418	2511	2469
C44, M872-M879 MELANOMA	493.4	621.8	731.0	889	910	892	948	986	1092	1016	1040	1105	1011	1110
C18 COLON	442.2	498.2	619.4	654	698	739	747	740	781	749	742	849	898	884
C33, C34 TRACHEA AND BRONCHUS & LUNG	203.8	278.8	361.4	435	454	433	497	539	584	529	645	648	669	685
C54 CORPUS UTERI	146.0	161.8	214.6	233	242	265	311	295	310	306	331	348	336	368
C73 THYROID GLAND	47.4	61.0	104.0	136	135	154	187	178	205	210	241	274	287	350
M959, M967-M972 NON-HODGKIN LYMPHOMA	124.2	159.2	198.6	216	250	269	283	281	259	264	292	341	346	334
C19, C20 RECTOSIGMOID JUNCTION AND RECTUM	141.6	167.8	224.6	254	264	243	263	276	291	309	319	306	350	327
C26, C39, C76, C77, C80 OTHER & ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE	150.0	174.0	227.6	227	265	259	276	214	249	222	241	268	296	325
C36 OVARY	144.4	161.0	196.8	183	204	197	206	220	222	187	218	222	232	212
C64-C66, C68 KIDNEY AND OTHER RENAL TRACT	82.0	113.4	147.2	153	166	189	172	180	193	179	191	177	229	207
C25 PANCREAS	77.6	99.4	121.2	140	155	162	155	155	163	172	184	186	192	182
C53 CERVIX UTERI	184.8	195.2	195.8	177	166	190	167	155	149	156	146	179	188	143
C67 BLADDER	93.0	108.0	139.8	152	157	157	175	149	170	158	175	137	157	136
C16 STOMACH	93.0	86.0	108.6	113	100	94	120	102	118	95	107	116	105	113
C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM	64.6	76.8	89.0	103	87	107	121	118	100	103	85	126	111	109
M984-M993 MYELOID LEUKAEMIA	55.2	65.4	84.4	92	85	89	66	85	74	82	89	77	93	92
M973 MYELOMA/PLASMA CELL TUMOURS	44.4	45.0	63.4	68	81	90	105	102	80	88	94	87	98	88
M998 MYELODYSPLASTIC DISEASES	2.4	7.8	19.0	33	36	52	75	82	101	80	89	81	94	86
M982-M983 LYMPHOID LEUKAEMIA	47.8	59.8	88.4	83	104	104	113	130	123	108	83	90	117	86

**Table 1d. Leading 20 Cancer Sites for 2007 (Counts), Mortality, Females, Queensland, 1982 - 2007**

ICD-O3/SITE	1982-1986	1987-1991	1992-1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>														
C33 C34 TRACHEA AND BRONCHUS & LUNG	159.4	202.4	279.4	349	334	366	374	398	457	423	488	537	530	555
C50 BREAST	290.4	344.4	412.6	417	430	412	407	462	432	454	452	475	432	498
C18 COLON	211.6	237.8	241.4	294	269	269	273	287	305	277	269	277	277	325
C26, C39, C76, C77, C80 OTHER & ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE	119.2	135.2	176.8	162	214	223	218	171	221	173	182	187	199	207
C25 PANCREAS	69.8	84.8	110.2	132	125	129	145	137	139	148	172	185	173	165
C56 OVARY	62.8	70.6	87.8	105	103	91	96	101	107	116	127	110	96	122
C19, C20 RECTOSIGMOID JUNCTION AND RECTUM	55.0	72.4	91.2	111	126	95	104	97	127	105	105	99	96	95
C44, M872-M879 MELANOMA	39.6	48.6	56.2	59	82	81	61	64	64	64	78	79	84	89
C16 STOMACH	72.8	67.4	73.0	79	69	65	68	73	67	82	82	86	86	84
C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM	45.4	60.4	69.8	84	68	87	88	75	95	86	74	79	86	82
C54 CORPUS UTERI	29.0	33.0	41.4	51	37	50	52	62	58	52	67	72	64	72
C64-C66, C68 KIDNEY AND OTHER RENAL TRACT	36.2	53.6	61.0	60	72	71	62	67	71	65	79	70	71	58
C15 OESOPHAGUS	25.0	32.0	39.2	46	43	40	47	51	47	43	50	41	42	58
C23, C24 GALLBLADDER AND OTHER & UNSPECIFIED PARTS OF BILIARY TRACT	31.4	42.4	45.6	52	48	41	39	40	44	47	45	58	38	55
M984-M993 MYELOID LEUKAEMIA	41.2	46.4	58.2	60	56	61	49	46	46	57	52	45	57	54
M973 MYELOMA/PLASMA CELL TUMOURS	26.0	30.8	40.0	42	38	35	53	53	45	47	59	54	45	53
C67 BLADDER	48.0	53.4	55.2	47	55	43	58	52	46	49	62	48	51	48
C53 CERVIX UTERI	0.8	2.0	4.6	13	7	15	13	23	37	39	47	42	42	36
M998 MYELODYSPLASTIC DISEASES														32

**Table 2. Cancer Incidence and Mortality (Counts) by Site and Sex,  
Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C00 LIP</b>															
Incidence	M	102.2	155.0	204.6	229	271	137	122	148	187	161	141	153	190	140
	F	19.8	40.8	55.0	85	93	43	52	57	82	55	50	50	49	46
	P	122.0	195.8	259.6	314	364	180	174	205	269	216	191	203	239	186
Mortality	M	1.8	2.6	3.6	4	3	6	3	4	6	4	10	9	1	2
	F	0.6	0.6	0.4	1	2	2	3	1	1	3	1	2	1	3
	P	2.4	3.2	4.0	5	5	8	6	5	7	7	11	11	2	5
<b>C01,C02 TONGUE</b>															
Incidence	M	41.2	49.4	57.8	57	60	69	56	64	72	62	86	83	63	91
	F	14.8	21.6	25.4	37	30	38	32	24	27	34	32	37	31	51
	P	56.0	71.0	83.2	94	90	107	88	88	99	96	118	120	94	142
Mortality	M	16.6	21.6	23.0	27	34	22	26	23	31	25	39	35	23	21
	F	4.8	9.4	8.8	6	10	12	18	15	13	14	14	15	11	12
	P	21.4	31.0	31.8	33	44	34	44	38	44	39	53	50	34	33
<b>C03 GUM</b>															
Incidence	M	3.4	3.2	7.4	6	3	9	10	5	4	8	11	13	9	11
	F	3.4	2.6	4.0	1	6	6	6	8	5	8	8	8	13	8
	P	6.8	5.8	11.4	7	9	15	16	13	9	16	19	21	22	19
Mortality	M	0.6	1.2	3.0	0	3	0	1	4	4	4	4	6	3	3
	F	0.8	1.2	1.0	4	1	3	3	3	3	1	2	3	1	7
	P	1.4	2.4	4.0	4	4	3	4	7	7	5	6	9	4	10
<b>C04 FLOOR OF MOUTH</b>															
Incidence	M	20.2	17.4	21.4	20	24	27	30	19	17	20	19	30	22	26
	F	7.0	7.2	7.4	5	14	9	14	8	9	12	6	18	9	8
	P	27.2	24.6	28.8	25	38	36	44	27	26	32	25	48	31	34
Mortality	M	6.8	6.6	9.0	7	10	12	11	7	6	10	9	12	8	9
	F	2.0	1.4	2.2	3	1	3	4	4	4	3	2	7	2	4
	P	8.8	8.0	11.2	10	11	15	15	11	10	13	11	19	10	13
<b>C05,C06 PALATE AND OTHER &amp; UNSPECIFIED PARTS OF MOUTH</b>															
Incidence	M	25.4	24.0	22.6	31	30	20	24	22	34	24	29	40	35	43
	F	9.2	14.8	19.4	20	15	15	19	12	12	18	20	18	26	20
	P	34.6	38.8	42.0	51	45	35	43	34	46	42	49	58	61	63
Mortality	M	9.2	8.2	10.8	8	9	6	5	10	8	8	14	14	15	14
	F	3.2	6.2	6.0	3	1	9	7	7	6	9	6	10	8	5
	P	12.4	14.4	16.8	11	10	15	12	17	14	17	20	24	23	19
<b>C07,C08 PAROTID AND OTHER &amp; UNSPECIFIED MAJOR SALIVARY GLANDS</b>															
Incidence	M	15.2	17.2	23.4	29	31	26	34	32	32	33	35	32	57	40
	F	9.2	10.4	17.2	14	18	16	15	19	16	17	20	22	26	28
	P	24.4	27.6	40.6	43	49	42	49	51	48	50	55	54	83	68
Mortality	M	4.0	6.2	6.2	7	6	4	7	9	13	10	5	14	16	7
	F	1.6	3.0	3.8	3	4	5	5	2	7	6	1	6	1	3
	P	5.6	9.2	10.0	10	10	9	12	11	20	16	6	20	17	10
<b>C09,C10 TONSIL AND OROPHARYNX</b>															
Incidence	M	29.0	25.0	36.0	37	51	41	38	50	46	54	56	63	73	85
	F	7.6	9.4	8.6	10	10	14	10	12	15	13	14	17	15	19
	P	36.6	34.4	44.6	47	61	55	48	62	61	67	70	80	88	104
Mortality	M	13.6	14.2	17.6	12	20	15	18	20	23	22	20	23	25	24
	F	4.2	4.2	3.8	5	4	9	4	4	5	5	7	6	3	6
	P	17.8	18.4	21.4	17	24	24	22	24	28	27	27	29	28	30
<b>C11 NASOPHARYNX</b>															
Incidence	M	10.8	8.6	12.4	15	10	11	12	9	9	9	8	16	14	10
	F	3.6	3.8	5.8	2	2	4	5	3	2	2	5	4	9	3
	P	14.4	12.4	18.2	17	12	15	17	12	11	11	13	20	23	13
Mortality	M	6.4	5.6	8.0	11	7	10	4	2	2	2	3	7	6	5
	F	2.4	2.0	2.4	3	3	3	4	2	1	2	0	2	3	2
	P	8.8	7.6	10.4	14	10	13	8	4	3	4	3	9	9	7
<b>C12,C13 PYRIFORM SINUS AND HYPOPHARYNX</b>															
Incidence	M	21.4	28.4	30.8	26	32	32	31	33	22	24	34	27	24	37
	F	3.0	4.2	4.2	6	2	2	8	6	6	2	6	8	7	4
	P	24.4	32.6	35.0	32	34	34	39	39	28	26	40	35	31	41
Mortality	M	10.6	17.2	17.2	23	16	18	18	19	23	22	17	14	22	18
	F	2.2	1.4	2.2	6	2	1	1	6	7	0	3	5	4	4
	P	12.8	18.6	19.4	29	18	19	19	25	30	22	20	19	26	22

**Table 2. Cancer Incidence and Mortality (Counts) by Site and Sex,  
Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C14 OTHER &amp; ILL-DEFINED SITES IN LIP, ORAL CAVITY &amp; PHARYNX</b>															
Incidence	M	7.0	10.0	11.2	9	16	8	20	15	13	20	12	22	20	25
	F	1.2	3.2	2.4	3	3	8	8	2	4	2	2	5	5	0
	P	8.2	13.2	13.6	12	19	16	28	17	17	22	14	27	25	25
Mortality	M	3.2	6.0	6.2	7	8	3	8	9	5	9	10	15	11	11
	F	0.6	1.2	1.8	2	1	4	1	4	2	2	1	1	3	1
	P	3.8	7.2	8.0	9	9	7	9	13	7	11	11	16	14	12
<b>C15 OESOPHAGUS</b>															
Incidence	M	54.0	80.6	110.2	108	114	157	143	135	142	142	143	149	166	173
	F	30.4	44.6	52.2	67	63	53	66	65	47	65	77	58	70	75
	P	84.4	125.2	162.4	175	177	210	209	200	189	207	220	207	236	248
Mortality	M	45.8	61.6	87.2	73	96	88	99	104	109	113	123	106	125	130
	F	25.0	32.0	39.2	46	43	40	47	51	47	43	50	61	42	58
	P	70.8	93.6	126.4	119	139	128	146	155	156	156	173	167	167	188
<b>C16 STOMACH</b>															
Incidence	M	178.6	187.0	198.8	200	199	237	221	206	212	229	233	217	241	198
	F	93.0	86.0	108.6	113	100	94	120	102	118	95	107	116	105	113
	P	271.6	273.0	307.4	313	299	331	341	308	330	324	340	333	346	311
Mortality	M	139.6	134.6	142.8	165	142	157	160	149	172	157	157	150	147	151
	F	72.8	67.4	73.0	79	69	65	68	73	67	82	82	86	60	84
	P	212.4	202.0	215.8	244	211	222	228	222	239	239	239	236	207	235
<b>C17 SMALL INTESTINE</b>															
Incidence	M	11.8	14.8	19.2	29	32	33	33	29	31	30	34	44	39	50
	F	10.4	12.6	14.6	16	19	30	21	22	25	22	31	43	36	37
	P	22.2	27.4	33.8	45	51	63	54	51	56	52	65	87	75	87
Mortality	M	5.6	7.6	7.8	10	12	12	14	13	12	13	9	15	14	16
	F	5.0	6.8	8.0	12	7	7	13	10	11	9	7	10	17	17
	P	10.6	14.4	15.8	22	19	19	27	23	23	22	16	25	31	33
<b>C18-C20, C218 COLORECTAL</b>															
Incidence	M	622.8	802.6	993.6	1135	1101	1156	1301	1361	1272	1272	1450	1431	1496	1565
	F	585.4	668.0	846.8	910	963	986	1019	1021	1087	1067	1070	1172	1266	1220
	P	1208.2	1470.6	1840.4	2045	2064	2142	2320	2382	2359	2339	2520	2603	2762	2785
Mortality	M	284.2	363.4	407.8	469	460	483	486	490	465	458	475	524	518	520
	F	274.8	309.0	329.6	399	374	361	374	391	414	396	400	388	377	451
	P	559.0	672.4	737.4	868	834	844	860	881	879	854	875	912	895	971
<b>C18 COLON</b>															
Incidence	M	413.2	537.0	612.6	718	694	725	826	870	788	798	884	893	933	995
	F	442.2	498.2	619.4	654	698	739	747	740	781	749	742	849	898	884
	P	855.4	1035.2	1232.0	1372	1392	1464	1573	1610	1569	1547	1626	1742	1831	1879
Mortality	M	191.8	238.4	246.4	306	282	310	296	310	321	271	306	323	332	306
	F	211.6	237.8	241.4	294	269	269	273	287	305	277	269	277	277	325
	P	403.4	476.2	487.8	600	551	579	569	597	626	548	575	600	609	631
<b>C19, C20 RECTOSIGMOID JUNCTION AND RECTUM</b>															
Incidence	M	208.4	263.6	378.0	413	405	424	469	483	476	471	557	530	552	558
	F	141.6	167.8	224.6	254	264	243	263	276	291	309	319	306	350	327
	P	350.0	431.4	602.6	667	669	667	732	759	767	780	876	836	902	885
Mortality	M	92.2	123.2	160.6	160	173	172	187	179	143	182	164	199	182	210
	F	62.8	70.6	87.8	105	103	91	96	101	107	116	127	110	96	122
	P	155.0	193.8	248.4	265	276	263	283	280	250	298	291	309	278	332
<b>C21 ANUS &amp; ANAL CANAL</b>															
Incidence	M	6.4	10.0	18.6	14	20	23	13	20	25	22	28	38	26	25
	F	10.6	15.8	18.2	17	17	22	27	19	34	37	30	44	52	31
	P	17.0	25.8	36.8	31	37	45	40	39	59	59	58	82	78	56
Mortality	M	2.0	3.2	5.0	6	10	5	6	2	5	10	11	10	12	19
	F	4.4	6.0	4.8	1	8	3	10	8	6	11	10	7	9	12
	P	6.4	9.2	9.8	7	18	8	16	10	11	21	21	17	21	31
<b>C22 LIVER &amp; INTRAHEPATIC BILE DUCTS</b>															
Incidence	M	25.8	42.4	62.4	66	80	67	98	107	89	97	99	129	141	159
	F	11.4	17.8	22.6	26	27	36	42	48	35	37	51	55	48	51
	P	37.2	60.2	85.0	92	107	103	140	155	124	134	150	184	189	210
Mortality	M	20.0	34.0	46.4	48	50	57	63	82	81	80	67	88	105	106
	F	7.2	13.6	17.6	20	19	31	29	38	29	31	36	45	40	30
	P	27.2	47.6	64.0	68	69	88	92	120	110	111	103	133	145	136

**Table 2. Cancer Incidence and Mortality (Counts) by Site and Sex,  
Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C23,C24 GALLBLADDER AND OTHER &amp; UNSPECIFIED PARTS OF BILIARY TRACT</b>															
Incidence	M	23.2	30.2	37.8	48	46	52	43	45	55	47	48	51	44	59
	F	41.0	51.2	56.4	63	61	51	53	50	65	58	59	65	69	56
	P	64.2	81.4	94.2	111	107	103	96	95	120	105	107	116	113	115
Mortality	M	19.4	22.4	24.0	32	40	26	34	28	36	43	34	41	32	37
	F	31.4	42.4	45.6	52	48	41	39	40	44	47	45	58	38	55
	P	50.8	64.8	69.6	84	88	67	73	68	80	90	79	99	70	92
<b>C25 PANCREAS</b>															
Incidence	M	100.6	116.4	140.0	171	161	171	191	173	165	203	198	188	235	255
	F	77.6	99.4	121.2	140	155	162	155	155	163	172	184	186	192	182
	P	178.2	215.8	261.2	311	316	333	346	328	328	375	382	374	427	437
Mortality	M	90.6	101.0	129.2	131	148	141	144	176	161	175	183	163	177	244
	F	69.8	84.8	110.2	132	125	129	145	137	139	148	172	185	173	165
	P	160.4	185.8	239.4	263	273	270	289	313	300	323	355	348	350	409
<b>C30,C31 NASAL CAVITY &amp; MIDDLE EAR AND ACCESSORY SINUSES</b>															
Incidence	M	10.0	10.8	14.8	14	13	12	12	14	10	12	20	15	18	11
	F	5.8	7.0	7.0	8	8	4	7	6	6	6	8	10	7	9
	P	15.8	17.8	21.8	22	21	16	19	20	16	18	28	25	25	20
Mortality	M	4.2	5.4	7.0	7	6	3	10	4	6	4	7	7	5	4
	F	2.4	3.4	3.0	1	4	1	3	0	3	3	5	3	1	2
	P	6.6	8.8	10.0	8	10	4	13	4	9	7	12	10	6	6
<b>C32 LARYNX</b>															
Incidence	M	86.0	93.2	100.6	100	107	88	92	109	101	103	114	99	118	108
	F	8.2	9.8	12.8	9	11	7	10	7	11	9	13	10	15	14
	P	94.2	103.0	113.4	109	118	95	102	116	112	112	127	109	133	122
Mortality	M	23.0	30.0	26.6	31	25	31	28	35	33	41	45	36	34	39
	F	4.0	3.6	3.2	3	3	2	3	1	7	7	3	5	4	5
	P	27.0	33.6	29.8	34	28	33	31	36	40	48	48	41	38	44
<b>C33,C34 TRACHEA AND BRONCHUS &amp; LUNG</b>															
Incidence	M	808.6	890.6	950.8	1058	1026	1082	1048	1085	1060	1060	1134	1158	1283	1216
	F	203.8	278.8	361.4	435	454	433	497	539	584	529	645	648	669	685
	P	1012.4	1169.4	1312.2	1493	1480	1515	1545	1624	1644	1589	1779	1806	1952	1901
Mortality	M	663.2	734.6	808.2	827	851	883	873	875	898	877	955	939	1005	1034
	F	159.4	202.4	279.4	349	334	366	374	398	457	423	488	537	530	555
	P	822.6	937.0	1087.6	1176	1185	1249	1247	1273	1355	1300	1443	1476	1535	1589
<b>C37, C38 THYMUS,HEART,MEDIASTINUM &amp; PLEURA</b>															
Incidence	M	4.6	6.0	7.4	10	9	10	8	10	12	10	7	8	6	10
	F	2.6	3.4	4.0	5	6	6	2	3	7	7	7	6	7	4
	P	7.2	9.4	11.4	15	15	16	10	13	19	17	14	14	13	14
Mortality	M	3.8	2.0	2.0	4	3	3	6	3	5	3	4	2	1	8
	F	1.6	2.4	2.2	3	0	4	1	2	3	1	3	4	3	1
	P	5.4	4.4	4.2	7	3	7	7	5	8	4	7	6	4	9
<b>C40,C41 BONES,JOINTS &amp; ARTICULAR CARTILAGES</b>															
Incidence	M	13.8	20.6	19.2	27	17	12	20	18	29	23	17	18	30	31
	F	7.4	11.6	13.6	14	12	14	18	21	19	11	27	19	12	14
	P	21.2	32.2	32.8	41	29	26	38	39	48	34	44	37	42	45
Mortality	M	5.8	8.2	8.0	7	14	8	6	6	10	7	11	6	4	18
	F	3.8	4.0	4.4	5	6	4	7	4	4	7	4	2	9	11
	P	9.6	12.2	12.4	12	20	12	13	10	14	14	15	8	13	29
<b>C44, M872-M879 MELANOMA</b>															
Incidence	M	514.8	750.0	955.6	1241	1230	1146	1299	1354	1464	1421	1307	1560	1454	1558
	F	493.4	621.8	731.0	889	910	892	948	986	1092	1016	1040	1105	1011	1110
	P	1008.2	1371.8	1686.6	2130	2140	2038	2247	2340	2556	2437	2347	2665	2465	2668
Mortality	M	68.4	92.4	120.2	118	137	142	142	149	134	182	189	184	145	196
	F	39.6	48.6	56.2	59	82	81	61	64	64	80	78	79	84	89
	P	108.0	141.0	176.4	177	219	223	203	213	198	262	267	263	229	285
<b>C44 OTHER SKIN (EXCL BCC/SCC)</b>															
Incidence	M	15.0	30.4	46.4	43	53	50	60	61	72	64	76	71	71	106
	F	7.6	16.0	21.0	30	36	36	34	37	43	35	35	46	46	54
	P	22.6	46.4	67.4	73	89	86	94	98	115	99	111	117	117	160
Mortality	M	1.4	4.8	8.0	13	6	10	15	11	13	8	21	23	14	25
	F	0.2	1.2	2.4	4	5	9	8	7	11	6	0	12	7	7
	P	1.6	6.0	10.4	17	11	19	23	18	24	14	21	35	21	32

**Table 2. Cancer Incidence and Mortality (Counts) by Site and Sex,  
Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>M905 MESOTHELIOMA</b>															
Incidence	M	21.6	36.8	50.0	72	77	77	81	88	92	92	89	91	109	111
	F	1.8	5.8	7.8	8	10	14	11	26	23	14	18	21	23	17
	P	23.4	42.6	57.8	80	87	91	92	114	115	106	107	112	132	128
Mortality	M	17.8	30.2	44.4	54	60	69	71	77	72	98	83	75	84	111
	F	1.6	4.0	6.6	7	7	10	13	11	20	17	13	18	18	17
	P	19.4	34.2	51.0	61	67	79	84	88	92	115	96	93	102	128
<b>M914 KAPOSI SARCOMA</b>															
Incidence	M	1.0	9.4	12.6	4	6	8	8	2	7	2	5	3	4	10
	F	0.0	0.6	0.8	0	0	2	0	0	0	0	1	2	0	1
	P	1.0	10.0	13.4	4	6	10	8	2	7	2	6	5	4	11
Mortality	M	0.4	0.2	0.4	0	0	0	0	0	0	1	0	0	1	0
	F	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	P	0.4	0.2	0.4	0	0	0	0	0	0	1	0	0	1	0
<b>C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVES</b>															
Incidence	M	28.6	31.6	37.2	41	51	39	53	48	57	52	56	51	51	43
	F	22.2	21.8	32.2	39	45	30	41	32	35	29	42	66	44	38
	P	50.8	53.4	69.4	80	96	69	94	80	92	81	98	117	95	81
Mortality	M	11.2	10.8	13.0	16	15	10	4	18	23	18	18	24	26	11
	F	9.4	8.4	12.0	11	15	12	12	18	8	13	13	22	25	15
	P	20.6	19.2	25.0	27	30	22	16	36	31	31	31	46	51	26
<b>C48 RETROPERITONEUM &amp; PERITONEUM</b>															
Incidence	M	3.2	4.4	4.0	7	6	7	8	5	8	8	7	7	12	15
	F	6.0	4.2	8.4	13	15	23	28	35	22	32	29	28	42	47
	P	9.2	8.6	12.4	20	21	30	36	40	30	40	36	35	54	62
Mortality	M	3.0	3.4	1.6	1	9	3	7	3	6	4	3	4	2	7
	F	3.0	3.8	3.4	4	9	11	13	11	18	15	17	17	26	31
	P	6.0	7.2	5.0	5	18	14	20	14	24	19	20	21	28	38
<b>C50 BREAST</b>															
Incidence	M	9.6	9.6	10.4	16	11	13	18	19	14	14	28	22	23	24
	F	912.2	1209.8	1556.8	1825	1930	2034	2124	2209	2228	2208	2290	2418	2511	2469
	P	921.8	1219.4	1567.2	1841	1941	2047	2142	2228	2242	2222	2318	2440	2534	2493
Mortality	M	2.8	2.4	4.0	3	1	1	4	4	0	2	6	4	4	3
	F	290.4	344.4	412.6	417	430	412	407	462	432	454	452	475	432	498
	P	293.2	346.8	416.6	420	431	413	411	466	432	456	458	479	436	501
<b>C51 VULVA</b>															
Incidence	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	26.8	28.8	34.0	49	29	29	33	42	42	34	41	39	48	50
	P	26.8	28.8	34.0	49	29	29	33	42	42	34	41	39	48	50
Mortality	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	5.4	8.2	8.4	11	12	7	5	5	11	4	17	10	11	13
	P	5.4	8.2	8.4	11	12	7	5	5	11	4	17	10	11	13
<b>C53 CERVIX UTERI</b>															
Incidence	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	184.8	195.2	195.8	177	166	190	167	155	149	156	146	179	188	143
	P	184.8	195.2	195.8	177	166	190	167	155	149	156	146	179	188	143
Mortality	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	48.0	53.4	55.2	47	55	43	58	51	37	39	47	42	58	36
	P	48.0	53.4	55.2	47	55	43	58	51	37	39	47	42	58	36
<b>C54 CORPUS UTERI</b>															
Incidence	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	146.0	161.8	214.6	233	242	265	311	295	310	306	331	348	336	368
	P	146.0	161.8	214.6	233	242	265	311	295	310	306	331	348	336	368
Mortality	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	29.0	33.0	41.4	51	37	50	52	52	58	52	67	72	64	72
	P	29.0	33.0	41.4	51	37	50	52	52	58	52	67	72	64	72
<b>C56 OVARY</b>															
Incidence	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	144.4	161.0	196.8	183	204	197	206	220	222	187	218	222	232	212
	P	144.4	161.0	196.8	183	204	197	206	220	222	187	218	222	232	212
Mortality	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	90.6	94.8	110.8	98	106	122	105	117	131	134	123	139	132	136
	P	90.6	94.8	110.8	98	106	122	105	117	131	134	123	139	132	136

**Table 2. Cancer Incidence and Mortality (Counts) by Site and Sex,  
Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANS</b>															
Incidence	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	21.8	21.0	21.8	25	30	29	37	28	30	27	52	56	44	55
	P	21.8	21.0	21.8	25	30	29	37	28	30	27	52	56	44	55
Mortality	M	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	F	8.0	8.6	8.8	11	12	10	15	19	8	13	18	33	21	18
	P	8.0	8.6	8.8	11	12	10	15	19	8	13	18	33	21	18
<b>C61 PROSTATE GLAND</b>															
Incidence	M	737.2	1022.2	1801.2	1631	1730	1791	1884	1972	2245	2674	2993	2945	3308	3680
	F	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	P	737.2	1022.2	1801.2	1631	1730	1791	1884	1972	2245	2674	2993	2945	3308	3680
Mortality	M	230.8	324.6	452.0	433	460	439	510	505	502	525	569	526	556	600
	F	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	P	230.8	324.6	452.0	433	460	439	510	505	502	525	569	526	556	600
<b>C62 TESTIS</b>															
Incidence	M	59.0	61.4	94.0	92	107	111	85	105	132	116	114	132	138	116
	F	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	P	59.0	61.4	94.0	92	107	111	85	105	132	116	114	132	138	116
Mortality	M	7.4	5.2	5.0	7	3	2	4	3	2	5	6	5	4	4
	F	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	P	7.4	5.2	5.0	7	3	2	4	3	2	5	6	5	4	4
<b>C60,C63 PENIS AND OTHER &amp; UNSPECIFIED MALE GENITAL ORGANS</b>															
Incidence	M	10.4	11.6	15.4	15	18	15	18	22	17	17	18	12	13	24
	F	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	P	10.4	11.6	15.4	15	18	15	18	22	17	17	18	12	13	24
Mortality	M	2.0	3.2	3.2	0	4	3	6	5	3	2	3	7	3	3
	F	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0
	P	2.0	3.2	3.2	0	4	3	6	5	3	2	3	7	3	3
<b>C64-C66,C68 KIDNEY AND OTHER RENAL TRACT</b>															
Incidence	M	126.6	154.6	222.4	254	261	287	308	268	261	294	300	346	397	395
	F	82.0	113.4	147.2	153	166	189	172	180	193	179	191	177	229	207
	P	208.6	268.0	369.6	407	427	476	480	448	454	473	491	523	626	602
Mortality	M	53.6	65.2	84.6	86	80	100	97	99	91	101	100	101	106	122
	F	36.2	53.6	61.0	60	72	71	62	67	71	65	79	70	71	58
	P	89.8	118.8	145.6	146	152	171	159	166	162	166	179	171	177	180
<b>C67 BLADDER</b>															
Incidence	M	286.6	331.2	408.4	479	511	466	523	534	509	523	528	533	543	364
	F	93.0	108.0	139.8	152	157	157	175	149	170	158	175	137	157	136
	P	379.6	439.2	548.2	631	668	623	698	683	679	681	703	670	700	500
Mortality	M	67.2	77.6	96.6	103	98	118	106	115	124	114	111	116	125	131
	F	26.0	30.8	40.0	55	38	35	43	52	46	49	62	48	51	48
	P	93.2	108.4	136.6	158	136	153	149	167	170	163	173	164	176	179
<b>C69 EYE &amp; ADNEXA</b>															
Incidence	M	15.8	21.6	34.0	26	47	32	21	40	32	44	22	37	43	26
	F	9.4	16.4	20.2	16	16	22	17	28	18	23	26	24	26	26
	P	25.2	38.0	54.2	42	63	54	38	68	50	67	48	61	69	52
Mortality	M	2.8	4.8	3.6	5	3	9	7	3	6	4	8	8	4	8
	F	1.8	2.8	5.4	3	3	4	4	4	1	3	5	6	1	4
	P	4.6	7.6	9.0	8	6	13	11	7	7	7	13	14	5	12
<b>C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM</b>															
Incidence	M	80.2	96.6	115.2	149	130	132	140	140	141	143	167	169	172	170
	F	64.6	76.8	89.0	103	87	107	121	118	100	103	85	126	111	109
	P	144.8	173.4	204.2	252	217	239	261	258	241	246	252	295	283	279
Mortality	M	62.8	73.8	83.2	122	111	108	116	95	114	117	126	127	142	125
	F	45.4	60.4	69.8	84	68	87	89	75	95	86	74	79	86	82
	P	108.2	134.2	153.0	206	179	195	205	170	209	203	200	206	228	207
<b>C73 THYROID GLAND</b>															
Incidence	M	18.6	21.8	34.2	41	59	60	55	66	70	90	74	87	92	112
	F	47.4	61.0	104.0	136	135	154	187	178	205	210	241	274	287	350
	P	66.0	82.8	138.2	177	194	214	242	244	275	300	315	361	379	462
Mortality	M	3.2	6.2	5.4	5	5	5	5	9	10	6	7	12	15	9
	F	4.6	5.0	5.6	6	4	8	3	8	5	10	12	8	12	8
	P	7.8	11.2	11.0	11	9	13	8	17	15	16	19	20	27	17

**Table 2. Cancer Incidence and Mortality (Counts) by Site and Sex,  
Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C74,C75 ADRENAL AND OTHER ENDOCRINE GLANDS</b>															
Incidence	M	3.8	5.8	7.6	11	5	8	9	12	3	9	6	8	9	6
	F	2.8	5.8	6.4	6	6	9	7	6	9	9	12	7	11	6
	P	6.6	11.6	14.0	17	11	17	16	18	12	18	18	15	20	12
Mortality	M	3.0	2.2	3.8	2	2	3	5	4	4	6	2	4	2	6
	F	0.8	3.4	3.6	2	2	4	5	1	7	4	6	4	7	3
	P	3.8	5.6	7.4	4	4	7	10	5	11	10	8	8	9	9
<b>C26, C39,C76,C77,C80 OTHER &amp; ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE</b>															
Incidence	M	185.4	218.8	269.4	272	301	268	278	266	296	274	302	312	319	351
	F	150.0	174.0	227.6	227	265	259	276	214	249	222	241	268	296	325
	P	335.4	392.8	497.0	499	566	527	554	480	545	496	543	580	615	676
Mortality	M	148.6	167.0	200.2	211	226	189	206	184	218	183	201	216	215	209
	F	119.2	135.2	176.8	162	214	223	218	171	221	173	182	187	199	207
	P	267.8	302.2	377.0	373	440	412	424	355	439	356	383	403	414	416
<b>M959-M972 ALL LYMPHOMAS</b>															
Incidence	M	168.2	213.4	274.0	324	329	343	357	369	387	403	391	439	467	462
	F	140.6	182.2	225.2	245	284	301	276	314	289	300	324	377	397	373
	P	308.8	395.6	499.2	569	613	644	633	683	676	703	715	816	864	835
Mortality	M	78.6	93.6	116.6	150	138	135	149	118	140	139	139	110	135	112
	F	60.4	77.8	95.6	119	128	96	108	100	133	107	110	105	102	97
	P	139.0	171.4	212.2	269	266	231	257	218	273	246	249	215	237	209
<b>M965-M966 HODGKIN LYMPHOMA</b>															
Incidence	M	29.4	30.8	31.8	33	36	35	30	40	43	42	27	47	52	48
	F	16.4	23.0	26.6	29	34	32	23	33	30	36	32	36	51	39
	P	45.8	53.8	58.4	62	70	67	53	73	73	78	59	83	103	87
Mortality	M	11.0	7.8	6.4	11	7	7	4	7	8	7	8	7	12	11
	F	5.4	5.4	4.4	8	2	1	4	3	6	2	5	6	6	2
	P	16.4	13.2	10.8	19	9	8	8	10	14	9	13	13	18	13
<b>M959,M967-M972 NON-HODGKIN LYMPHOMA</b>															
Incidence	M	138.8	182.6	242.2	291	293	308	327	329	344	361	364	392	415	414
	F	124.2	159.2	198.6	216	250	269	253	281	259	264	292	341	346	334
	P	263.0	341.8	440.8	507	543	577	580	610	603	625	656	733	761	748
Mortality	M	67.6	85.8	110.2	139	131	128	145	111	132	132	131	103	123	101
	F	55.0	72.4	91.2	111	126	95	104	97	127	105	105	99	96	95
	P	122.6	158.2	201.4	250	257	223	249	208	259	237	236	202	219	196
<b>M980-M994 ALL LEUKAEMIAS</b>															
Incidence	M	168.6	187.4	256.4	249	298	316	303	280	323	314	313	290	305	342
	F	111.6	133.8	183.8	188	205	202	196	235	219	206	196	190	237	208
	P	280.2	321.2	440.2	437	503	518	499	515	542	520	509	480	542	550
Mortality	M	88.8	101.0	127.6	131	146	140	125	121	143	129	131	134	131	150
	F	62.6	74.0	94.2	89	101	103	95	88	88	95	114	77	100	91
	P	151.4	175.0	221.8	220	247	243	220	209	231	224	245	211	231	241
<b>M982-M983 LYMPHOID LEUKAEMIA</b>															
Incidence	M	81.4	85.0	119.8	115	164	171	154	135	158	155	160	146	166	157
	F	47.8	59.8	88.4	83	104	104	113	130	123	108	83	90	117	86
	P	129.2	144.8	208.2	198	268	275	267	265	281	263	243	236	283	243
Mortality	M	28.0	31.0	46.0	49	50	53	33	49	49	49	41	50	46	42
	F	16.6	21.8	29.0	25	39	33	40	31	33	29	49	21	29	27
	P	44.6	52.8	75.0	74	89	86	73	80	82	78	90	71	75	69
<b>M984-M993 MYELOID LEUKAEMIA</b>															
Incidence	M	74.6	87.0	108.4	115	109	113	117	92	123	127	108	102	101	125
	F	55.2	65.4	84.4	92	85	89	66	85	74	82	89	77	93	92
	P	129.8	152.4	192.8	207	194	202	183	177	197	209	197	179	194	217
Mortality	M	54.6	61.6	72.8	72	89	78	74	62	75	71	78	59	68	91
	F	41.2	46.4	58.2	60	56	61	49	46	46	57	52	45	57	54
	P	95.8	108.0	131.0	132	145	139	123	108	121	128	130	104	125	145
<b>M994 OTHER SPECIFIED LEUKAEMIA</b>															
Incidence	M	5.4	7.2	18.8	15	20	24	26	52	39	30	41	39	36	51
	F	2.6	2.4	4.0	5	9	4	11	17	19	12	19	21	21	25
	P	8.0	9.6	22.8	20	29	28	37	69	58	42	60	60	57	76
Mortality	M	1.4	2.0	3.8	5	5	5	13	9	16	8	11	23	16	12
	F	0.6	0.8	1.6	0	3	1	3	7	8	6	9	9	9	6
	P	2.0	2.8	5.4	5	8	6	16	16	24	14	20	32	25	18

**Table 2. Cancer Incidence and Mortality (Counts) by Site and Sex,  
Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>M980 UNSPECIFIED LEUKAEMIA</b>															
Incidence	M	7.2	8.2	9.4	4	5	8	6	1	3	2	4	3	2	9
	F	6.0	6.2	7.0	8	7	5	6	3	3	4	5	2	6	5
	P	13.2	14.4	16.4	12	12	13	12	4	6	6	9	5	8	14
Mortality	M	4.8	6.4	5.0	5	2	4	5	1	3	1	1	2	1	5
	F	4.2	5.0	5.4	4	3	8	3	4	1	3	4	2	5	4
	P	9.0	11.4	10.4	9	5	12	8	5	4	4	5	4	6	9
<b>M973 MYELOMA/PLASMA CELL TUMOURS</b>															
Incidence	M	52.6	63.4	76.2	103	132	105	119	119	109	116	106	120	134	132
	F	44.4	45.0	63.4	68	81	90	105	102	80	88	94	87	98	88
	P	97.0	108.4	139.6	171	213	195	224	221	189	204	200	207	232	220
Mortality	M	27.6	45.6	43.0	53	65	68	65	69	69	60	70	67	57	70
	F	26.0	31.2	41.4	42	41	38	53	45	47	54	59	54	45	53
	P	53.6	76.8	84.4	95	106	106	118	114	116	114	129	121	102	123
<b>M998 MYELOYDYSPLASTIC DISEASES</b>															
Incidence	M	3.8	11.2	26.2	47	61	78	96	134	118	138	131	118	128	134
	F	2.4	7.8	19.0	33	36	52	75	82	101	80	89	81	94	86
	P	6.2	19.0	45.2	80	97	130	171	216	219	218	220	199	222	220
Mortality	M	2.4	3.6	6.8	16	17	12	25	37	46	36	48	54	47	55
	F	0.8	2.0	4.6	13	7	15	13	23	28	25	23	37	42	32
	P	3.2	5.6	11.4	29	24	27	38	60	74	61	71	91	89	87
<b>M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASES</b>															
Incidence	M	23.6	31.6	65.0	86	87	83	104	79	82	91	69	92	81	88
	F	19.4	31.6	57.8	60	70	68	72	67	46	64	63	51	63	65
	P	43.0	63.2	122.8	146	157	151	176	146	128	155	132	143	144	153
Mortality	M	5.0	6.0	6.6	16	12	19	10	7	15	12	16	11	7	21
	F	1.6	5.8	6.4	12	7	12	10	6	6	13	9	8	17	10
	P	6.6	11.8	13.0	28	19	31	20	13	21	25	25	19	24	31
<b>M974-M976 OTHER NEOPLASMS OF LYMPHATIC &amp; HAEMATOPOIETIC TISSUE</b>															
Incidence	M	3.4	2.4	4.0	9	4	7	14	12	12	18	9	5	7	12
	F	2.0	1.2	3.2	3	3	5	9	4	11	9	11	7	5	4
	P	5.4	3.6	7.2	12	7	12	23	16	23	27	20	12	12	16
Mortality	M	0.8	1.4	0.8	5	2	4	1	4	0	4	3	1	2	2
	F	0.8	0.8	0.4	0	2	0	2	0	3	2	2	1	2	1
	P	1.6	2.2	1.2	5	4	4	3	4	3	6	5	2	4	3
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>															
Incidence	M	4758.4	5968.6	7917.8	8647	8965	8915	9435	9696	10082	10579	11058	11466	12219	12638
	F	3901.4	4826.8	6093.6	6865	7216	7405	7825	7946	8250	7964	8454	8938	9256	9217
	P	8659.8	10795.4	14011.4	15512	16181	16320	17260	17642	18332	18543	19512	20404	21475	21855
Mortality	M	2269.4	2720.8	3236.4	3463	3568	3581	3707	3713	3848	3848	4067	4047	4132	4416
	F	1595.0	1899.0	2274.8	2505	2524	2567	2612	2655	2827	2763	2920	3050	2949	3115
	P	3864.4	4619.8	5511.2	5968	6092	6148	6319	6368	6675	6611	6987	7097	7081	7531

**Table 3. Cancer Incidence and Mortality (ASR (World)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C00 LIP</b>															
Incidence	M	7.3	9.6	10.5	10.8	12.3	6.0	5.3	6.2	7.5	6.5	5.3	5.6	6.7	4.9
	F	1.3	2.1	2.3	3.2	3.4	1.6	1.9	1.9	3.0	1.9	1.7	1.4	1.5	1.3
	P	4.2	5.8	6.3	7.0	7.8	3.8	3.6	4.0	5.2	4.2	3.5	3.4	4.1	3.1
Mortality	M	0.1	0.2	0.2	0.2	0.1	0.2	0.1	0.2	0.2	0.1	0.3	0.3	0.0	0.1
	F	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1
	P	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.0	0.1
<b>C01,C02 TONGUE</b>															
Incidence	M	3.0	3.1	3.1	2.8	2.8	3.0	2.4	2.6	2.8	2.4	3.4	3.1	2.2	3.2
	F	0.9	1.2	1.2	1.6	1.3	1.5	1.3	0.9	1.0	1.1	1.1	1.3	1.0	1.7
	P	1.9	2.1	2.2	2.2	2.0	2.3	1.9	1.7	1.9	1.8	2.2	2.2	1.6	2.5
Mortality	M	1.2	1.3	1.2	1.3	1.5	0.9	1.1	0.9	1.2	0.9	1.4	1.2	0.8	0.7
	F	0.2	0.5	0.4	0.2	0.3	0.4	0.6	0.6	0.4	0.4	0.4	0.5	0.3	0.3
	P	0.7	0.9	0.8	0.7	0.9	0.7	0.8	0.7	0.8	0.6	0.9	0.9	0.5	0.5
<b>C03 GUM</b>															
Incidence	M	0.2	0.2	0.4	0.3	0.1	0.4	0.5	0.2	0.2	0.3	0.4	0.5	0.3	0.4
	F	0.2	0.1	0.2	0.1	0.2	0.2	0.3	0.4	0.2	0.2	0.2	0.2	0.4	0.2
	P	0.2	0.2	0.3	0.2	0.2	0.3	0.4	0.3	0.2	0.3	0.3	0.4	0.4	0.3
Mortality	M	0.0	0.1	0.2	0.0	0.2	0.0	0.1	0.2	0.2	0.2	0.1	0.2	0.1	0.1
	F	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.2
	P	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.1
<b>C04 FLOOR OF MOUTH</b>															
Incidence	M	1.5	1.1	1.1	1.0	1.2	1.3	1.3	0.8	0.7	0.7	0.8	1.1	0.8	0.9
	F	0.4	0.4	0.4	0.2	0.6	0.4	0.6	0.3	0.3	0.5	0.3	0.6	0.3	0.2
	P	1.0	0.8	0.7	0.6	0.9	0.8	1.0	0.6	0.5	0.6	0.5	0.9	0.5	0.5
Mortality	M	0.5	0.4	0.5	0.3	0.5	0.5	0.5	0.3	0.2	0.4	0.3	0.4	0.3	0.3
	F	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.1
	P	0.3	0.2	0.3	0.2	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.3	0.2	0.2
<b>C05,C06 PALATE AND OTHER &amp; UNSPECIFIED PARTS OF MOUTH</b>															
Incidence	M	1.9	1.5	1.2	1.5	1.4	0.8	1.1	0.9	1.4	1.0	1.0	1.5	1.2	1.4
	F	0.5	0.8	0.9	0.9	0.6	0.5	0.8	0.3	0.4	0.5	0.7	0.6	0.9	0.6
	P	1.2	1.2	1.0	1.2	1.0	0.7	0.9	0.6	0.9	0.8	0.9	1.0	1.0	1.0
Mortality	M	0.6	0.5	0.6	0.3	0.4	0.3	0.2	0.4	0.4	0.3	0.5	0.4	0.5	0.4
	F	0.2	0.3	0.2	0.1	0.0	0.3	0.2	0.2	0.1	0.2	0.2	0.3	0.3	0.1
	P	0.4	0.4	0.4	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.4	0.4	0.3
<b>C07,C08 PAROTID AND OTHER &amp; UNSPECIFIED MAJOR SALIVARY GLANDS</b>															
Incidence	M	1.1	1.0	1.2	1.4	1.3	1.1	1.5	1.2	1.2	1.2	1.1	1.0	1.8	1.3
	F	0.6	0.6	0.8	0.6	0.7	0.6	0.6	0.6	0.6	0.6	0.7	0.8	0.7	0.9
	P	0.8	0.8	0.9	1.0	1.0	0.9	1.0	0.8	0.9	0.9	0.9	0.9	0.8	1.1
Mortality	M	0.3	0.3	0.3	0.3	0.3	0.1	0.3	0.3	0.4	0.3	0.1	0.4	0.4	0.2
	F	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.0	0.1	0.0	0.1
	P	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.3	0.2	0.1	0.3	0.2	0.1
<b>C09,C10 TONSIL AND OROPHARYNX</b>															
Incidence	M	2.2	1.6	1.9	1.9	2.5	1.8	1.7	2.1	1.8	2.2	2.1	2.4	2.7	3.0
	F	0.5	0.5	0.4	0.4	0.4	0.7	0.5	0.5	0.6	0.5	0.5	0.6	0.5	0.6
	P	1.3	1.1	1.2	1.1	1.5	1.2	1.1	1.3	1.2	1.3	1.3	1.5	1.6	1.8
Mortality	M	1.0	0.9	0.9	0.6	0.9	0.7	0.8	0.8	1.0	0.8	0.8	0.8	0.9	0.8
	F	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2
	P	0.6	0.6	0.6	0.4	0.5	0.5	0.5	0.5	0.6	0.5	0.5	0.5	0.5	0.5
<b>C11 NASOPHARYNX</b>															
Incidence	M	0.8	0.5	0.6	0.7	0.5	0.6	0.5	0.4	0.4	0.4	0.3	0.6	0.5	0.4
	F	0.3	0.2	0.3	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.1
	P	0.5	0.4	0.5	0.4	0.3	0.4	0.4	0.3	0.2	0.2	0.2	0.3	0.4	0.2
Mortality	M	0.4	0.3	0.4	0.5	0.4	0.4	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.2
	F	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.0	0.1	0.1	0.1
	P	0.3	0.2	0.3	0.3	0.3	0.3	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0.1
<b>C12,C13 PYRIFORM SINUS AND HYPOPHARYNX</b>															
Incidence	M	1.5	1.8	1.7	1.2	1.5	1.4	1.3	1.3	0.8	0.9	1.2	0.9	0.8	1.2
	F	0.2	0.2	0.2	0.3	0.1	0.1	0.3	0.2	0.3	0.1	0.2	0.3	0.2	0.2
	P	0.8	1.0	0.9	0.7	0.8	0.8	0.8	0.8	0.5	0.5	0.7	0.6	0.5	0.7
Mortality	M	0.7	1.1	0.9	1.1	0.7	0.8	0.8	0.7	0.9	0.8	0.6	0.4	0.7	0.5
	F	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.2	0.3	0.0	0.1	0.2	0.1	0.1
	P	0.4	0.6	0.5	0.7	0.4	0.4	0.4	0.4	0.6	0.4	0.4	0.3	0.4	0.3

**Table 3. Cancer Incidence and Mortality (ASR (World)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C14 OTHER &amp; ILL-DEFINED SITES IN LIP, ORAL CAVITY &amp; PHARYNX</b>															
Incidence	M	0.5	0.6	0.6	0.4	0.7	0.3	0.9	0.7	0.5	0.7	0.5	0.8	0.7	0.8
	F	0.1	0.2	0.1	0.2	0.1	0.3	0.3	0.0	0.1	0.0	0.1	0.2	0.1	0.0
	P	0.3	0.4	0.3	0.3	0.4	0.3	0.6	0.3	0.3	0.4	0.3	0.5	0.4	0.4
Mortality	M	0.2	0.4	0.3	0.3	0.3	0.2	0.4	0.4	0.2	0.3	0.3	0.5	0.4	0.4
	F	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.0
	P	0.1	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.1	0.2	0.2	0.3	0.2	0.2
<b>C15 OESOPHAGUS</b>															
Incidence	M	3.7	4.8	5.6	4.6	4.6	6.5	6.0	5.4	5.4	4.9	4.9	4.9	5.3	5.4
	F	1.6	2.0	2.1	2.4	2.3	1.8	1.9	1.9	1.4	1.6	2.2	1.5	1.8	2.0
	P	2.6	3.3	3.8	3.5	3.4	4.1	3.9	3.6	3.3	3.3	3.5	3.1	3.5	3.6
Mortality	M	3.1	3.6	4.3	3.3	3.9	3.5	3.7	4.0	4.0	3.9	4.2	3.3	3.8	4.0
	F	1.3	1.4	1.5	1.4	1.4	1.3	1.4	1.3	1.1	1.2	1.3	1.5	1.0	1.3
	P	2.2	2.5	2.8	2.3	2.6	2.3	2.5	2.6	2.5	2.5	2.7	2.4	2.4	2.6
<b>C16 STOMACH</b>															
Incidence	M	11.9	10.5	9.5	8.5	8.4	9.3	8.6	7.7	7.5	8.1	7.6	7.0	7.3	5.8
	F	4.8	3.9	4.1	4.2	3.7	3.1	4.2	3.2	3.5	2.8	3.0	3.3	2.8	2.9
	P	8.0	6.9	6.7	6.2	5.9	5.9	6.3	5.3	5.4	5.3	5.2	5.1	4.9	4.3
Mortality	M	9.3	7.4	6.8	6.9	5.9	6.1	6.0	5.4	6.0	5.3	5.2	4.5	4.3	4.4
	F	3.6	2.9	2.6	2.6	2.3	2.0	2.0	2.2	1.9	2.2	2.2	2.0	1.4	2.1
	P	6.2	4.9	4.6	4.6	4.0	3.9	3.9	3.6	3.9	3.7	3.6	3.2	2.8	3.2
<b>C17 SMALL INTESTINE</b>															
Incidence	M	0.8	0.9	1.0	1.3	1.4	1.4	1.4	1.1	1.2	1.1	1.2	1.5	1.4	1.6
	F	0.6	0.7	0.7	0.7	0.8	1.1	0.8	0.8	0.8	0.9	1.0	1.4	1.1	1.1
	P	0.7	0.8	0.8	1.0	1.1	1.2	1.1	0.9	1.0	1.0	1.1	1.5	1.2	1.3
Mortality	M	0.4	0.4	0.4	0.4	0.4	0.5	0.6	0.5	0.5	0.5	0.3	0.5	0.5	0.5
	F	0.3	0.3	0.3	0.5	0.2	0.3	0.3	0.3	0.3	0.3	0.2	0.3	0.5	0.5
	P	0.3	0.4	0.4	0.5	0.3	0.4	0.5	0.4	0.4	0.4	0.3	0.4	0.5	0.5
<b>C18-C20, C218 COLORECTAL</b>															
Incidence	M	42.8	47.0	49.9	51.1	47.6	48.6	52.9	52.8	47.2	45.3	50.1	47.3	48.2	49.2
	F	34.6	33.2	36.4	34.7	36.3	35.6	35.3	34.0	35.1	33.8	32.4	33.8	36.3	34.0
	P	38.4	39.7	42.8	42.7	41.8	41.9	43.8	43.2	41.0	39.3	41.0	40.4	42.1	41.5
Mortality	M	19.2	20.9	19.8	21.0	19.2	19.4	19.3	18.7	16.8	15.9	15.5	16.5	15.7	15.1
	F	15.3	14.3	13.0	14.8	12.8	11.6	11.8	11.9	11.9	11.2	11.0	9.7	9.2	10.7
	P	17.1	17.4	16.2	17.7	15.9	15.3	15.4	15.3	14.3	13.5	13.1	13.0	12.3	12.8
<b>C18 COLON</b>															
Incidence	M	28.3	31.4	30.6	31.8	29.3	29.8	33.4	33.5	28.8	27.7	29.8	28.8	29.6	30.7
	F	26.1	24.5	26.2	24.6	25.7	26.4	25.2	24.2	24.8	22.9	21.8	23.9	25.1	23.9
	P	27.1	27.8	28.3	28.1	27.3	28.0	29.1	28.7	26.7	25.2	25.6	26.2	27.3	27.2
Mortality	M	13.0	13.6	11.9	13.6	11.4	12.2	11.6	11.8	11.6	9.2	9.8	9.9	10.0	8.5
	F	11.8	11.0	9.4	10.6	8.9	8.5	8.6	8.6	8.6	7.7	7.1	7.0	6.7	7.6
	P	12.4	12.2	10.5	12.0	10.1	10.2	10.0	10.2	10.1	8.4	8.4	8.4	8.2	8.0
<b>C19, C20 RECTOSIGMOID JUNCTION AND RECTUM</b>															
Incidence	M	14.4	15.5	19.2	19.0	18.3	18.4	19.3	19.0	18.1	17.5	20.0	18.3	18.2	18.2
	F	8.4	8.6	10.1	10.0	10.6	9.0	9.8	9.6	9.9	10.5	10.3	9.3	10.6	9.7
	P	11.2	11.8	14.4	14.4	14.4	13.6	14.4	14.2	13.9	13.9	15.1	13.8	14.3	13.9
Mortality	M	6.2	7.2	7.9	7.3	7.6	7.1	7.6	6.9	5.2	6.6	5.5	6.5	5.6	6.5
	F	3.5	3.3	3.6	4.2	3.9	3.1	3.0	3.2	3.2	3.5	3.8	2.7	2.4	3.0
	P	4.7	5.1	5.6	5.6	5.7	5.0	5.2	5.0	4.2	5.0	4.6	4.6	3.9	4.7
<b>C21 ANUS &amp; ANAL CANAL</b>															
Incidence	M	0.5	0.6	1.0	0.7	0.9	1.1	0.5	0.8	1.0	0.8	1.0	1.3	0.9	0.8
	F	0.6	0.8	0.8	0.6	0.7	0.9	1.0	0.7	1.2	1.3	1.0	1.4	1.7	1.0
	P	0.5	0.7	0.9	0.7	0.8	1.0	0.8	0.8	1.1	1.1	1.0	1.3	1.3	0.9
Mortality	M	0.1	0.2	0.3	0.3	0.5	0.2	0.3	0.1	0.2	0.3	0.4	0.3	0.3	0.6
	F	0.3	0.3	0.2	0.0	0.2	0.1	0.3	0.3	0.2	0.3	0.3	0.2	0.2	0.3
	P	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.2	0.3	0.3	0.3	0.3	0.4
<b>C22 LIVER &amp; INTRAHEPATIC BILE DUCTS</b>															
Incidence	M	1.9	2.6	3.2	3.1	3.6	2.8	4.1	4.3	3.4	3.5	3.5	4.6	4.6	5.1
	F	0.7	1.0	1.0	1.2	1.0	1.2	1.7	1.7	1.3	1.1	1.6	1.6	1.6	1.4
	P	1.3	1.8	2.0	2.1	2.3	2.0	2.8	3.0	2.3	2.3	2.5	3.1	3.0	3.2
Mortality	M	1.4	2.0	2.3	2.2	2.2	2.4	2.6	3.3	2.9	2.9	2.3	3.0	3.4	3.3
	F	0.4	0.7	0.7	0.8	0.6	1.0	0.9	1.3	0.9	0.9	1.1	1.3	1.1	0.8
	P	0.9	1.3	1.5	1.5	1.4	1.7	1.8	2.2	1.9	1.9	1.7	2.1	2.2	2.0

**Table 3. Cancer Incidence and Mortality (ASR (World)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C23,C24 GALLBLADDER AND OTHER &amp; UNSPECIFIED PARTS OF BILIARY TRACT</b>															
Incidence	M	1.6	1.7	1.8	2.1	1.9	2.0	1.8	1.7	2.0	1.6	1.6	1.6	1.4	1.7
	F	2.2	2.3	2.2	2.4	2.0	1.7	1.4	1.5	1.9	1.8	1.5	1.7	1.7	1.4
	P	1.9	2.1	2.0	2.3	2.0	1.8	1.6	1.6	2.0	1.7	1.6	1.7	1.6	1.6
Mortality	M	1.3	1.3	1.2	1.4	1.7	1.0	1.3	1.0	1.3	1.4	1.2	1.3	1.0	1.1
	F	1.7	1.9	1.8	1.9	1.5	1.2	1.1	1.0	1.2	1.4	1.2	1.4	1.0	1.3
	P	1.5	1.6	1.5	1.6	1.6	1.1	1.2	1.0	1.2	1.4	1.2	1.4	1.0	1.2
<b>C25 PANCREAS</b>															
Incidence	M	6.8	6.6	6.8	7.5	6.7	6.9	7.5	6.6	5.9	7.0	6.7	6.1	7.6	7.6
	F	4.2	4.7	4.6	5.0	5.2	5.2	4.6	4.7	4.9	4.9	5.2	4.7	5.0	4.4
	P	5.4	5.6	5.7	6.2	5.9	6.1	6.0	5.6	5.4	5.9	6.0	5.4	6.3	6.0
Mortality	M	6.0	5.8	6.2	5.7	6.1	5.7	5.6	6.5	5.8	5.9	6.1	5.4	5.6	7.2
	F	3.7	3.9	4.2	4.4	4.2	3.9	4.3	4.1	4.0	4.1	4.6	4.7	4.2	4.0
	P	4.8	4.8	5.2	5.0	5.1	4.8	4.9	5.3	4.9	5.0	5.3	5.1	4.9	5.6
<b>C30,C31 NASAL CAVITY &amp; MIDDLE EAR AND ACCESSORY SINUSES</b>															
Incidence	M	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.6	0.5	0.5	0.8	0.5	0.7	0.4
	F	0.3	0.4	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.3	0.3	0.2	0.3
	P	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.5	0.4	0.4
Mortality	M	0.3	0.3	0.3	0.3	0.3	0.2	0.4	0.2	0.3	0.2	0.3	0.2	0.2	0.1
	F	0.1	0.2	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0
	P	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.1
<b>C32 LARYNX</b>															
Incidence	M	6.2	5.7	5.3	4.8	4.8	3.9	3.8	4.4	4.0	4.0	4.0	3.4	3.8	3.4
	F	0.5	0.6	0.6	0.4	0.5	0.3	0.3	0.3	0.4	0.3	0.4	0.3	0.5	0.4
	P	3.3	3.1	2.9	2.6	2.6	2.1	2.0	2.3	2.2	2.1	2.2	1.9	2.1	1.9
Mortality	M	1.6	1.8	1.4	1.4	1.0	1.3	1.1	1.4	1.3	1.4	1.7	1.1	1.0	1.1
	F	0.2	0.2	0.2	0.1	0.1	0.0	0.1	0.0	0.3	0.2	0.1	0.1	0.1	0.1
	P	0.8	0.9	0.7	0.7	0.5	0.6	0.6	0.7	0.8	0.8	0.8	0.6	0.6	0.6
<b>C33,C34 TRACHEA AND BRONCHUS &amp; LUNG</b>															
Incidence	M	55.3	51.8	46.8	46.8	44.2	44.6	40.8	40.9	38.1	36.7	38.1	38.1	39.8	36.8
	F	13.0	15.0	16.5	17.9	18.1	16.5	17.9	19.6	20.1	17.2	20.0	20.3	20.0	20.0
	P	32.6	32.2	30.8	31.6	30.4	29.7	28.8	29.7	28.6	26.5	28.7	28.8	29.4	28.0
Mortality	M	44.8	42.2	39.2	36.5	35.6	36.3	33.9	32.4	31.7	29.8	31.2	30.2	30.2	30.8
	F	9.9	10.6	12.4	14.0	13.5	13.6	13.2	14.3	15.2	13.1	14.1	15.8	15.5	15.6
	P	25.9	25.2	24.9	24.5	23.7	24.3	23.0	22.7	23.0	21.0	22.3	22.7	22.4	22.9
<b>C37, C38 THYMUS, HEART, MEDIASTINUM &amp; PLEURA</b>															
Incidence	M	0.4	0.4	0.4	0.5	0.4	0.4	0.3	0.5	0.5	0.4	0.3	0.3	0.2	0.4
	F	0.2	0.2	0.2	0.2	0.3	0.3	0.1	0.1	0.3	0.4	0.2	0.3	0.3	0.2
	P	0.3	0.3	0.3	0.4	0.3	0.4	0.2	0.3	0.4	0.4	0.3	0.3	0.3	0.3
Mortality	M	0.3	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.1	0.0	0.3
	F	0.1	0.1	0.1	0.1	0.0	0.2	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.0
	P	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1
<b>C40,C41 BONES, JOINTS &amp; ARTICULAR CARTILAGES</b>															
Incidence	M	1.0	1.4	1.1	1.3	1.0	0.7	1.1	1.0	1.4	1.3	0.9	0.8	1.3	1.4
	F	0.5	0.7	0.8	0.6	0.7	0.8	1.0	1.0	1.1	0.5	1.2	0.8	0.6	0.6
	P	0.8	1.0	1.0	1.0	0.8	0.8	1.0	1.0	1.2	0.9	1.1	0.8	1.0	1.0
Mortality	M	0.4	0.5	0.5	0.4	0.7	0.4	0.3	0.4	0.5	0.4	0.6	0.3	0.2	0.8
	F	0.2	0.2	0.3	0.2	0.2	0.2	0.4	0.1	0.2	0.4	0.2	0.1	0.3	0.5
	P	0.3	0.4	0.4	0.3	0.5	0.3	0.3	0.3	0.3	0.4	0.4	0.2	0.2	0.6
<b>C44, M872-M879 MELANOMA</b>															
Incidence	M	36.7	46.0	49.7	58.5	56.4	51.4	56.2	56.4	58.9	54.2	48.7	56.1	50.2	52.1
	F	34.7	37.0	37.3	42.5	41.6	39.4	40.6	41.5	44.0	40.0	38.7	40.6	34.7	37.8
	P	35.4	41.2	43.1	50.0	48.7	45.1	48.1	48.6	51.1	46.8	43.4	48.0	42.1	44.6
Mortality	M	4.8	5.5	5.9	5.5	5.9	5.9	5.6	6.1	5.0	6.5	6.2	6.0	4.4	5.7
	F	2.6	2.5	2.5	2.5	3.1	2.9	2.3	2.1	2.1	2.5	2.3	2.5	2.6	2.6
	P	3.6	3.9	4.1	3.9	4.4	4.4	3.8	4.1	3.4	4.4	4.2	4.2	3.4	4.0
<b>C44 OTHER SKIN (EXCL BCC/SCC)</b>															
Incidence	M	1.0	1.7	2.3	1.8	2.1	2.0	2.3	2.2	2.5	2.2	2.4	2.3	2.1	3.0
	F	0.5	0.8	0.9	1.1	1.2	1.2	1.2	1.2	1.4	1.1	1.0	1.5	1.4	1.5
	P	0.7	1.2	1.6	1.4	1.6	1.6	1.7	1.6	1.9	1.6	1.6	1.8	1.7	2.2
Mortality	M	0.1	0.2	0.4	0.5	0.3	0.4	0.5	0.4	0.4	0.2	0.6	0.7	0.3	0.7
	F	0.0	0.0	0.1	0.1	0.1	0.3	0.2	0.2	0.3	0.2	0.0	0.2	0.1	0.1
	P	0.0	0.1	0.2	0.3	0.2	0.3	0.3	0.3	0.4	0.2	0.3	0.4	0.2	0.4

**Table 3. Cancer Incidence and Mortality (ASR (World)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>M905 MESOTHELIOMA</b>															
Incidence	M	1.5	2.1	2.5	3.3	3.4	3.2	3.3	3.4	3.2	3.1	2.9	2.8	3.4	3.3
	F	0.1	0.3	0.4	0.3	0.4	0.4	0.3	0.9	0.7	0.5	0.6	0.5	0.7	0.5
	P	0.8	1.2	1.4	1.8	1.8	1.7	1.8	2.1	1.9	1.7	1.7	1.6	2.0	1.9
Mortality	M	1.2	1.7	2.2	2.4	2.6	2.8	2.7	3.2	2.6	3.1	2.6	2.4	2.5	3.1
	F	0.1	0.2	0.3	0.3	0.3	0.3	0.4	0.4	0.6	0.5	0.4	0.5	0.5	0.5
	P	0.6	0.9	1.2	1.3	1.4	1.5	1.5	1.7	1.5	1.7	1.4	1.4	1.4	1.7
<b>M914 KAPOSI SARCOMA</b>															
Incidence	M	0.1	0.6	0.7	0.2	0.3	0.3	0.4	0.1	0.3	0.1	0.2	0.1	0.2	0.4
	F	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0
	P	0.0	0.3	0.4	0.1	0.1	0.2	0.2	0.0	0.2	0.1	0.1	0.1	0.1	0.2
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVES</b>															
Incidence	M	2.1	1.9	2.0	2.0	2.4	1.9	2.5	2.2	2.5	2.3	2.2	2.0	1.9	1.5
	F	1.5	1.3	1.6	1.8	2.0	1.5	1.7	1.3	1.5	1.1	1.7	2.8	1.9	1.5
	P	1.8	1.6	1.8	1.9	2.2	1.7	2.1	1.8	2.0	1.7	1.9	2.4	1.9	1.5
Mortality	M	0.8	0.6	0.7	0.8	0.7	0.4	0.2	0.8	0.9	0.7	0.6	0.9	1.0	0.4
	F	0.7	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.3	0.5	0.4	0.7	0.9	0.5
	P	0.7	0.5	0.6	0.6	0.6	0.4	0.3	0.7	0.6	0.6	0.5	0.8	1.0	0.5
<b>C48 RETROPERITONEUM &amp; PERITONEUM</b>															
Incidence	M	0.2	0.3	0.2	0.4	0.3	0.3	0.4	0.2	0.3	0.3	0.3	0.3	0.5	0.5
	F	0.4	0.2	0.4	0.5	0.7	1.0	1.0	1.3	0.8	1.1	1.0	0.9	1.4	1.4
	P	0.3	0.3	0.3	0.4	0.5	0.6	0.7	0.8	0.6	0.7	0.7	0.6	0.9	1.0
Mortality	M	0.2	0.2	0.1	0.0	0.4	0.1	0.3	0.1	0.2	0.2	0.1	0.2	0.1	0.2
	F	0.2	0.2	0.1	0.2	0.4	0.4	0.4	0.3	0.5	0.6	0.6	0.5	0.8	0.8
	P	0.2	0.2	0.1	0.1	0.4	0.2	0.4	0.2	0.4	0.4	0.4	0.4	0.4	0.5
<b>C50 BREAST</b>															
Incidence	M	0.7	0.6	0.5	0.7	0.5	0.6	0.7	0.7	0.5	0.5	1.0	0.7	0.8	0.7
	F	60.7	69.3	76.8	82.2	84.6	87.5	88.0	89.2	88.0	83.4	83.3	85.4	86.5	81.8
	P	31.5	35.6	39.1	41.9	43.0	44.4	44.8	45.4	44.6	42.3	42.5	43.5	44.0	41.7
Mortality	M	0.2	0.1	0.2	0.1	0.0	0.0	0.2	0.2	0.0	0.1	0.2	0.2	0.1	0.1
	F	18.2	18.6	18.5	17.1	16.8	15.8	15.0	16.4	14.7	14.9	14.6	14.6	13.1	13.8
	P	9.6	9.7	9.7	8.9	8.7	8.2	7.8	8.5	7.6	7.7	7.6	7.6	6.7	7.2
<b>C51 VULVA</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	1.5	1.3	1.4	1.8	1.2	1.1	1.1	1.6	1.4	1.0	1.3	1.1	1.4	1.4
	P	0.8	0.7	0.7	0.9	0.6	0.6	0.6	0.8	0.7	0.5	0.7	0.6	0.7	0.7
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	0.2	0.3	0.3	0.3	0.3	0.3	0.2	0.1	0.3	0.1	0.4	0.2	0.2	0.3
	P	0.1	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1	0.2
<b>C53 CERVIX UTERI</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	12.9	11.5	10.0	8.2	7.6	8.7	7.4	6.6	6.1	6.2	5.8	6.9	7.3	5.2
	P	6.5	5.8	5.0	4.1	3.8	4.4	3.7	3.4	3.1	3.2	2.9	3.5	3.7	2.6
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	3.2	2.8	2.5	2.0	2.4	1.7	2.4	1.9	1.2	1.2	1.7	1.5	1.8	1.1
	P	1.6	1.5	1.3	1.0	1.2	0.9	1.2	1.0	0.6	0.6	0.8	0.7	0.9	0.6
<b>C54 CORPUS UTERI</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	9.6	9.1	10.3	10.3	10.3	10.4	12.5	11.6	11.7	11.1	11.6	11.7	11.0	11.7
	P	5.0	4.7	5.3	5.2	5.2	5.3	6.3	5.9	5.9	5.6	5.8	5.9	5.6	5.9
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	1.7	1.5	1.7	1.8	1.2	1.7	1.6	1.8	1.8	1.6	2.0	2.0	1.7	2.0
	P	0.9	0.8	0.9	1.0	0.7	0.9	0.9	0.9	0.9	0.9	0.8	1.0	0.9	1.0
<b>C56 OVARY</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	9.6	9.1	9.6	7.9	8.4	8.2	8.0	8.7	8.3	6.9	7.2	7.6	7.4	6.7
	P	4.9	4.7	4.9	4.0	4.3	4.2	4.1	4.4	4.2	3.5	3.7	3.9	3.8	3.4
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	5.7	5.1	5.0	3.7	4.2	4.4	3.7	3.8	4.4	4.3	4.0	3.9	3.8	3.8
	P	3.0	2.7	2.6	1.9	2.2	2.3	1.9	2.0	2.3	2.2	2.0	2.1	1.9	2.0

**Table 3. Cancer Incidence and Mortality (ASR (World)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANS</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	1.4	1.1	1.0	1.0	1.1	1.0	1.3	0.9	1.1	0.8	1.7	1.8	1.4	1.6
	P	0.7	0.6	0.5	0.5	0.6	0.5	0.7	0.5	0.6	0.4	0.9	0.9	0.7	0.8
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	0.4	0.4	0.4	0.4	0.4	0.3	0.4	0.5	0.3	0.4	0.5	0.9	0.6	0.4
	P	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.1	0.2	0.3	0.5	0.3	0.2
<b>C61 PROSTATE GLAND</b>															
Incidence	M	47.2	55.0	84.0	70.0	71.8	71.5	73.2	74.3	82.7	94.8	104.3	99.5	108.9	117.7
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	20.5	24.2	38.4	32.6	33.6	33.4	34.6	35.4	39.6	45.7	50.7	48.4	53.4	57.8
Mortality	M	14.5	17.0	19.7	16.9	16.6	15.3	17.2	16.3	15.7	15.6	16.4	14.2	14.4	14.9
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	6.0	7.1	8.3	7.2	7.1	6.4	7.4	7.1	6.9	6.8	7.1	6.3	6.3	6.6
<b>C62 TESTIS</b>															
Incidence	M	4.2	3.9	5.2	4.7	5.6	5.9	4.4	5.4	6.8	5.5	5.5	6.1	6.2	5.1
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	2.1	2.0	2.6	2.4	2.8	2.9	2.2	2.7	3.4	2.7	2.7	3.0	3.1	2.6
Mortality	M	0.5	0.3	0.3	0.4	0.1	0.1	0.2	0.1	0.1	0.2	0.3	0.2	0.2	0.2
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.3	0.2	0.1	0.2	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1
<b>C60,C63 PENIS AND OTHER &amp; UNSPECIFIED MALE GENITAL ORGANS</b>															
Incidence	M	0.7	0.7	0.8	0.7	0.7	0.6	0.7	0.8	0.7	0.6	0.6	0.4	0.5	0.7
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.2	0.2	0.3
Mortality	M	0.1	0.2	0.2	0.0	0.2	0.1	0.2	0.2	0.1	0.1	0.1	0.2	0.1	0.1
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0
<b>C64-C66,C68 KIDNEY AND OTHER RENAL TRACT</b>															
Incidence	M	8.9	9.3	11.3	11.7	11.5	12.7	12.6	10.7	9.8	10.9	10.8	12.0	13.0	12.5
	F	5.2	6.2	6.6	6.0	6.3	7.5	6.1	6.5	6.5	5.6	6.2	5.4	7.0	6.2
	P	7.0	7.6	8.9	8.8	8.9	10.0	9.2	8.6	8.1	8.2	8.4	8.6	9.9	9.2
Mortality	M	3.7	3.8	4.2	3.8	3.3	4.1	3.7	3.7	3.2	3.5	3.3	3.2	3.3	3.4
	F	2.1	2.7	2.4	1.8	2.4	2.2	2.1	1.9	2.1	1.7	2.0	1.6	1.8	1.4
	P	2.8	3.2	3.2	2.7	2.9	3.2	2.8	2.8	2.6	2.6	2.6	2.3	2.5	2.4
<b>C67 BLADDER</b>															
Incidence	M	19.2	18.9	19.9	21.1	20.9	18.6	19.8	19.9	18.4	17.9	17.3	16.9	16.3	10.6
	F	5.4	5.4	5.8	5.7	5.4	5.3	6.0	4.6	5.0	5.0	5.2	3.8	4.1	3.2
	P	11.7	11.6	12.4	12.9	12.6	11.5	12.4	11.9	11.3	11.1	10.9	10.0	9.9	6.7
Mortality	M	4.3	4.3	4.4	4.4	3.9	4.5	3.8	3.9	3.9	3.7	3.3	3.4	3.6	3.4
	F	1.3	1.2	1.4	1.6	1.0	0.9	1.1	1.3	1.1	1.2	1.3	1.1	1.1	1.0
	P	2.6	2.5	2.6	2.8	2.3	2.5	2.3	2.5	2.3	2.3	2.2	2.1	2.2	2.1
<b>C69 EYE &amp; ADNEXA</b>															
Incidence	M	1.2	1.3	1.8	1.3	2.3	1.5	1.0	1.9	1.3	1.8	0.8	1.4	1.6	1.1
	F	0.7	0.9	1.0	0.7	0.8	1.2	0.9	1.4	0.7	0.8	0.8	0.9	1.0	1.0
	P	1.0	1.1	1.4	1.0	1.5	1.3	0.9	1.6	1.0	1.3	0.8	1.2	1.3	1.1
Mortality	M	0.2	0.3	0.2	0.2	0.1	0.4	0.3	0.1	0.2	0.2	0.3	0.2	0.1	0.2
	F	0.1	0.2	0.2	0.2	0.1	0.2	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1
	P	0.2	0.2	0.2	0.2	0.1	0.3	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.2
<b>C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM</b>															
Incidence	M	6.0	6.2	6.4	7.3	6.3	6.4	6.6	6.4	6.2	5.9	7.0	6.9	6.8	6.5
	F	4.7	4.7	4.6	4.9	4.1	4.7	5.6	5.0	4.3	4.0	3.4	4.6	4.0	4.1
	P	5.3	5.4	5.5	6.1	5.2	5.6	6.1	5.7	5.2	5.0	5.2	5.7	5.4	5.3
Mortality	M	4.7	4.6	4.5	5.8	5.1	5.1	5.0	4.2	4.7	4.7	5.1	4.7	5.1	4.4
	F	3.1	3.5	3.5	3.9	3.1	3.3	3.7	3.0	3.6	3.3	2.8	2.6	3.0	2.8
	P	3.9	4.1	4.0	4.8	4.1	4.2	4.3	3.6	4.2	3.9	3.9	3.7	4.1	3.6
<b>C73 THYROID GLAND</b>															
Incidence	M	1.4	1.3	1.8	2.0	2.7	2.8	2.4	2.9	3.0	3.6	2.8	3.4	3.5	4.0
	F	3.3	3.8	5.5	6.6	6.6	7.1	8.8	8.0	8.7	8.8	9.9	11.2	11.2	13.6
	P	2.3	2.6	3.7	4.3	4.6	5.0	5.6	5.4	5.9	6.2	6.4	7.3	7.4	8.8
Mortality	M	0.2	0.4	0.3	0.2	0.2	0.2	0.2	0.3	0.4	0.3	0.2	0.4	0.5	0.3
	F	0.2	0.2	0.2	0.2	0.1	0.3	0.1	0.3	0.2	0.2	0.3	0.2	0.3	0.2
	P	0.2	0.3	0.2	0.2	0.2	0.2	0.1	0.3	0.3	0.2	0.3	0.3	0.4	0.2

**Table 3. Cancer Incidence and Mortality (ASR (World)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C74,C75 ADRENAL AND OTHER ENDOCRINE GLANDS</b>															
Incidence	M	0.3	0.5	0.5	0.8	0.4	0.4	0.6	0.8	0.2	0.5	0.2	0.5	0.6	0.3
	F	0.2	0.5	0.4	0.4	0.3	0.6	0.3	0.4	0.5	0.4	0.6	0.3	0.5	0.2
	P	0.3	0.5	0.5	0.6	0.4	0.5	0.4	0.6	0.3	0.4	0.4	0.4	0.5	0.3
Mortality	M	0.3	0.2	0.3	0.2	0.1	0.2	0.3	0.2	0.2	0.4	0.1	0.2	0.1	0.3
	F	0.1	0.3	0.2	0.1	0.1	0.2	0.3	0.0	0.4	0.2	0.2	0.2	0.3	0.1
	P	0.2	0.2	0.2	0.1	0.1	0.2	0.3	0.1	0.3	0.3	0.1	0.2	0.2	0.2
<b>C26, C39,C76,C77,C80 OTHER &amp; ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE</b>															
Incidence	M	12.5	12.5	13.1	11.7	12.5	10.8	10.5	10.0	10.7	9.5	10.0	9.7	9.7	10.4
	F	8.2	8.1	9.0	7.8	8.8	8.3	8.7	6.2	6.9	6.2	6.4	7.0	7.0	7.8
	P	10.1	10.1	10.9	9.7	10.6	9.5	9.5	8.1	8.8	7.8	8.2	8.3	8.4	9.1
Mortality	M	10.0	9.4	9.6	9.0	9.4	7.2	7.6	6.8	7.7	6.3	6.5	6.5	6.3	5.9
	F	6.4	6.1	6.8	5.2	7.0	7.0	6.6	4.8	5.7	4.5	4.5	4.4	4.3	4.3
	P	8.0	7.7	8.1	7.0	8.2	7.1	7.1	5.7	6.7	5.3	5.5	5.4	5.2	5.1
<b>M959-M972 ALL LYMPHOMAS</b>															
Incidence	M	12.0	12.9	14.3	15.6	14.9	14.7	15.2	15.6	15.2	15.7	14.8	16.1	16.4	15.6
	F	8.8	9.7	10.4	10.2	11.7	12.2	10.9	11.8	10.8	10.5	10.7	12.2	13.4	11.5
	P	10.3	11.2	12.3	12.9	13.2	13.3	13.0	13.7	12.9	13.0	12.8	14.1	14.8	13.5
Mortality	M	5.5	5.5	5.8	6.7	5.8	5.5	5.7	4.4	5.0	4.8	4.5	3.3	4.2	3.4
	F	3.4	3.5	3.6	4.5	4.1	3.3	3.2	3.2	4.1	2.9	3.1	2.6	2.3	2.3
	P	4.4	4.5	4.6	5.5	5.0	4.4	4.4	3.8	4.4	3.8	3.7	2.9	3.2	2.8
<b>M965-M966 HODGKIN LYMPHOMA</b>															
Incidence	M	2.1	2.0	1.8	1.9	1.9	1.8	1.7	2.1	2.1	2.0	1.2	2.3	2.4	2.1
	F	1.1	1.4	1.5	1.7	1.8	1.8	1.1	1.7	1.7	1.6	1.6	1.7	2.6	1.7
	P	1.6	1.7	1.7	1.8	1.8	1.8	1.4	1.9	1.9	1.8	1.4	2.0	2.4	1.9
Mortality	M	0.7	0.4	0.3	0.6	0.3	0.3	0.1	0.3	0.4	0.3	0.3	0.2	0.5	0.4
	F	0.4	0.3	0.2	0.4	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.3	0.1
	P	0.5	0.3	0.3	0.5	0.2	0.2	0.1	0.2	0.3	0.2	0.2	0.2	0.4	0.3
<b>M959,M967-M972 NON-HODGKIN LYMPHOMA</b>															
Incidence	M	9.8	10.9	12.5	13.8	13.0	12.8	13.6	13.6	13.1	13.7	13.6	13.7	14.1	13.5
	F	7.7	8.3	8.8	8.5	9.8	10.4	9.8	10.2	9.1	8.9	9.2	10.5	10.8	9.9
	P	8.7	9.5	10.6	11.1	11.4	11.5	11.8	11.0	11.3	11.4	12.1	12.4	12.4	11.6
Mortality	M	4.8	5.1	5.4	6.2	5.5	5.1	5.6	4.1	4.6	4.5	4.2	3.0	3.7	2.9
	F	3.1	3.3	3.4	4.1	4.1	3.3	3.1	3.1	3.9	2.9	2.9	2.4	2.0	2.2
	P	3.9	4.2	4.4	5.0	4.8	4.2	4.3	3.6	4.2	3.7	3.5	2.7	2.9	2.5
<b>M980-M994 ALL LEUKAEMIAS</b>															
Incidence	M	12.2	11.5	13.6	12.1	13.8	14.4	13.1	12.3	12.9	12.6	12.4	10.7	11.0	12.4
	F	7.0	7.5	8.7	8.4	8.7	8.0	7.9	9.2	8.3	8.2	7.1	7.0	8.5	7.0
	P	9.4	9.3	11.0	10.2	11.1	11.1	10.4	10.7	10.5	10.3	9.7	8.7	9.7	9.6
Mortality	M	6.3	6.0	6.4	5.8	6.3	5.7	4.8	4.8	5.3	4.8	4.5	4.5	3.9	4.3
	F	3.6	3.8	3.8	3.3	3.6	3.8	3.2	2.8	2.6	2.9	3.3	2.1	2.3	2.6
	P	4.8	4.8	5.0	4.4	4.8	4.7	3.9	3.8	3.9	3.8	3.8	3.2	3.0	3.4
<b>M982-M983 LYMPHOID LEUKAEMIA</b>															
Incidence	M	6.1	5.5	6.7	5.8	8.0	8.1	7.0	6.3	6.7	6.6	6.7	5.6	6.3	6.2
	F	3.2	3.5	4.6	3.7	4.7	4.0	4.9	5.2	4.9	4.6	3.3	3.6	4.7	3.3
	P	4.6	4.4	5.6	4.8	6.3	6.0	5.9	5.7	5.7	5.6	5.0	4.6	5.5	4.7
Mortality	M	2.0	1.9	2.4	2.2	2.4	2.4	1.3	2.1	1.9	2.0	1.5	1.6	1.4	1.3
	F	1.0	1.1	1.3	1.0	1.5	1.1	1.3	0.9	1.0	0.9	1.4	0.6	0.6	0.8
	P	1.5	1.5	1.8	1.5	2.0	1.8	1.3	1.5	1.4	1.4	1.4	1.1	1.0	1.0
<b>M984-M993 MYELOID LEUKAEMIA</b>															
Incidence	M	5.1	5.1	5.5	5.4	4.7	5.0	4.9	4.0	4.8	4.9	4.2	3.7	3.6	4.4
	F	3.3	3.6	3.7	4.1	3.4	3.7	2.5	3.6	2.8	3.1	3.3	2.8	3.0	3.0
	P	4.1	4.2	4.6	4.7	3.9	4.3	3.7	3.8	3.8	3.9	3.7	3.2	3.3	3.6
Mortality	M	3.8	3.6	3.6	3.2	3.7	3.0	2.8	2.4	2.8	2.4	2.6	2.1	2.1	2.7
	F	2.4	2.4	2.3	2.2	1.9	2.4	1.8	1.6	1.5	1.8	1.6	1.3	1.4	1.6
	P	3.0	2.9	2.9	2.7	2.7	2.6	2.3	2.0	2.1	2.1	2.1	1.7	1.7	2.1
<b>M994 OTHER SPECIFIED LEUKAEMIA</b>															
Incidence	M	0.4	0.4	0.9	0.7	0.9	1.0	1.0	1.9	1.3	1.0	1.4	1.2	1.1	1.5
	F	0.2	0.1	0.2	0.2	0.3	0.1	0.3	0.4	0.6	0.3	0.5	0.5	0.5	0.6
	P	0.3	0.3	0.5	0.4	0.6	0.5	0.6	1.1	0.9	0.6	0.9	0.9	0.8	1.0
Mortality	M	0.1	0.1	0.2	0.2	0.2	0.2	0.5	0.3	0.5	0.3	0.3	0.7	0.4	0.3
	F	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.2	0.1	0.2	0.2	0.2	0.2	0.1
	P	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.3	0.3	0.2	0.4	0.3	0.2

**Table 3. Cancer Incidence and Mortality (ASR (World)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>M980 UNSPECIFIED LEUKAEMIA</b>															
Incidence	M	0.5	0.5	0.4	0.2	0.2	0.3	0.3	0.0	0.1	0.2	0.2	0.1	0.0	0.3
	F	0.3	0.2	0.2	0.3	0.2	0.2	0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.1
	P	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.2
Mortality	M	0.3	0.4	0.2	0.2	0.1	0.2	0.2	0.0	0.1	0.1	0.0	0.1	0.0	0.1
	F	0.2	0.2	0.2	0.1	0.1	0.3	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1
	P	0.3	0.3	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
<b>M973 MYELOMA/PLASMA CELL TUMOURS</b>															
Incidence	M	3.5	3.7	3.7	4.4	5.4	4.5	4.6	4.5	3.8	3.9	3.4	3.9	4.1	4.0
	F	2.5	2.1	2.6	2.8	3.0	3.3	3.7	3.4	2.3	2.6	2.8	2.6	2.7	2.5
	P	3.0	2.8	3.0	3.6	4.1	3.8	4.1	3.9	3.0	3.2	3.1	3.2	3.4	3.2
Mortality	M	1.9	2.6	2.0	2.2	2.6	2.6	2.4	2.5	2.3	1.8	2.2	2.0	1.6	1.9
	F	1.4	1.4	1.5	1.5	1.3	1.1	1.5	1.3	1.4	1.4	1.5	1.4	1.1	1.3
	P	1.6	1.9	1.7	1.8	2.0	1.8	1.9	1.8	1.8	1.5	1.8	1.7	1.4	1.6
<b>M998 MYELOYDYSPLASTIC DISEASES</b>															
Incidence	M	0.2	0.7	1.3	1.8	2.4	2.8	3.4	4.6	4.0	4.4	3.8	3.3	3.5	3.7
	F	0.1	0.4	0.7	1.1	1.0	1.8	2.2	2.2	2.7	2.0	2.3	1.9	2.2	1.9
	P	0.2	0.5	0.9	1.4	1.7	2.2	2.7	3.2	3.3	3.1	2.9	2.5	2.8	2.7
Mortality	M	0.1	0.2	0.3	0.7	0.7	0.4	0.8	1.2	1.4	1.1	1.3	1.5	1.2	1.3
	F	0.0	0.1	0.1	0.4	0.2	0.4	0.4	0.5	0.6	0.5	0.5	0.9	0.8	0.6
	P	0.1	0.1	0.2	0.5	0.4	0.4	0.5	0.8	0.9	0.8	0.8	1.1	1.0	0.9
<b>M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASES</b>															
Incidence	M	1.7	1.8	3.2	4.0	3.7	3.5	4.3	3.1	3.2	3.3	2.5	3.0	2.6	2.8
	F	1.1	1.5	2.4	2.4	2.9	2.6	2.6	2.3	1.6	2.1	2.1	1.5	1.9	2.0
	P	1.4	1.7	2.8	3.2	3.2	3.0	3.5	2.7	2.4	2.7	2.3	2.2	2.3	2.4
Mortality	M	0.3	0.3	0.3	0.7	0.4	0.7	0.3	0.2	0.5	0.4	0.5	0.3	0.2	0.6
	F	0.1	0.2	0.2	0.4	0.2	0.4	0.2	0.2	0.1	0.4	0.2	0.2	0.4	0.2
	P	0.2	0.3	0.2	0.5	0.3	0.5	0.3	0.2	0.3	0.4	0.3	0.3	0.3	0.4
<b>M974-M976 OTHER NEOPLASMS OF LYMPHATIC &amp; HAEMATOPOIETIC TISSUE</b>															
Incidence	M	0.3	0.1	0.2	0.4	0.2	0.3	0.6	0.5	0.5	0.6	0.4	0.1	0.3	0.4
	F	0.1	0.1	0.2	0.2	0.1	0.1	0.4	0.1	0.3	0.3	0.4	0.2	0.2	0.2
	P	0.2	0.1	0.2	0.3	0.2	0.2	0.5	0.3	0.4	0.4	0.4	0.2	0.2	0.3
Mortality	M	0.1	0.1	0.0	0.2	0.1	0.1	0.0	0.2	0.0	0.1	0.1	0.0	0.1	0.1
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.1
	P	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>															
Incidence	M	327.1	349.3	394.3	391.5	390.5	376.3	384.2	383.0	382.5	385.6	391.1	392.8	403.7	406.2
	F	249.0	263.7	284.4	292.5	298.1	297.7	304.1	300.8	302.1	281.8	287.4	296.2	298.1	287.8
	P	281.9	300.3	333.4	337.5	339.7	332.4	340.1	338.4	338.9	330.3	336.5	341.9	348.3	344.7
Mortality	M	153.4	155.5	156.0	151.1	147.7	143.2	141.7	137.8	135.9	130.7	132.4	126.9	123.5	127.8
	F	93.4	94.0	94.3	94.2	91.1	88.8	86.9	85.7	87.4	83.0	84.2	84.0	79.5	81.3
	P	120.0	121.3	122.0	119.9	116.8	113.4	111.8	109.8	109.6	104.8	106.3	103.9	99.6	102.9

**Table 4. Cancer Incidence and Mortality (ASR (Aust 2001)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C00 LIP</b>															
Incidence	M	9.9	13.3	15.2	15.1	17.9	8.8	7.5	8.7	10.8	8.6	7.6	8.2	9.6	6.8
	F	1.8	3.2	3.7	5.1	5.5	2.5	2.9	3.0	4.3	2.8	2.5	2.4	2.3	2.0
	P	5.7	8.0	9.2	10.0	11.4	5.4	5.1	5.8	7.4	5.7	4.9	5.2	5.8	4.3
Mortality	M	0.3	0.2	0.3	0.3	0.2	0.4	0.2	0.2	0.3	0.3	0.5	0.6	0.0	0.1
	F	0.1	0.1	0.0	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.0	0.1	0.1	0.1
	P	0.1	0.1	0.1	0.2	0.2	0.3	0.2	0.1	0.2	0.2	0.3	0.3	0.0	0.1
<b>C01,C02 TONGUE</b>															
Incidence	M	4.1	4.4	4.2	3.7	3.9	4.3	3.3	3.8	4.0	3.3	4.3	4.1	3.1	4.1
	F	1.4	1.7	1.7	2.3	1.8	2.2	1.8	1.3	1.4	1.7	1.6	1.8	1.4	2.2
	P	2.7	3.0	3.0	3.1	2.8	3.3	2.6	2.5	2.7	2.5	3.0	2.9	2.2	3.2
Mortality	M	1.7	1.9	1.7	1.9	2.3	1.4	1.6	1.4	1.8	1.4	2.1	1.7	1.1	1.0
	F	0.4	0.7	0.6	0.4	0.6	0.7	1.0	0.8	0.7	0.7	0.7	0.7	0.5	0.5
	P	1.0	1.3	1.1	1.1	1.4	1.1	1.3	1.1	1.2	1.0	1.3	1.2	0.8	0.8
<b>C03 GUM</b>															
Incidence	M	0.3	0.3	0.6	0.4	0.2	0.6	0.6	0.3	0.2	0.5	0.6	0.6	0.4	0.5
	F	0.3	0.2	0.3	0.1	0.4	0.3	0.3	0.4	0.3	0.4	0.4	0.4	0.6	0.4
	P	0.3	0.2	0.4	0.2	0.3	0.5	0.5	0.4	0.2	0.4	0.5	0.5	0.5	0.4
Mortality	M	0.1	0.1	0.3	0.0	0.2	0.0	0.1	0.3	0.2	0.3	0.2	0.3	0.2	0.1
	F	0.1	0.1	0.1	0.3	0.1	0.2	0.2	0.2	0.2	0.0	0.1	0.1	0.0	0.3
	P	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0.1	0.2
<b>C04 FLOOR OF MOUTH</b>															
Incidence	M	1.9	1.5	1.5	1.3	1.5	1.6	1.8	1.1	0.9	1.1	1.0	1.5	1.0	1.3
	F	0.6	0.6	0.5	0.3	0.8	0.5	0.8	0.4	0.5	0.6	0.3	0.9	0.4	0.3
	P	1.3	1.0	1.0	0.8	1.2	1.1	1.3	0.8	0.7	0.8	0.6	1.2	0.7	0.8
Mortality	M	0.7	0.6	0.7	0.5	0.6	0.7	0.7	0.4	0.3	0.6	0.5	0.6	0.4	0.4
	F	0.2	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.2	0.1	0.1	0.3	0.1	0.2
	P	0.4	0.3	0.4	0.3	0.3	0.5	0.4	0.3	0.3	0.3	0.3	0.5	0.2	0.3
<b>C05,C06 PALATE AND OTHER &amp; UNSPECIFIED PARTS OF MOUTH</b>															
Incidence	M	2.5	2.1	1.7	2.1	1.9	1.3	1.5	1.3	1.9	1.3	1.5	2.0	1.7	2.1
	F	0.8	1.2	1.3	1.3	0.9	0.9	1.1	0.6	0.6	0.9	0.9	0.9	1.2	0.9
	P	1.7	1.6	1.5	1.7	1.4	1.1	1.3	1.0	1.2	1.1	1.2	1.4	1.5	1.5
Mortality	M	0.9	0.7	0.8	0.7	0.6	0.4	0.4	0.6	0.4	0.4	0.7	0.8	0.8	0.7
	F	0.3	0.5	0.4	0.2	0.1	0.5	0.4	0.4	0.3	0.4	0.3	0.5	0.4	0.2
	P	0.6	0.6	0.6	0.4	0.3	0.5	0.4	0.5	0.4	0.5	0.5	0.6	0.6	0.5
<b>C07,C08 PAROTID AND OTHER &amp; UNSPECIFIED MAJOR SALIVARY GLANDS</b>															
Incidence	M	1.8	1.7	1.9	2.0	2.2	1.7	2.1	2.1	2.0	1.9	2.1	1.8	3.1	2.0
	F	0.9	0.8	1.1	0.9	1.1	0.9	0.8	1.0	0.8	0.9	1.0	1.0	1.2	1.2
	P	1.2	1.2	1.4	1.4	1.6	1.3	1.4	1.5	1.3	1.3	1.4	1.4	2.0	1.6
Mortality	M	0.5	0.7	0.5	0.6	0.5	0.3	0.5	0.6	0.8	0.6	0.3	0.9	1.0	0.4
	F	0.2	0.2	0.3	0.2	0.2	0.3	0.3	0.1	0.3	0.3	0.1	0.3	0.0	0.1
	P	0.3	0.4	0.4	0.3	0.3	0.3	0.4	0.3	0.6	0.4	0.2	0.5	0.4	0.2
<b>C09,C10 TONSIL AND OROPHARYNX</b>															
Incidence	M	2.8	2.1	2.7	2.4	3.2	2.6	2.2	2.8	2.5	2.8	2.9	3.2	3.5	3.9
	F	0.7	0.7	0.6	0.6	0.6	0.8	0.6	0.7	0.8	0.7	0.7	0.8	0.7	0.9
	P	1.7	1.4	1.6	1.5	1.9	1.7	1.4	1.7	1.7	1.7	1.8	2.0	2.1	2.4
Mortality	M	1.4	1.2	1.3	0.8	1.3	0.9	1.1	1.2	1.2	1.2	1.0	1.2	1.3	1.1
	F	0.4	0.3	0.3	0.3	0.2	0.5	0.2	0.2	0.3	0.3	0.4	0.3	0.1	0.3
	P	0.9	0.7	0.8	0.5	0.7	0.7	0.6	0.7	0.8	0.7	0.7	0.7	0.7	0.7
<b>C11 NASOPHARYNX</b>															
Incidence	M	1.1	0.8	0.9	1.0	0.6	0.6	0.7	0.5	0.5	0.5	0.5	0.8	0.7	0.5
	F	0.3	0.3	0.4	0.1	0.1	0.2	0.3	0.2	0.1	0.1	0.3	0.2	0.4	0.1
	P	0.7	0.5	0.6	0.5	0.4	0.4	0.5	0.3	0.3	0.3	0.3	0.5	0.5	0.3
Mortality	M	0.7	0.5	0.6	0.7	0.4	0.6	0.2	0.1	0.1	0.1	0.2	0.4	0.3	0.2
	F	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.0	0.1	0.1	0.1
	P	0.4	0.3	0.4	0.4	0.3	0.4	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.2
<b>C12,C13 PYRIFORM SINUS AND HYPOPHARYNX</b>															
Incidence	M	2.2	2.5	2.3	1.8	2.1	2.0	1.9	2.0	1.2	1.3	1.7	1.4	1.2	1.8
	F	0.3	0.3	0.3	0.4	0.1	0.1	0.4	0.3	0.3	0.1	0.3	0.4	0.4	0.2
	P	1.1	1.3	1.3	1.1	1.1	1.0	1.2	1.1	0.8	0.7	1.0	0.9	0.8	0.9
Mortality	M	1.1	1.6	1.3	1.6	1.1	1.2	1.1	1.2	1.4	1.2	0.9	0.8	1.1	0.9
	F	0.2	0.1	0.1	0.4	0.1	0.1	0.1	0.3	0.4	0.0	0.2	0.2	0.2	0.2
	P	0.6	0.8	0.7	1.0	0.6	0.6	0.6	0.7	0.8	0.6	0.5	0.5	0.6	0.5

**Table 4. Cancer Incidence and Mortality (ASR (Aust 2001)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C14 OTHER &amp; ILL-DEFINED SITES IN LIP, ORAL CAVITY &amp; PHARYNX</b>															
Incidence	M	0.7	0.9	0.8	0.7	1.1	0.5	1.2	0.9	0.7	1.1	0.6	1.1	1.0	1.2
	F	0.1	0.2	0.2	0.2	0.2	0.5	0.4	0.1	0.2	0.1	0.1	0.2	0.2	0.0
	P	0.4	0.5	0.5	0.4	0.6	0.5	0.8	0.5	0.5	0.6	0.4	0.7	0.6	0.6
Mortality	M	0.3	0.6	0.5	0.5	0.6	0.2	0.5	0.5	0.3	0.5	0.6	0.8	0.5	0.5
	F	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.0	0.1	0.0
	P	0.2	0.3	0.3	0.3	0.3	0.2	0.3	0.4	0.2	0.3	0.3	0.4	0.3	0.3
<b>C15 OESOPHAGUS</b>															
Incidence	M	5.7	7.4	8.7	7.7	8.1	10.6	9.2	8.4	8.5	8.2	7.9	8.1	8.6	8.6
	F	2.8	3.5	3.5	4.1	3.8	3.1	3.6	3.5	2.4	3.2	3.7	2.7	3.2	3.4
	P	4.2	5.4	5.9	5.8	5.7	6.5	6.3	5.8	5.3	5.6	5.7	5.2	5.8	5.8
Mortality	M	4.9	5.8	7.0	5.1	6.7	6.1	6.8	6.6	6.9	6.5	6.9	5.8	6.7	6.6
	F	2.3	2.5	2.6	2.8	2.5	2.3	2.5	2.7	2.4	2.1	2.4	2.8	1.9	2.7
	P	3.6	4.0	4.7	4.0	4.5	4.0	4.4	4.5	4.4	4.2	4.5	4.2	4.1	4.5
<b>C16 STOMACH</b>															
Incidence	M	20.7	18.7	16.3	15.0	14.2	17.0	14.4	13.2	13.0	13.5	13.5	11.8	12.8	10.2
	F	8.7	6.8	7.3	6.9	5.9	5.4	6.7	5.4	6.0	4.8	5.2	5.5	4.8	4.9
	P	13.9	12.0	11.3	10.4	9.6	10.4	10.2	9.0	9.2	8.8	8.9	8.5	8.5	7.3
Mortality	M	16.7	14.1	12.0	12.5	10.4	11.3	10.8	9.9	10.5	9.4	9.1	8.4	7.9	7.8
	F	6.9	5.3	4.9	4.7	4.0	3.7	3.7	3.9	3.4	4.0	4.0	3.9	2.7	3.7
	P	11.1	9.0	8.1	8.2	6.8	7.0	6.9	6.5	6.7	6.5	6.3	6.0	5.1	5.5
<b>C17 SMALL INTESTINE</b>															
Incidence	M	1.3	1.3	1.4	2.0	2.1	2.3	2.0	1.8	1.8	1.7	1.8	2.3	2.0	2.4
	F	1.0	1.0	1.0	1.0	1.1	1.8	1.2	1.2	1.3	1.1	1.6	2.1	1.7	1.7
	P	1.1	1.2	1.2	1.5	1.6	1.9	1.6	1.5	1.5	1.4	1.7	2.2	1.8	2.1
Mortality	M	0.6	0.7	0.6	0.8	0.9	0.8	0.9	0.9	0.7	0.8	0.5	0.8	0.8	0.8
	F	0.5	0.6	0.5	0.7	0.4	0.4	0.7	0.5	0.6	0.5	0.3	0.5	0.8	0.8
	P	0.5	0.6	0.6	0.7	0.6	0.6	0.8	0.7	0.6	0.6	0.4	0.6	0.8	0.8
<b>C18-C20, C218 COLORECTAL</b>															
Incidence	M	68.1	74.8	78.3	80.3	75.7	76.8	84.1	84.4	76.2	73.5	80.3	76.7	77.7	77.4
	F	54.5	52.9	57.4	55.8	57.5	57.0	57.1	55.2	56.8	54.2	52.5	55.8	58.8	54.9
	P	60.6	62.8	67.0	67.4	66.0	66.4	69.7	69.1	65.9	63.2	65.6	65.8	67.7	65.6
Mortality	M	32.7	35.3	34.0	34.9	32.7	34.0	32.5	31.1	28.5	27.2	27.7	29.2	27.9	26.6
	F	25.7	24.6	22.2	24.6	22.0	20.5	20.5	20.7	21.2	19.6	19.3	17.9	17.0	19.6
	P	28.8	29.4	27.4	29.1	27.0	26.6	26.1	25.7	24.7	23.2	23.0	23.2	22.0	22.9
<b>C18 COLON</b>															
Incidence	M	45.5	50.2	48.8	51.4	48.6	49.0	54.3	54.5	47.6	46.8	50.0	48.8	49.0	49.9
	F	41.2	39.4	41.9	40.0	41.6	42.6	41.7	39.9	40.8	38.0	36.3	40.4	41.7	39.8
	P	43.1	44.3	45.0	45.4	44.8	45.5	47.4	46.9	44.0	42.0	42.7	44.3	45.1	44.6
Mortality	M	22.1	23.1	20.8	22.9	20.5	22.2	20.1	19.9	19.9	16.4	18.0	18.3	18.1	16.0
	F	19.8	19.0	16.2	18.0	15.7	15.2	15.0	15.2	15.6	13.7	12.9	12.8	12.6	14.2
	P	20.8	20.9	18.2	20.1	18.0	18.3	17.3	17.5	17.6	14.9	15.2	15.3	15.0	15.0
<b>C19, C20 RECTOSIGMOID JUNCTION AND RECTUM</b>															
Incidence	M	22.5	24.5	29.2	28.6	27.0	27.4	29.4	29.4	28.1	26.5	29.8	27.5	28.2	26.8
	F	13.1	13.3	15.3	15.7	15.8	14.1	14.9	15.0	15.3	15.7	15.7	14.6	16.3	14.6
	P	17.4	18.4	21.7	21.9	21.1	20.6	21.8	21.9	21.3	20.8	22.5	20.9	21.9	20.5
Mortality	M	10.6	12.1	13.1	11.8	11.8	11.8	12.2	11.1	8.6	10.5	9.4	10.8	9.6	10.4
	F	5.9	5.6	5.9	6.5	6.1	5.2	5.3	5.3	5.5	5.8	6.2	5.1	4.3	5.2
	P	8.0	8.4	9.2	8.9	8.8	8.2	8.5	8.1	7.0	8.0	7.6	7.8	6.8	7.7
<b>C21 ANUS &amp; ANAL CANAL</b>															
Incidence	M	0.7	0.9	1.4	0.9	1.3	1.4	0.8	1.2	1.5	1.2	1.5	2.1	1.3	1.3
	F	1.0	1.3	1.2	1.0	1.0	1.3	1.5	1.1	1.8	1.9	1.5	2.1	2.4	1.4
	P	0.9	1.1	1.3	1.0	1.2	1.4	1.2	1.1	1.6	1.6	1.5	2.1	1.9	1.3
Mortality	M	0.2	0.3	0.4	0.4	0.7	0.3	0.4	0.1	0.3	0.6	0.6	0.5	0.7	1.0
	F	0.4	0.5	0.3	0.1	0.5	0.2	0.5	0.4	0.3	0.6	0.5	0.3	0.4	0.6
	P	0.3	0.4	0.4	0.2	0.6	0.2	0.5	0.3	0.3	0.6	0.5	0.4	0.5	0.7
<b>C22 LIVER &amp; INTRAHEPATIC BILE DUCTS</b>															
Incidence	M	2.6	3.7	4.9	4.6	5.3	4.5	6.3	6.5	5.1	5.5	5.3	6.7	7.1	7.8
	F	1.1	1.4	1.5	1.6	1.6	2.1	2.4	2.6	1.8	1.8	2.4	2.7	2.3	2.3
	P	1.8	2.5	3.0	3.0	3.4	3.2	4.2	4.5	3.4	3.6	3.9	4.6	4.6	4.9
Mortality	M	2.1	3.1	3.6	3.5	3.4	3.9	4.1	5.1	4.9	4.6	3.7	4.7	5.5	5.2
	F	0.7	1.1	1.2	1.2	1.1	1.8	1.6	2.1	1.5	1.5	1.8	2.1	1.8	1.3
	P	1.3	2.0	2.3	2.3	2.2	2.8	2.8	3.5	3.1	3.0	2.7	3.4	3.5	3.2

**Table 4. Cancer Incidence and Mortality (ASR (Aust 2001)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C23,C24 GALLBLADDER AND OTHER &amp; UNSPECIFIED PARTS OF BILIARY TRACT</b>															
Incidence	M	2.8	2.8	3.1	3.4	3.2	3.6	2.7	2.9	3.4	2.9	2.7	2.8	2.3	3.0
	F	3.8	4.1	3.8	3.9	3.6	2.9	2.9	2.6	3.3	2.9	2.8	3.0	3.1	2.4
	P	3.3	3.6	3.5	3.7	3.5	3.2	2.9	2.8	3.4	2.8	2.8	2.9	2.7	2.7
Mortality	M	2.4	2.2	2.0	2.4	2.8	1.9	2.3	1.9	2.3	2.5	2.0	2.3	1.8	1.9
	F	2.9	3.4	3.1	3.2	2.8	2.3	2.2	2.1	2.2	2.4	2.1	2.6	1.7	2.3
	P	2.6	2.9	2.6	2.9	2.9	2.1	2.2	2.0	2.2	2.4	2.1	2.5	1.7	2.2
<b>C25 PANCREAS</b>															
Incidence	M	11.3	11.0	11.2	12.4	11.5	11.5	12.5	11.0	10.0	11.8	11.1	10.1	12.2	12.9
	F	7.1	7.8	8.1	8.5	9.1	9.2	8.5	8.2	8.4	8.5	8.9	8.5	8.6	7.9
	P	9.0	9.3	9.6	10.3	10.2	10.5	10.5	9.6	9.2	10.1	9.9	9.4	10.4	10.3
Mortality	M	10.2	9.6	10.5	9.7	10.6	9.6	9.5	11.2	9.8	10.2	10.2	8.7	9.5	12.4
	F	6.4	6.7	7.4	8.1	7.3	7.3	8.0	7.3	7.1	7.2	8.3	8.5	7.7	7.2
	P	8.1	8.0	8.8	8.9	8.8	8.5	8.8	9.2	8.4	8.7	9.3	8.7	8.6	9.7
<b>C30,C31 NASAL CAVITY &amp; MIDDLE EAR AND ACCESSORY SINUSES</b>															
Incidence	M	1.0	0.9	1.1	1.0	0.8	0.7	0.8	0.8	0.5	0.7	1.1	0.8	0.9	0.5
	F	0.5	0.5	0.5	0.5	0.5	0.2	0.4	0.3	0.3	0.3	0.4	0.5	0.3	0.4
	P	0.8	0.7	0.8	0.7	0.7	0.5	0.6	0.6	0.4	0.5	0.7	0.6	0.6	0.5
Mortality	M	0.5	0.5	0.5	0.4	0.4	0.2	0.7	0.2	0.4	0.2	0.4	0.4	0.2	0.2
	F	0.2	0.3	0.2	0.1	0.2	0.1	0.2	0.0	0.1	0.2	0.2	0.2	0.0	0.1
	P	0.3	0.4	0.4	0.2	0.3	0.1	0.4	0.1	0.3	0.2	0.3	0.3	0.1	0.1
<b>C32 LARYNX</b>															
Incidence	M	8.5	8.1	7.5	6.7	7.1	5.5	5.7	6.6	5.7	5.6	6.1	5.1	6.1	5.2
	F	0.7	0.8	0.9	0.6	0.7	0.4	0.6	0.4	0.6	0.5	0.6	0.5	0.7	0.6
	P	4.4	4.2	4.0	3.5	3.7	2.9	3.0	3.3	3.1	3.0	3.2	2.7	3.3	2.8
Mortality	M	2.5	2.7	2.1	2.3	1.8	2.2	1.9	2.2	2.0	2.4	2.5	1.9	1.8	2.1
	F	0.3	0.3	0.2	0.2	0.2	0.1	0.2	0.1	0.4	0.4	0.2	0.2	0.2	0.2
	P	1.3	1.4	1.1	1.1	0.9	1.0	0.9	1.0	1.1	1.3	1.3	1.0	0.9	1.1
<b>C33,C34 TRACHEA AND BRONCHUS &amp; LUNG</b>															
Incidence	M	85.7	81.7	74.4	75.4	71.4	73.3	68.2	67.8	63.9	61.8	63.0	62.3	67.2	61.3
	F	18.5	21.8	24.6	27.1	27.4	25.3	28.2	29.8	31.0	27.2	31.8	31.0	30.6	30.9
	P	48.6	48.6	47.1	49.0	47.2	46.9	46.5	47.1	46.0	43.0	46.2	45.5	47.5	45.0
Mortality	M	71.8	68.7	64.3	59.9	60.3	60.0	57.6	55.6	54.8	51.8	54.2	51.0	53.2	52.5
	F	14.4	15.8	18.9	21.6	20.2	21.3	21.1	21.9	24.2	21.5	23.9	25.6	24.4	24.9
	P	39.8	39.2	39.2	38.8	38.0	38.8	37.6	37.1	38.1	35.3	37.8	37.3	37.5	37.6
<b>C37, C38 THYMUS, HEART, MEDIASTINUM &amp; PLEURA</b>															
Incidence	M	0.4	0.5	0.5	0.6	0.5	0.6	0.5	0.6	0.7	0.5	0.4	0.4	0.3	0.5
	F	0.2	0.3	0.3	0.3	0.4	0.4	0.1	0.2	0.4	0.4	0.4	0.3	0.3	0.2
	P	0.3	0.4	0.4	0.5	0.4	0.5	0.3	0.4	0.5	0.4	0.4	0.3	0.3	0.3
Mortality	M	0.3	0.2	0.2	0.2	0.2	0.2	0.4	0.2	0.3	0.2	0.2	0.1	0.1	0.4
	F	0.1	0.2	0.1	0.2	0.0	0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.0
	P	0.2	0.2	0.1	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.2	0.1	0.1	0.2
<b>C40,C41 BONES, JOINTS &amp; ARTICULAR CARTILAGES</b>															
Incidence	M	1.2	1.6	1.3	1.7	1.0	0.7	1.2	1.0	1.6	1.2	0.9	0.9	1.5	1.5
	F	0.6	0.8	0.9	0.8	0.7	0.8	1.0	1.1	1.0	0.6	1.4	0.9	0.6	0.7
	P	0.9	1.2	1.1	1.3	0.9	0.8	1.1	1.1	1.3	0.9	1.1	0.9	1.0	1.1
Mortality	M	0.5	0.7	0.5	0.5	0.9	0.5	0.4	0.3	0.6	0.4	0.6	0.3	0.2	0.9
	F	0.3	0.3	0.3	0.3	0.3	0.2	0.4	0.2	0.2	0.4	0.2	0.1	0.4	0.5
	P	0.4	0.5	0.4	0.4	0.6	0.3	0.4	0.3	0.4	0.4	0.4	0.2	0.3	0.7
<b>C44, M872-M879 MELANOMA</b>															
Incidence	M	50.2	62.8	69.6	82.2	79.0	71.9	79.6	80.4	84.2	78.7	70.7	81.9	74.2	76.3
	F	44.0	47.8	48.3	54.4	54.3	51.7	53.4	54.3	58.2	52.5	52.0	53.8	47.6	51.1
	P	46.3	54.5	57.9	67.1	65.7	60.9	65.5	66.3	70.2	64.5	60.5	66.7	59.9	62.8
Mortality	M	7.2	8.4	9.5	8.2	9.6	9.6	9.3	9.1	8.3	10.7	10.7	10.1	7.9	10.3
	F	3.7	3.8	3.8	3.6	4.8	4.6	3.4	3.4	3.3	4.0	3.8	3.7	3.8	3.9
	P	5.3	5.9	6.4	5.7	7.0	6.9	6.1	6.1	5.5	7.0	6.9	6.6	5.6	6.7
<b>C44 OTHER SKIN (EXCL BCC/SCC)</b>															
Incidence	M	1.6	3.0	3.8	3.3	4.1	3.5	4.1	4.1	4.7	3.9	4.7	4.1	3.8	5.6
	F	0.7	1.2	1.4	1.8	2.1	2.0	1.9	1.9	2.2	1.8	1.7	2.2	2.1	2.4
	P	1.1	2.0	2.4	2.5	2.9	2.7	2.8	2.9	3.3	2.7	2.9	3.0	2.9	3.8
Mortality	M	0.2	0.5	0.6	1.1	0.4	0.7	1.1	0.8	0.9	0.5	1.3	1.4	0.8	1.4
	F	0.0	0.1	0.2	0.3	0.3	0.5	0.4	0.4	0.6	0.3	0.0	0.6	0.3	0.3
	P	0.1	0.3	0.4	0.6	0.4	0.6	0.7	0.5	0.7	0.4	0.6	0.9	0.5	0.8

**Table 4. Cancer Incidence and Mortality (ASR (Aust 2001)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>M905 MESOTHELIOMA</b>															
Incidence	M	2.3	3.4	3.9	4.9	5.4	5.3	5.3	5.7	5.6	5.4	5.0	5.0	5.7	5.6
	F	0.2	0.5	0.5	0.5	0.6	0.8	0.6	1.4	1.2	0.7	0.9	1.0	1.1	0.8
	P	1.1	1.8	2.1	2.6	2.8	2.8	2.8	3.3	3.2	2.9	2.8	2.8	3.2	3.0
Mortality	M	1.9	2.8	3.5	3.8	4.2	4.8	4.9	5.0	4.4	5.9	4.8	4.0	4.5	5.7
	F	0.1	0.3	0.5	0.4	0.4	0.6	0.7	0.6	1.1	0.9	0.7	0.9	0.8	0.7
	P	0.9	1.4	1.8	2.0	2.1	2.5	2.5	2.6	2.6	3.1	2.5	2.3	2.5	3.0
<b>M914 KAPOSI SARCOMA</b>															
Incidence	M	0.1	0.7	0.8	0.2	0.4	0.5	0.5	0.1	0.4	0.1	0.3	0.2	0.2	0.5
	F	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0
	P	0.1	0.4	0.4	0.1	0.2	0.3	0.2	0.1	0.2	0.1	0.2	0.1	0.1	0.3
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVES</b>															
Incidence	M	2.7	2.8	2.7	2.7	3.1	2.4	3.2	2.7	3.2	2.8	3.0	2.6	2.6	2.1
	F	2.0	1.7	2.1	2.3	2.7	1.8	2.3	1.7	1.9	1.4	2.1	3.3	2.1	1.8
	P	2.3	2.2	2.4	2.5	2.9	2.0	2.8	2.3	2.5	2.1	2.5	2.9	2.3	1.9
Mortality	M	1.1	1.0	1.0	1.1	1.0	0.7	0.3	1.1	1.4	1.1	1.1	1.2	1.3	0.5
	F	0.9	0.6	0.8	0.7	0.9	0.7	0.7	1.0	0.4	0.7	0.6	1.0	1.2	0.7
	P	1.0	0.8	0.9	0.9	0.9	0.7	0.5	1.0	0.9	0.8	0.8	1.1	1.3	0.6
<b>C48 RETROPERITONEUM &amp; PERITONEUM</b>															
Incidence	M	0.4	0.4	0.3	0.5	0.4	0.6	0.5	0.3	0.4	0.5	0.4	0.4	0.6	0.7
	F	0.5	0.3	0.6	0.8	0.9	1.4	1.6	1.9	1.2	1.6	1.5	1.4	2.0	2.2
	P	0.5	0.4	0.4	0.6	0.7	0.9	1.1	1.1	0.8	1.0	0.9	0.9	1.3	1.5
Mortality	M	0.3	0.3	0.1	0.1	0.6	0.3	0.4	0.2	0.3	0.2	0.2	0.2	0.1	0.4
	F	0.3	0.3	0.2	0.3	0.5	0.6	0.7	0.6	0.9	0.8	0.8	0.8	1.2	1.4
	P	0.3	0.3	0.2	0.2	0.6	0.4	0.6	0.4	0.7	0.5	0.5	0.5	0.7	0.9
<b>C50 BREAST</b>															
Incidence	M	1.1	0.9	0.8	1.2	0.7	0.9	1.2	1.2	0.8	0.8	1.5	1.2	1.2	1.3
	F	86.2	97.6	107.0	114.0	117.1	119.8	121.2	121.7	118.7	113.4	113.5	116.7	117.3	112.0
	P	45.9	51.5	55.8	59.3	60.7	61.9	62.8	63.0	61.0	58.4	58.9	60.2	60.5	57.9
Mortality	M	0.4	0.3	0.3	0.2	0.1	0.1	0.2	0.3	0.0	0.1	0.3	0.2	0.2	0.1
	F	27.2	27.8	28.2	25.8	25.8	23.9	22.8	25.0	22.5	22.9	22.0	22.3	19.6	21.7
	P	14.9	15.0	15.3	13.8	13.8	12.7	12.2	13.4	12.0	12.2	11.8	11.9	10.4	11.6
<b>C51 VULVA</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	2.5	2.2	2.3	3.0	1.8	1.7	1.8	2.3	2.2	1.6	2.0	1.8	2.2	2.3
	P	1.4	1.3	1.3	1.6	0.9	0.9	1.0	1.2	1.2	0.9	1.0	1.0	1.2	1.2
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	0.5	0.7	0.6	0.6	0.7	0.4	0.3	0.3	0.6	0.2	0.8	0.4	0.5	0.5
	P	0.3	0.4	0.3	0.4	0.4	0.2	0.2	0.1	0.3	0.1	0.4	0.2	0.3	0.3
<b>C53 CERVIX UTERI</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	16.5	15.0	12.9	10.6	9.8	11.0	9.5	8.5	8.0	8.1	7.4	8.8	9.1	6.7
	P	8.4	7.7	6.6	5.5	5.0	5.6	4.8	4.3	4.1	4.2	3.8	4.5	4.6	3.4
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	4.5	4.2	3.7	2.9	3.3	2.5	3.3	2.8	1.9	2.0	2.3	2.0	2.6	1.6
	P	2.4	2.3	2.0	1.5	1.7	1.3	1.7	1.5	1.0	1.1	1.2	1.0	1.4	0.8
<b>C54 CORPUS UTERI</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	13.3	12.9	14.8	14.6	14.7	15.6	17.8	16.3	16.5	15.7	16.4	16.7	15.6	16.5
	P	7.0	6.8	7.8	7.6	7.6	8.2	9.2	8.4	8.5	8.1	8.4	8.6	8.0	8.4
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	2.6	2.6	2.8	3.2	2.2	2.9	2.9	2.8	3.0	2.6	3.2	3.5	2.9	3.2
	P	1.4	1.5	1.6	1.8	1.2	1.6	1.6	1.5	1.6	1.4	1.7	1.9	1.6	1.7
<b>C56 OVARY</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	13.2	12.7	13.4	11.4	12.3	11.5	11.6	12.1	11.8	9.6	10.7	10.7	10.8	9.5
	P	7.0	6.7	7.0	6.0	6.5	6.0	6.1	6.3	6.1	5.0	5.6	5.5	5.6	4.9
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	8.3	7.5	7.5	6.1	6.4	7.1	5.9	6.3	6.8	6.8	6.0	6.6	6.0	6.0
	P	4.5	4.0	4.0	3.3	3.4	3.8	3.2	3.4	3.6	3.6	3.2	3.5	3.2	3.2

**Table 4. Cancer Incidence and Mortality (ASR (Aust 2001)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANS</b>															
Incidence	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	2.0	1.7	1.5	1.5	1.8	1.6	2.0	1.5	1.6	1.3	2.6	2.7	2.0	2.4
	P	1.1	0.9	0.8	0.8	1.0	0.9	1.1	0.8	0.8	0.7	1.4	1.4	1.1	1.3
Mortality	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	0.8	0.7	0.6	0.7	0.7	0.5	0.8	1.0	0.4	0.6	0.9	1.6	0.9	0.7
	P	0.4	0.4	0.3	0.4	0.4	0.3	0.5	0.6	0.2	0.4	0.5	0.8	0.5	0.4
<b>C61 PROSTATE GLAND</b>															
Incidence	M	92.1	105.7	150.1	121.6	124.6	125.4	126.1	125.8	136.1	154.4	163.9	154.8	165.5	176.9
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	38.1	44.3	65.6	54.1	55.8	56.1	57.0	57.5	62.8	71.9	77.3	73.2	79.3	84.9
Mortality	M	31.8	37.3	43.2	36.7	37.4	35.5	38.4	36.0	34.6	34.7	36.6	31.9	32.6	33.7
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	12.5	14.8	17.3	14.9	15.3	14.2	15.8	15.0	14.4	14.5	15.2	13.6	13.8	14.3
<b>C62 TESTIS</b>															
Incidence	M	4.7	4.3	5.7	5.3	6.2	6.3	4.8	5.9	7.2	6.3	6.0	6.7	6.9	5.7
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	2.4	2.2	2.9	2.7	3.1	3.1	2.4	2.9	3.6	3.1	3.0	3.4	3.4	2.9
Mortality	M	0.7	0.4	0.3	0.4	0.2	0.1	0.2	0.2	0.1	0.3	0.3	0.3	0.2	0.2
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.3	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1
<b>C60,C63 PENIS AND OTHER &amp; UNSPECIFIED MALE GENITAL ORGANS</b>															
Incidence	M	1.1	1.1	1.2	1.1	1.3	1.0	1.2	1.4	1.0	1.0	0.9	0.7	0.7	1.3
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.5	0.5	0.5	0.5	0.6	0.5	0.5	0.6	0.5	0.5	0.5	0.3	0.3	0.6
Mortality	M	0.2	0.3	0.3	0.0	0.2	0.2	0.5	0.3	0.2	0.1	0.2	0.4	0.2	0.2
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0.1
<b>C64-C66,C68 KIDNEY AND OTHER RENAL TRACT</b>															
Incidence	M	13.2	14.1	17.1	17.6	17.2	18.4	19.7	16.2	15.3	16.5	16.2	18.1	20.5	19.6
	F	7.4	8.9	9.9	9.4	9.9	11.0	9.7	9.9	10.2	9.1	9.7	8.4	10.6	9.2
	P	10.0	11.2	13.2	13.3	13.5	14.6	14.4	12.9	12.6	12.7	12.8	13.1	15.2	14.1
Mortality	M	5.8	6.2	6.8	6.3	5.6	6.8	6.8	6.2	5.7	5.8	5.7	5.7	5.6	6.4
	F	3.3	4.2	4.1	3.6	4.2	4.0	3.5	3.6	3.7	3.2	3.8	3.2	3.2	2.6
	P	4.4	5.1	5.3	4.9	4.9	5.3	4.8	4.8	4.6	4.5	4.7	4.3	4.3	4.3
<b>C67 BLADDER</b>															
Incidence	M	32.4	32.0	33.2	34.6	36.8	32.7	35.2	34.0	31.7	30.9	30.3	29.5	28.9	19.1
	F	8.6	8.5	9.3	9.3	9.3	9.0	9.8	8.0	8.9	8.1	8.5	6.5	7.2	5.9
	P	19.0	18.7	19.9	20.8	21.5	19.5	21.1	19.9	19.1	18.5	18.5	17.0	17.1	12.0
Mortality	M	8.6	8.7	9.1	8.3	7.7	9.1	7.9	7.9	8.5	7.4	6.8	6.9	7.0	7.1
	F	2.4	2.4	2.7	3.3	2.2	1.9	2.3	2.7	2.3	2.4	2.9	2.2	2.2	2.1
	P	5.0	4.9	5.2	5.4	4.5	4.9	4.6	5.0	4.8	4.5	4.6	4.2	4.3	4.3
<b>C69 EYE &amp; ADNEXA</b>															
Incidence	M	1.5	1.9	2.5	1.7	3.0	2.0	1.2	2.4	1.9	2.5	1.2	2.0	2.2	1.2
	F	0.8	1.2	1.3	1.0	1.0	1.3	1.0	1.5	1.0	1.2	1.3	1.2	1.3	1.2
	P	1.1	1.5	1.9	1.3	1.9	1.6	1.1	1.9	1.4	1.8	1.2	1.5	1.7	1.2
Mortality	M	0.3	0.4	0.3	0.3	0.2	0.5	0.4	0.2	0.4	0.2	0.4	0.5	0.2	0.4
	F	0.2	0.2	0.4	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.3	0.0	0.2
	P	0.2	0.3	0.3	0.2	0.2	0.4	0.3	0.2	0.2	0.2	0.3	0.3	0.1	0.3
<b>C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM</b>															
Incidence	M	7.3	8.0	8.1	9.9	8.4	8.0	8.3	8.2	7.9	7.9	8.7	8.6	8.5	8.2
	F	5.6	5.8	5.9	6.3	5.1	6.2	6.8	6.5	5.3	5.3	4.3	6.2	5.2	5.1
	P	6.4	6.8	7.0	8.0	6.7	7.2	7.6	7.3	6.6	6.5	6.4	7.4	6.8	6.6
Mortality	M	5.9	6.2	6.1	8.2	7.4	6.6	7.1	5.6	6.5	6.5	6.6	6.5	7.1	6.0
	F	4.0	4.6	4.7	5.1	4.1	5.0	5.1	4.1	5.1	4.4	3.7	3.9	4.1	3.7
	P	5.0	5.4	5.3	6.6	5.6	5.9	6.0	4.8	5.8	5.4	5.1	5.2	5.5	4.9
<b>C73 THYROID GLAND</b>															
Incidence	M	1.7	1.9	2.4	2.5	3.7	3.6	3.4	3.9	3.8	4.9	3.8	4.4	4.6	5.3
	F	4.0	4.7	6.8	8.1	7.9	8.9	10.6	9.8	11.0	10.9	12.2	13.5	13.8	16.6
	P	2.9	3.2	4.6	5.4	5.8	6.3	6.9	6.8	7.5	7.9	8.0	9.0	9.2	11.0
Mortality	M	0.4	0.7	0.4	0.4	0.3	0.4	0.4	0.7	0.6	0.3	0.4	0.6	0.8	0.5
	F	0.4	0.4	0.4	0.4	0.2	0.5	0.2	0.4	0.3	0.4	0.6	0.3	0.5	0.4
	P	0.4	0.5	0.4	0.4	0.3	0.4	0.2	0.5	0.4	0.4	0.5	0.5	0.6	0.4

**Table 4. Cancer Incidence and Mortality (ASR (Aust 2001)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>C74,C75 ADRENAL AND OTHER ENDOCRINE GLANDS</b>															
Incidence	M	0.3	0.4	0.5	0.6	0.3	0.5	0.5	0.7	0.2	0.5	0.4	0.4	0.4	0.3
	F	0.2	0.4	0.4	0.4	0.4	0.5	0.4	0.3	0.5	0.5	0.6	0.3	0.5	0.3
	P	0.3	0.4	0.5	0.5	0.3	0.5	0.5	0.5	0.3	0.5	0.5	0.4	0.5	0.3
Mortality	M	0.3	0.2	0.3	0.1	0.1	0.2	0.3	0.3	0.2	0.3	0.1	0.2	0.1	0.3
	F	0.1	0.2	0.2	0.1	0.1	0.2	0.3	0.0	0.4	0.2	0.3	0.2	0.3	0.1
	P	0.2	0.2	0.2	0.1	0.1	0.2	0.3	0.1	0.3	0.3	0.2	0.2	0.2	0.2
<b>C26, C39,C76,C77,C80 OTHER &amp; ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE</b>															
Incidence	M	21.4	21.1	22.2	20.3	21.4	18.8	18.8	17.4	18.1	16.7	17.2	17.5	17.1	18.0
	F	13.8	13.8	15.2	13.8	15.5	14.7	15.1	11.2	12.6	10.9	11.5	12.2	12.9	14.0
	P	17.1	17.0	18.3	16.8	18.3	16.6	16.8	14.1	15.3	13.5	14.3	14.7	15.0	16.0
Mortality	M	17.2	16.2	16.7	15.9	16.1	13.7	14.2	12.2	13.7	11.3	11.9	12.4	12.0	11.0
	F	10.9	10.7	11.8	9.7	12.5	12.6	11.9	8.9	11.0	8.5	8.5	8.5	8.5	8.6
	P	13.6	13.2	14.0	12.5	14.3	13.0	12.9	10.4	12.4	9.7	10.1	10.3	10.2	9.8
<b>M959-M972 ALL LYMPHOMAS</b>															
Incidence	M	16.7	18.8	20.4	22.0	21.9	22.6	22.6	22.0	22.9	22.7	21.0	23.0	23.8	22.9
	F	12.6	14.1	14.9	15.0	16.8	17.5	15.5	17.2	15.2	15.3	15.9	18.0	18.5	16.8
	P	14.5	16.2	17.5	18.3	19.2	19.7	18.7	19.5	18.7	18.7	18.5	20.4	20.9	19.6
Mortality	M	8.3	8.8	9.4	10.9	9.8	9.2	10.1	7.6	8.9	8.3	8.0	6.4	7.4	5.9
	F	5.5	6.1	6.4	7.3	7.5	5.5	5.9	5.4	6.9	5.3	5.3	4.9	4.5	4.2
	P	6.8	7.3	7.7	8.9	8.6	7.2	7.8	6.4	7.7	6.7	6.5	5.5	5.9	5.0
<b>M965-M966 HODGKIN LYMPHOMA</b>															
Incidence	M	2.5	2.3	2.1	1.9	2.1	2.1	1.7	2.2	2.4	2.3	1.4	2.3	2.6	2.3
	F	1.3	1.6	1.6	1.7	2.0	1.8	1.3	1.8	1.6	1.9	1.6	1.8	2.5	1.9
	P	1.9	1.9	1.8	1.8	2.0	1.9	1.5	2.0	2.0	2.1	1.5	2.1	2.5	2.1
Mortality	M	1.1	0.7	0.4	0.7	0.5	0.5	0.3	0.4	0.4	0.4	0.4	0.4	0.6	0.6
	F	0.5	0.4	0.3	0.5	0.1	0.1	0.2	0.2	0.3	0.1	0.3	0.3	0.3	0.1
	P	0.7	0.5	0.4	0.6	0.3	0.2	0.2	0.3	0.4	0.2	0.3	0.4	0.4	0.3
<b>M959,M967-M972 NON-HODGKIN LYMPHOMA</b>															
Incidence	M	14.2	16.5	18.3	20.1	19.7	20.5	20.9	19.8	20.5	20.4	19.6	20.7	21.1	20.6
	F	11.2	12.5	13.3	13.3	14.9	15.7	14.3	15.3	13.6	13.4	14.3	16.2	16.0	14.9
	P	12.6	14.2	15.6	16.5	17.1	17.8	17.2	17.5	16.7	16.7	16.9	18.3	18.4	17.5
Mortality	M	7.3	8.1	9.0	10.1	9.4	8.7	9.8	7.2	8.4	7.9	7.6	6.0	6.7	5.3
	F	5.0	5.6	6.1	6.9	7.4	5.4	5.7	5.2	6.6	5.2	5.0	4.6	4.2	4.2
	P	6.0	6.8	7.4	8.3	8.3	7.0	7.6	6.1	7.3	6.5	6.2	5.2	5.4	4.7
<b>M980-M994 ALL LEUKAEMIAS</b>															
Incidence	M	18.0	17.5	19.9	17.5	20.7	20.8	19.1	17.2	19.5	18.0	17.3	15.4	15.5	16.9
	F	9.9	10.2	12.1	11.3	12.1	11.6	10.9	12.7	11.5	10.3	9.7	9.1	11.1	9.4
	P	13.4	13.3	15.6	14.1	15.9	15.8	14.8	14.8	15.1	13.9	13.2	12.1	13.1	13.0
Mortality	M	9.9	9.9	10.5	9.9	10.8	10.0	8.4	7.7	8.9	7.7	7.8	7.7	7.3	7.9
	F	5.5	5.7	6.3	5.4	5.8	5.8	5.2	4.7	4.5	4.8	5.5	3.5	4.5	4.0
	P	7.4	7.5	8.1	7.3	8.0	7.6	6.7	6.1	6.5	6.1	6.5	5.4	5.8	5.8
<b>M982-M983 LYMPHOID LEUKAEMIA</b>															
Incidence	M	8.2	7.5	9.2	7.9	10.8	11.1	9.5	8.1	9.3	8.7	8.7	7.5	8.4	7.6
	F	4.1	4.5	5.8	5.0	6.1	5.9	6.3	7.0	6.5	5.4	4.1	4.3	5.5	3.9
	P	6.0	5.8	7.3	6.4	8.4	8.4	7.9	7.6	7.8	7.0	6.3	5.9	6.8	5.7
Mortality	M	2.8	3.0	3.7	4.0	3.5	3.5	2.2	3.1	3.0	2.9	2.6	2.9	2.6	2.3
	F	1.5	1.7	1.9	1.5	2.2	1.8	2.2	1.6	1.7	1.4	2.3	1.0	1.2	1.2
	P	2.1	2.2	2.7	2.5	2.8	2.7	2.2	2.3	2.3	2.1	2.4	1.8	1.8	1.7
<b>M984-M993 MYELOID LEUKAEMIA</b>															
Incidence	M	8.3	8.4	8.4	8.2	8.0	7.4	7.5	5.5	7.3	7.3	5.9	5.5	5.1	6.2
	F	4.9	5.0	5.6	5.5	5.0	5.1	3.7	4.6	3.9	4.2	4.4	3.7	4.4	4.2
	P	6.3	6.4	6.9	6.7	6.2	6.1	5.4	5.0	5.5	5.6	5.1	4.5	4.7	5.1
Mortality	M	6.2	6.1	5.9	5.2	6.8	5.8	4.8	3.9	4.6	4.2	4.5	3.3	3.7	4.7
	F	3.6	3.6	3.9	3.7	3.3	3.5	2.7	2.5	2.4	2.9	2.6	2.1	2.7	2.4
	P	4.7	4.6	4.8	4.4	4.7	4.3	3.7	3.1	3.4	3.5	3.4	2.6	3.1	3.4
<b>M994 OTHER SPECIFIED LEUKAEMIA</b>															
Incidence	M	0.6	0.7	1.5	1.1	1.4	1.7	1.7	3.5	2.7	1.8	2.4	2.2	1.9	2.7
	F	0.2	0.2	0.3	0.3	0.5	0.2	0.6	0.9	1.0	0.6	0.9	1.0	0.9	1.1
	P	0.4	0.4	0.8	0.6	0.9	0.9	1.1	2.0	1.6	1.1	1.6	1.5	1.4	1.8
Mortality	M	0.2	0.2	0.3	0.3	0.3	0.3	1.0	0.6	1.1	0.5	0.7	1.4	0.9	0.7
	F	0.1	0.1	0.1	0.0	0.2	0.1	0.2	0.4	0.4	0.3	0.4	0.4	0.4	0.2
	P	0.1	0.1	0.2	0.2	0.3	0.2	0.5	0.5	0.7	0.4	0.5	0.8	0.6	0.4

**Table 4. Cancer Incidence and Mortality (ASR (Aust 2001)/100,000) by Site and Sex, Queensland, 1982 - 2007**

ICD-O3/SITE	Sex	82-86	87-91	92-96	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>M980 UNSPECIFIED LEUKAEMIA</b>															
Incidence	M	0.9	0.8	0.8	0.3	0.4	0.6	0.4	0.1	0.2	0.1	0.2	0.1	0.1	0.5
	F	0.6	0.5	0.5	0.5	0.4	0.3	0.3	0.1	0.1	0.2	0.2	0.1	0.3	0.2
	P	0.7	0.6	0.6	0.4	0.4	0.4	0.4	0.1	0.2	0.2	0.2	0.1	0.2	0.3
Mortality	M	0.7	0.6	0.5	0.3	0.2	0.3	0.4	0.1	0.2	0.0	0.1	0.1	0.1	0.3
	F	0.4	0.4	0.4	0.2	0.2	0.4	0.1	0.2	0.1	0.1	0.2	0.1	0.2	0.2
	P	0.5	0.5	0.4	0.3	0.2	0.4	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.2
<b>M973 MYELOMA/PLASMA CELL TUMOURS</b>															
Incidence	M	6.0	6.1	6.5	7.3	9.6	7.0	8.0	7.5	6.8	6.9	6.0	6.6	7.0	6.6
	F	4.1	3.5	4.3	4.2	4.8	5.2	5.9	5.5	4.2	4.4	4.5	4.1	4.5	4.0
	P	4.9	4.7	5.2	5.6	6.9	6.0	6.8	6.4	5.3	5.5	5.2	5.2	5.6	5.1
Mortality	M	3.3	4.6	3.8	4.1	4.6	4.9	4.4	4.7	4.5	3.9	4.1	4.0	3.1	3.7
	F	2.4	2.4	2.8	2.6	2.4	2.1	2.9	2.3	2.5	2.7	2.8	2.6	2.1	2.3
	P	2.8	3.3	3.2	3.2	3.4	3.4	3.6	3.4	3.3	3.1	3.4	3.1	2.6	2.9
<b>M998 MYELOYDYSPLASTIC DISEASES</b>															
Incidence	M	0.4	1.0	2.3	3.8	4.5	5.8	7.1	9.4	7.9	8.8	8.1	7.1	7.2	7.2
	F	0.2	0.6	1.3	2.0	2.1	3.0	4.1	4.3	5.1	3.9	4.3	3.6	4.1	3.7
	P	0.3	0.8	1.7	2.7	3.2	4.1	5.3	6.4	6.2	6.0	5.8	5.1	5.5	5.3
Mortality	M	0.3	0.4	0.6	1.2	1.4	1.0	1.9	2.7	3.2	2.5	3.1	3.4	2.7	3.1
	F	0.1	0.2	0.3	0.8	0.4	0.8	0.7	1.1	1.4	1.2	1.0	1.7	1.8	1.3
	P	0.2	0.3	0.4	1.0	0.8	0.9	1.2	1.8	2.1	1.7	1.9	2.4	2.2	2.0
<b>M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASES</b>															
Incidence	M	2.5	3.0	5.2	6.1	6.3	5.6	6.6	4.8	4.7	5.2	3.7	5.0	4.1	4.5
	F	1.7	2.5	3.8	3.7	4.2	3.9	4.0	3.6	2.4	3.3	3.1	2.4	2.9	2.9
	P	2.1	2.7	4.5	4.8	5.0	4.7	5.2	4.2	3.5	4.1	3.4	3.6	3.5	3.6
Mortality	M	0.6	0.6	0.6	1.5	1.0	1.5	0.8	0.5	1.0	0.8	1.0	0.6	0.4	1.0
	F	0.1	0.5	0.4	0.7	0.4	0.7	0.5	0.3	0.3	0.7	0.4	0.4	0.8	0.4
	P	0.3	0.5	0.5	1.0	0.6	1.0	0.6	0.4	0.6	0.7	0.7	0.5	0.6	0.7
<b>M974-M976 OTHER NEOPLASMS OF LYMPHATIC &amp; HAEMATOPOIETIC TISSUE</b>															
Incidence	M	0.3	0.2	0.3	0.6	0.2	0.5	1.0	0.7	0.7	1.1	0.5	0.3	0.3	0.6
	F	0.2	0.1	0.2	0.2	0.2	0.3	0.5	0.2	0.6	0.5	0.6	0.3	0.2	0.2
	P	0.2	0.1	0.3	0.4	0.2	0.4	0.7	0.5	0.6	0.7	0.5	0.3	0.3	0.4
Mortality	M	0.1	0.2	0.1	0.4	0.2	0.3	0.1	0.2	0.0	0.3	0.2	0.0	0.1	0.1
	F	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.1	0.1	0.1	0.1	0.0
	P	0.1	0.1	0.0	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>															
Incidence	M	515.1	553.7	621.1	609.7	615.7	596.4	608.8	601.0	601.0	606.7	608.7	609.7	626.1	622.5
	F	357.9	380.2	411.0	422.7	431.9	430.6	441.2	433.8	435.5	406.5	417.5	428.6	430.0	416.5
	P	421.8	451.3	500.4	504.0	511.3	500.7	513.5	507.1	508.1	496.1	504.3	510.9	520.1	512.2
Mortality	M	257.6	266.1	269.2	259.4	258.3	253.1	252.4	241.2	241.0	232.1	237.0	226.7	224.3	229.4
	F	147.2	150.3	153.2	153.5	149.3	147.0	144.8	142.3	146.1	138.1	141.2	142.3	133.3	136.6
	P	193.8	199.1	202.6	198.9	196.7	192.5	191.4	185.8	187.6	179.2	183.1	179.8	173.3	178.1

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (World)/ 100,000	ASR	Lower Limit	Upper Limit	
<b>C00 LIP</b>																										
Incidence M	0	0	0	1	1	5	2	6	11	12	13	15	22	16	13	6	8	9	140	1.1	0.6	165	4.9	4.1	5.8	
F	0	0	0	0	0	0	0	0	1	4	0	4	9	7	5	7	4	5	46	0.5	0.2	441	1.3	1.0	1.8	
P	0	0	0	1	1	5	2	6	12	16	13	19	31	23	18	13	12	14	186	0.9	0.4	240	3.1	2.7	3.6	
Rate Per 100,000 M	0.0	0.0	0.0	0.7	0.7	3.5	1.4	3.9	7.4	8.1	9.6	11.7	20.2	20.0	21.9	12.9	25.8	42.9	6.7							
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.6	0.0	3.2	8.5	8.9	8.2	13.2	9.6	12.4	2.2							
P	0.0	0.0	0.0	0.3	0.3	1.8	0.7	1.9	4.0	5.3	4.8	7.5	14.5	14.5	15.0	13.1	16.5	22.9	4.4							
Mortality M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	3	0.0	0.0	11851	0.1	0.0	0.2	
F	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	1	3	0.1	0.0	27472	0.1	0.0	0.2	
P	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	2	5	0.1	0.0	16684	0.1	0.0	0.1	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	4.8	0.1							
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	2.4	2.5	0.1							
P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.8	0.0	1.4	3.3	0.1							
<b>C01,C02 TONGUE</b>																										
Incidence M	0	0	0	0	0	0	1	1	5	9	8	14	21	18	7	4	2	1	91	0.7	0.4	223	3.2	2.6	3.9	
F	0	0	0	0	0	0	0	2	3	8	6	9	9	5	2	2	1	4	51	0.6	0.2	477	1.7	1.3	2.2	
P	0	0	0	0	0	0	1	3	8	17	14	23	30	23	9	6	3	5	142	0.6	0.3	304	2.5	2.1	2.9	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	3.3	6.0	5.9	10.9	19.3	22.5	11.8	8.6	6.5	4.8	4.4							
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	2.0	5.2	4.4	7.1	8.5	6.4	3.3	3.8	2.4	10.0	2.4							
P	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.0	2.6	5.6	5.1	9.0	14.0	14.5	7.5	6.0	4.1	8.2	3.4							
Mortality M	0	0	0	0	0	0	0	1	0	2	3	2	5	3	0	4	0	1	21	0.5	0.1	881	0.7	0.4	1.1	
F	0	0	0	0	0	0	0	0	0	0	0	2	2	1	3	2	0	2	12	0.4	0.0	2073	0.3	0.2	0.6	
P	0	0	0	0	0	0	0	1	0	2	3	4	6	6	2	4	2	3	33	0.4	0.1	1256	0.5	0.4	0.7	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.3	2.2	1.6	4.6	3.8	0.0	8.6	0.0	4.8	1.0							
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	1.6	0.9	3.8	3.3	0.0	4.8	5.0	0.6							
P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.7	1.1	1.6	2.8	3.8	1.7	4.0	2.8	4.9	0.8							
<b>C03 GUM</b>																										
Incidence M	0	0	0	0	0	0	0	0	0	1	2	1	3	2	0	2	0	0	11	0.1	0.1	1602	0.4	0.2	0.7	
F	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	2	0	2	8	0.1	0.0	2454	0.2	0.1	0.4	
P	0	0	0	0	0	0	0	0	1	1	2	2	3	3	1	4	0	2	19	0.1	0.1	1936	0.3	0.2	0.5	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.5	0.8	2.8	2.5	0.0	4.3	0.0	0.0	0.5							
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.8	0.0	1.3	1.6	3.8	0.0	5.0	0.4							
P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.7	0.8	1.4	1.9	0.8	4.0	0.0	3.3	0.5							
Mortality M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0.1	0.0	5330	0.1	0.0	0.3	
F	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	2	2	7	0.2	0.0	4722	0.2	0.1	0.3	
P	0	0	0	0	0	0	0	0	0	0	0	0	1	3	2	0	2	2	10	0.1	0.0	4965	0.1	0.1	0.3	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.1							
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	3.3	0.0	4.8	5.0	0.3							
P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.9	1.7	0.0	2.8	3.3	0.2							
<b>C04 FLOOR OF MOUTH</b>																										
Incidence M	0	0	0	0	0	0	0	1	0	1	5	6	2	3	4	2	1	1	26	0.2	0.1	760	0.9	0.6	1.3	
F	0	0	0	0	0	0	0	0	0	1	2	1	1	1	0	0	0	2	8	0.1	0.0	3903	0.2	0.1	0.5	
P	0	0	0	0	0	0	0	1	0	2	7	7	3	4	4	2	1	3	34	0.2	0.1	1285	0.5	0.4	0.8	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.7	3.7	4.7	1.8	3.8	6.8	4.3	3.2	4.8	1.2							
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.5	0.8	0.0	1.3	0.0	0.0	0.0	5.0	0.4							
P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.7	2.6	2.8	1.4	2.5	3.3	2.0	1.4	4.9	0.8							
Mortality M	0	0	0	0	0	0	0	0	1	0	0	3	1	2	1	1	0	0	9	0.2	0.1	1947	0.3	0.1	0.6	
F	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	2	4	0.1	0.0	27472	0.1	0.0	0.2	
P	0	0	0	0	0	0	0	0	1	0	1	3	1	2	1	1	1	2	13	0.2	0.0	3673	0.2	0.1	0.3	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	2.3	0.9	2.5	1.7	2.2	0.0	0.0	0.4							
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	2.4	5.0	0.2							
P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	1.2	0.5	1.3	0.8	1.0	1.4	3.3	0.3							

Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007

ICD-O3/SITE Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (World)/ 100,000	Lower Limit	Upper Limit	
<b>C05.C06 PALATE AND OTHER &amp; UNSPECIFIED PARTS OF MOUTH</b>																									
Incidence	M	0	0	0	0	0	0	0	2	2	4	7	7	6	8	3	3	1	43	0.3	0.2	445	1.4	1.0	1.9
	F	0	0	0	0	1	0	0	1	1	1	1	4	3	2	1	2	3	20	0.2	0.1	1225	0.6	0.4	1.0
	P	0	0	0	0	1	0	0	3	3	5	8	11	9	10	4	5	4	63	0.3	0.2	657	1.0	0.8	1.3
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.3	2.9	5.5	6.4	7.5	13.5	6.5	9.7	4.8	2.1						
	F	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.7	0.7	0.7	0.8	3.8	3.3	1.9	4.8	7.5	1.0	4.8						
	P	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.0	1.0	1.8	3.1	5.1	5.7	8.3	4.0	6.9	6.5	1.5						
Mortality	M	0	0	0	0	0	0	0	0	1	0	1	2	1	5	1	3	0	14	0.3	0.1	1322	0.4	0.2	0.7
	F	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	1	5	0.2	0.0	5171	0.1	0.0	0.3
	P	0	0	0	0	0	0	0	0	1	0	1	3	2	6	1	4	1	19	0.3	0.0	2130	0.3	0.2	0.4
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.8	1.8	1.3	8.4	2.2	9.7	0.0	0.7						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.3	1.6	0.0	2.4	2.5	0.2						
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	1.4	1.3	5.0	1.0	5.5	1.6	0.5						
<b>C07.C08 PAROTID AND OTHER &amp; UNSPECIFIED MAJOR SALIVARY GLANDS</b>																									
Incidence	M	0	0	0	1	1	0	1	1	2	5	2	3	9	6	1	4	4	40	0.3	0.2	563	1.3	1.0	1.8
	F	0	0	1	2	0	1	1	3	1	2	5	3	1	0	2	3	3	28	0.3	0.1	1034	0.9	0.6	1.3
	P	0	0	1	2	1	1	2	4	3	7	7	6	10	6	3	7	7	68	0.3	0.1	729	1.1	0.9	1.4
Rate Per 100,000	M	0.0	0.0	0.0	0.7	0.7	0.0	0.6	0.7	1.3	3.7	1.6	2.8	11.3	10.1	2.2	12.9	19.1	1.9						
	F	0.0	0.0	0.7	1.4	0.0	0.7	0.6	2.0	0.7	1.5	4.0	2.8	1.3	0.0	3.8	7.2	7.5	1.3						
	P	0.0	0.0	0.3	0.7	0.3	0.4	0.3	1.3	1.0	2.6	2.8	2.8	6.3	5.0	3.0	9.6	11.4	1.6						
Mortality	M	0	0	0	0	0	0	0	0	1	0	0	0	3	1	1	0	1	7	0.2	0.0	2421	0.2	0.1	0.5
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	3	0.1	0.0	12158	0.1	0.0	0.2
	P	0	0	0	0	0	0	0	0	1	0	0	0	3	2	1	1	2	10	0.1	0.0	4082	0.1	0.1	0.3
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	3.8	1.7	2.2	0.0	4.8	0.3						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	2.4	2.5	0.1						
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.9	1.7	1.0	1.4	3.3	0.2						
<b>C09.C10 TONSIL AND OROPHARYNX</b>																									
Incidence	M	0	0	0	0	0	2	0	4	10	16	18	12	10	7	2	2	2	85	0.7	0.4	263	3.0	2.4	3.7
	F	0	0	0	0	0	0	1	0	5	3	6	0	1	1	1	1	0	19	0.2	0.1	1278	0.6	0.4	1.0
	P	0	0	0	0	0	2	1	4	15	19	24	12	11	8	3	3	2	104	0.5	0.2	436	1.8	1.5	2.2
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	1.4	0.0	2.7	6.7	11.8	14.1	11.0	12.5	11.8	4.3	6.5	9.5	4.1						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	3.3	2.2	4.7	0.0	1.3	1.6	1.9	2.4	0.0	0.9						
	P	0.0	0.0	0.0	0.0	0.0	0.7	0.3	1.3	5.0	6.9	9.4	5.6	7.0	6.7	3.0	4.1	3.3	2.5						
Mortality	M	0	0	0	0	0	0	0	0	1	2	4	5	4	5	1	1	1	24	0.5	0.1	786	0.8	0.5	1.2
	F	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	2	0	6	0.2	0.0	4867	0.2	0.1	0.4
	P	0	0	0	0	0	0	0	0	1	3	5	6	4	6	1	3	1	30	0.4	0.1	1359	0.5	0.3	0.7
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.5	3.1	4.6	5.0	8.4	2.2	3.2	4.8	1.1						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.9	0.0	1.6	0.0	4.8	0.0	0.3						
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.1	2.0	2.8	2.5	5.0	1.0	4.1	1.6	0.7						
<b>C11 NASOPHARYNX</b>																									
Incidence	M	0	0	0	0	0	0	0	1	1	1	2	1	3	1	0	0	0	10	0.1	0.0	2001	0.4	0.2	0.7
	F	0	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	3	0.0	0.0	9625	0.1	0.0	0.4
	P	0	0	0	0	1	0	1	1	1	2	2	1	3	1	0	0	0	13	0.1	0.0	3307	0.2	0.1	0.4
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.7	1.6	0.9	3.8	1.7	0.0	0.0	0.0	0.5						
	F	0.0	0.0	0.0	0.0	0.7	0.0	0.6	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1						
	P	0.0	0.0	0.0	0.0	0.4	0.0	0.3	0.3	0.3	0.7	0.8	0.5	1.9	0.8	0.0	0.0	0.0	0.3						
Mortality	M	0	0	0	0	0	0	0	1	2	0	0	0	2	0	0	0	0	5	0.1	0.0	4430	0.2	0.1	0.5
	F	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	2	0.1	0.0	11516	0.1	0.0	0.3
	P	0	0	0	0	0	0	0	1	2	0	1	1	2	0	0	0	0	7	0.1	0.0	6416	0.1	0.1	0.3
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.2						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.9	0.0	0.0	0.0	0.0	0.0	0.1						
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.0	0.4	0.5	1.3	0.0	0.0	0.0	0.0	0.2						

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (World)/ 100,000	ASR	Lower Limit	Upper Limit	
<b>C12.C13 PYRIFORM SINUS AND HYPOPHARYNX</b>																										
Incidence	M	0	0	0	0	0	0	0	1	1	3	4	1	16	3	4	1	3	37	0.3	0.2	485	1.2	0.9	1.7	
	F	0	0	0	0	0	0	0	0	1	0	0	2	1	0	0	0	0	4	0.0	0.0	5231	0.2	0.0	0.4	
	P	0	0	0	0	0	0	0	1	2	3	4	3	17	3	4	1	3	41	0.2	0.1	896	0.7	0.5	0.9	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	2.2	3.1	0.9	20.0	5.1	8.6	3.2	14.3	1.8							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.3	0.0	1.3	0.0	0.0	0.0	0.0	0.2							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	1.1	1.6	1.4	10.7	2.5	4.0	1.4	4.9	1.0							
Mortality	M	0	0	0	0	0	0	0	0	0	0	4	4	2	2	2	4	0	18	0.4	0.1	1178	0.5	0.3	0.8	
	F	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	4	0.1	0.0	4090	0.1	0.0	0.4	
	P	0	0	0	0	0	0	0	1	0	0	4	5	2	4	2	4	0	22	0.3	0.1	1845	0.3	0.2	0.5	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	3.7	2.5	3.4	4.3	12.9	0.0	0.9							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.9	0.0	0.9	0.0	3.3	0.0	0.0	0.2							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	1.6	2.3	1.3	3.3	2.0	5.5	0.0	0.5							
<b>C14. OTHER &amp; ILL-DEFINED SITES IN LIP, ORAL CAVITY &amp; PHARYNX</b>																										
Incidence	M	0	0	0	0	0	0	0	1	3	0	4	1	6	6	2	1	1	25	0.2	0.1	698	0.8	0.5	1.2	
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	
	P	0	0	0	0	0	0	0	1	3	0	4	1	6	6	2	1	1	25	0.1	0.1	1412	0.4	0.3	0.6	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.0	0.0	3.1	0.9	7.5	10.1	4.3	3.2	4.8	1.2							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.0	0.0	1.6	0.5	3.8	5.0	2.0	1.4	1.6	0.6							
Mortality	M	0	0	0	0	0	0	0	0	0	0	3	1	3	3	0	0	1	11	0.2	0.1	1656	0.4	0.2	0.7	
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.0	0.0	0.0	0.0	0.0	0.1	
	P	0	0	0	0	0	0	0	0	0	0	3	1	3	3	0	0	2	12	0.2	0.0	3311	0.2	0.1	0.3	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.9	3.8	5.1	0.0	0.0	4.8	0.5							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.5	1.9	2.5	0.0	0.0	3.3	0.3							
<b>C15 OESOPHAGUS</b>																										
Incidence	M	0	0	0	0	1	0	0	0	6	17	23	27	27	22	23	24	14	16	173	1.4	0.9	113	5.4	4.6	6.2
	F	0	0	0	0	0	1	1	1	0	5	6	6	10	16	10	12	7	75	0.8	0.4	271	2.0	1.6	2.6	
	P	0	0	0	0	1	1	1	1	6	22	29	33	32	39	34	26	23	248	1.1	0.6	160	3.6	3.2	4.1	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	4.0	12.5	18.0	24.8	27.5	38.8	51.6	45.2	26.2	8.3							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	4.7	5.7	12.8	26.3	18.9	28.7	17.4	3.6							
	P	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.3	2.0	8.0	11.4	15.4	20.2	32.5	34.2	35.8	37.6	5.9							
Mortality	M	0	0	0	0	1	0	0	2	10	8	20	11	12	23	16	15	12	130	2.9	0.6	156	4.0	3.3	4.7	
	F	0	0	0	0	0	0	0	1	2	1	3	1	1	7	22	10	8	58	1.9	0.3	325	1.3	1.0	1.6	
	P	0	0	0	0	1	0	0	3	12	9	23	12	13	38	25	20	188	2.5	0.5	210	2.6	2.2	3.0		
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.3	6.7	5.9	15.6	10.1	15.0	38.8	34.4	48.4	57.2	6.2							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	0.7	2.4	0.9	1.3	11.5	41.6	24.0	19.9	2.8							
	P	0.0	0.0	0.0	0.0	0.3	0.0	0.6	1.0	4.0	3.3	9.0	5.6	8.2	25.0	38.2	34.4	32.7	4.5							
<b>C16 STOMACH</b>																										
Incidence	M	0	0	1	0	0	0	2	1	3	8	21	19	31	18	32	26	28	198	1.6	0.9	107	5.8	5.0	6.7	
	F	0	0	0	0	0	0	1	0	7	2	3	8	14	10	14	15	25	113	1.2	0.5	221	2.9	2.4	3.5	
	P	0	0	1	0	0	0	3	1	10	10	29	33	41	32	46	41	53	311	1.4	0.7	145	4.3	3.8	4.8	
Rate Per 100,000	M	0.0	0.0	0.7	0.0	0.0	0.0	1.4	0.6	2.0	5.4	16.4	17.5	38.8	30.4	68.8	84.0	133.4	9.5							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	4.6	1.3	2.2	3.2	12.8	23.0	26.5	35.9	62.2	5.4							
	P	0.0	0.0	0.3	0.0	0.0	0.0	1.0	0.3	3.3	4.0	11.4	15.4	25.9	26.7	46.3	56.4	86.6	7.4							
Mortality	M	0	0	0	0	0	1	1	1	4	12	13	18	17	14	18	25	27	151	3.4	0.6	162	4.4	3.7	5.1	
	F	0	0	0	0	0	0	1	1	2	4	5	6	8	11	16	11	16	84	2.7	0.4	264	2.1	1.7	2.6	
	P	0	0	0	0	0	0	2	2	6	16	18	24	25	25	34	36	43	235	3.1	0.5	201	3.2	2.8	3.6	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.7	0.7	0.6	0.0	2.7	8.8	10.2	16.6	21.3	23.6	38.7	80.7	128.6	7.2							
	F	0.0	0.0	0.0	0.0	0.0	0.7	0.6	1.3	1.3	2.9	4.0	5.7	10.2	18.1	30.3	26.4	39.8	4.0							
	P	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.7	2.0	5.9	7.1	11.2	15.8	20.8	34.2	49.5	70.3	5.6							

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE_Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (1 in x)	ASR (World)/100,000	Lower Limit	Upper Limit	
<b>C17 SMALL INTESTINE</b>																										
Incidence	M	0	0	0	0	0	0	0	2	2	3	6	7	10	5	9	4	2	50	0.4	0.3	356	1.6	1.2	2.1	
	F	0	0	0	0	0	1	0	1	1	5	3	2	8	4	6	2	4	37	0.4	0.2	526	1.1	0.8	1.5	
	P	0	0	0	0	0	0	0	3	3	8	9	9	18	9	15	6	6	87	0.4	0.2	426	1.3	1.1	1.6	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.3	2.2	4.7	6.4	12.5	8.4	19.4	12.9	9.5	2.4							
	F	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.7	0.7	3.6	2.4	1.9	10.2	6.6	11.3	4.8	10.0	1.8							
	P	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.0	1.0	2.9	3.5	4.2	11.4	7.5	15.1	8.3	9.8	2.1							
Mortality	M	0	0	0	0	0	0	0	1	2	1	2	3	1	3	1	1	1	16	0.4	0.1	1288	0.5	0.3	0.9	
	F	0	0	0	0	0	0	0	1	2	0	2	2	2	1	5	1	2	17	0.5	0.1	1093	0.5	0.3	0.7	
	P	0	0	0	0	0	0	0	2	4	1	3	5	3	4	6	2	3	33	0.4	0.1	1168	0.5	0.3	0.7	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	0.7	1.6	2.8	1.3	5.1	2.2	3.2	4.8	0.8							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	0.0	1.6	2.6	1.6	9.5	2.4	5.0	8.8	0.8							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	0.4	1.2	2.3	1.9	3.3	6.0	2.8	4.9	0.8							
<b>C18-C20 COLORECTAL</b>																										
Incidence	M	0	0	0	1	8	8	15	20	53	101	177	218	281	234	208	138	103	1565	12.4	8.4	12	49.2	46.8	51.7	
	F	0	0	0	6	3	7	16	27	45	76	105	123	171	169	175	171	126	1220	13.2	5.8	18	34.0	32.1	36.0	
	P	0	0	0	7	11	15	31	47	98	177	282	341	452	403	383	309	229	2785	12.7	7.1	15	41.5	39.9	43.0	
Rate Per 100,000	M	0.0	0.0	0.0	0.7	5.5	5.5	9.7	13.4	35.6	74.2	138.3	200.5	351.5	394.9	447.3	445.6	490.6	75.0							
	F	0.0	0.0	0.0	4.0	2.1	4.8	10.2	17.7	29.5	55.3	83.1	116.3	218.4	278.0	331.0	409.6	313.7	58.3							
	P	0.0	0.0	0.0	2.3	3.9	5.2	10.0	15.6	32.5	64.7	110.8	159.0	285.7	335.7	385.5	425.0	374.4	66.6							
Mortality	M	0	0	0	0	1	1	2	7	18	19	54	53	79	64	80	89	53	520	11.8	2.5	40	15.1	13.8	16.4	
	F	0	0	0	0	0	0	2	3	13	22	19	37	48	55	63	90	451	58							
	P	0	0	0	0	1	1	2	4	10	31	41	73	90	127	119	143	186	971	12.9	2.1	48	12.8	12.0	13.7	
Rate Per 100,000	M	0.0	0.0	0.0	0.7	0.7	0.7	1.3	4.7	12.1	14.0	42.2	48.7	98.8	108.0	172.0	287.4	252.4	24.9							
	F	0.0	0.0	0.0	0.0	0.0	0.0	1.4	2.0	8.5	16.0	15.0	35.0	61.3	90.5	119.2	232.4	224.0	21.5							
	P	0.0	0.0	0.0	0.3	0.4	0.7	1.3	3.3	10.3	15.0	28.7	42.0	80.3	99.1	143.9	255.8	233.8	23.2							
<b>C18 COLON</b>																										
Incidence	M	0	0	0	1	5	6	7	10	30	50	95	122	181	165	147	104	72	985	7.9	5.4	19	30.7	28.8	32.6	
	F	0	0	0	5	3	4	8	12	28	51	61	87	116	135	140	138	96	884	9.6	4.2	24	23.9	22.4	25.6	
	P	0	0	0	6	8	10	15	22	58	101	156	209	297	300	287	242	168	1879	8.6	4.8	21	27.2	26.0	28.5	
Rate Per 100,000	M	0.0	0.0	0.0	0.7	3.5	4.1	4.5	6.7	20.1	36.7	74.2	112.2	226.4	278.5	316.1	335.8	342.9	47.7							
	F	0.0	0.0	0.0	3.4	2.1	2.7	5.1	7.9	18.3	37.1	48.2	82.3	148.2	222.1	264.8	330.6	239.0	42.2							
	P	0.0	0.0	0.0	2.0	2.8	3.4	4.8	7.3	19.2	36.9	61.3	97.5	187.7	249.9	288.8	332.8	274.7	44.9							
Mortality	M	0	0	0	0	1	0	1	5	6	10	23	27	43	37	49	68	36	306	6.9	1.4	72	8.5	7.6	9.5	
	F	0	0	0	0	0	0	2	1	11	12	13	21	36	39	52	77	60	325	10.4	1.3	78	7.6	6.8	8.4	
	P	0	0	0	0	1	2	2	6	17	22	36	48	79	76	101	145	96	631	8.4	1.3	75	8.0	7.4	8.6	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.7	0.0	0.6	3.3	4.0	7.3	18.0	24.8	53.8	62.4	105.4	219.6	171.5	14.7							
	F	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.7	7.2	8.7	10.3	19.9	46.0	64.2	98.4	184.5	149.4	15.5							
	P	0.0	0.0	0.0	0.0	0.4	0.7	0.6	2.0	5.6	8.0	14.2	22.4	49.9	63.3	101.6	199.4	156.9	15.1							
<b>C19-C20 RECTOSIGMOID JUNCTION AND RECTUM</b>																										
Incidence	M	0	0	0	0	2	2	8	10	22	50	81	96	99	68	57	34	29	558	4.4	2.9	35	18.2	16.7	19.7	
	F	0	0	0	0	1	0	3	8	14	24	43	34	54	33	34	33	30	327	3.5	1.5	67	9.7	8.7	10.9	
	P	0	0	0	0	1	2	5	16	24	38	74	130	153	101	91	67	59	885	4.0	2.2	46	13.9	13.0	14.8	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	1.4	1.4	5.2	6.7	14.8	36.7	63.3	88.3	123.8	114.8	122.6	109.8	138.1	26.7							
	F	0.0	0.0	0.0	0.0	0.7	0.0	2.1	5.1	9.2	10.5	17.5	34.0	69.0	54.3	64.3	79.1	74.7	15.6							
	P	0.0	0.0	0.0	0.0	0.3	0.7	1.7	5.1	7.9	12.6	27.1	48.7	96.7	84.1	91.6	92.1	96.5	21.2							
Mortality	M	0	0	0	0	1	0	0	1	2	11	9	26	36	26	31	19	17	210	4.8	1.1	91	6.5	5.6	7.4	
	F	0	0	0	0	0	0	0	1	2	9	6	15	12	15	11	20	29	132	3.9	0.4	224	3.0	2.5	3.6	
	P	0	0	0	0	1	0	0	2	4	13	18	37	41	48	41	42	39	46	332	4.4	0.8	131	4.7	4.2	5.3
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.7	0.0	0.6	1.3	7.4	6.6	24.2	23.9	45.0	43.9	66.7	61.4	81.0	10.1							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.3	1.3	6.6	4.7	14.2	15.3	24.7	20.8	47.9	72.2	5.8							
	P	0.0	0.0	0.0	0.0	0.3	0.0	0.6	1.3	4.3	6.6	14.5	19.1	30.3	34.2	42.3	53.6	75.2	7.9							

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (World)/ 100,000	ASR	Lower Limit	Upper Limit	
<b>C21 ANUS &amp; ANAL CANAL</b>																										
Incidence	M	0	0	0	0	0	0	1	1	3	3	1	2	2	2	6	0	3	25	0.2	0.1	724	0.8	0.5	1.2	
	F	0	0	0	0	0	0	0	3	3	3	4	6	3	2	3	2	2	31	0.3	0.1	721	1.0	0.7	1.4	
	P	0	0	0	0	0	0	1	4	6	6	5	8	5	4	9	2	5	56	0.3	0.1	730	0.9	0.7	1.2	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.7	2.0	2.2	0.8	1.8	2.5	3.4	12.9	0.0	14.3	1.2							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	2.0	2.2	3.2	5.7	3.8	5.0	17.4	0.0	20.1	1.5							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.3	2.0	2.2	2.0	3.7	3.2	3.3	9.1	2.8	8.2	1.3							
Mortality	M	0	0	0	0	0	0	0	0	1	2	1	3	0	4	3	3	1	19	0.4	0.1	1027	0.6	0.3	0.9	
	F	0	0	0	0	0	0	0	0	0	3	2	2	0	2	2	2	1	12	0.4	0.1	1794	0.3	0.2	0.6	
	P	0	0	0	0	0	0	0	1	2	4	1	5	0	6	5	5	2	31	0.4	0.1	1315	0.4	0.3	0.6	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	0.7	0.8	2.8	0.0	6.8	6.5	9.7	4.8	0.9							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	1.9	0.0	3.3	3.8	4.8	2.5	0.6							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	1.5	0.4	2.3	0.0	5.0	5.0	6.9	3.3	0.7							
<b>C22 LIVER &amp; INTRAHEPATIC BILE DUCTS</b>																										
Incidence	M	0	0	0	0	0	0	4	2	13	15	15	29	20	18	14	16	12	159	1.3	0.7	135	5.1	4.3	5.9	
	F	0	0	0	1	0	1	1	2	3	1	3	5	4	8	7	8	7	51	0.6	0.2	448	1.4	1.0	1.9	
	P	0	0	0	1	0	1	5	4	16	16	18	34	24	26	21	24	19	210	1.0	0.5	209	3.2	2.8	3.7	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.7	2.6	1.3	8.7	11.0	11.7	26.7	25.0	30.4	30.1	51.7	57.2	7.6							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.3	2.0	0.7	2.4	4.7	5.1	13.2	13.2	19.2	17.4	2.4							
	P	0.0	0.0	0.0	0.3	0.0	0.4	1.6	1.3	5.3	5.9	7.1	15.9	15.2	21.7	21.1	33.0	31.1	5.0							
Mortality	M	0	0	0	0	0	0	0	0	5	11	11	22	11	10	19	9	7	106	2.4	0.6	178	3.3	2.7	4.0	
	F	0	0	0	0	0	1	0	1	3	2	3	5	2	5	2	5	5	5	1.2	0.1	863	0.8	0.6	1.2	
	P	0	0	0	0	0	0	0	1	6	14	13	25	13	15	21	14	12	136	1.8	0.3	300	2.0	1.7	2.4	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	8.1	8.6	20.2	13.8	16.9	40.9	29.1	33.3	5.1							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	2.2	1.6	2.8	2.6	8.2	3.8	12.4	1.4	1.4							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.0	5.1	5.1	11.7	8.2	12.5	21.1	19.3	19.6	3.3							
<b>C23-C24 GALLBLADDER AND OTHER &amp; UNSPECIFIED PARTS OF BILIARY TRACT</b>																										
Incidence	M	0	0	0	0	0	0	0	0	1	1	7	11	6	9	7	9	7	59	0.5	0.3	361	1.7	1.3	2.2	
	F	1	0	0	0	0	0	0	0	0	4	3	3	6	9	3	8	11	11	56	0.6	0.2	463	1.4	1.1	1.8
	P	1	0	0	0	0	0	0	0	1	5	10	17	15	12	15	20	18	115	0.5	0.2	406	1.6	1.3	1.9	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	5.5	10.1	7.5	15.2	15.1	29.1	33.3	2.8							
	F	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	2.4	5.7	11.5	4.9	15.1	26.4	27.4	2.7							
	P	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.8	3.9	7.9	9.5	10.0	15.1	27.5	29.4	2.8							
Mortality	M	0	0	0	0	0	0	0	0	0	0	4	3	5	7	8	4	5	37	0.8	0.2	479	1.1	0.7	1.5	
	F	0	0	0	0	0	0	0	0	2	2	3	7	6	5	7	12	11	55	1.8	0.2	490	1.3	1.0	1.7	
	P	0	0	0	0	0	0	0	0	3	2	7	10	11	12	15	16	16	92	1.2	0.2	486	1.2	1.0	1.5	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	3.1	2.8	6.3	11.8	17.2	12.9	23.8	1.8							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.5	2.4	6.6	7.7	8.2	13.2	28.7	27.4	2.6							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.7	2.8	4.7	7.0	10.0	15.1	22.0	26.2	2.2							
<b>C25 PANCREAS</b>																										
Incidence	M	0	0	0	0	0	0	1	3	7	18	24	31	40	37	41	35	18	255	2.0	1.3	75	7.6	6.7	8.6	
	F	0	0	0	1	0	0	1	2	4	10	10	10	30	17	30	17	34	37	182	2.0	0.7	134	4.4	3.8	5.1
	P	0	0	0	1	0	0	1	3	5	11	22	34	41	70	54	71	55	437	2.0	1.0	97	6.0	5.4	6.6	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.6	2.0	4.7	13.2	18.8	28.5	50.0	62.4	88.2	113.0	85.7	12.2							
	F	0.0	0.0	0.0	0.7	0.0	0.0	0.7	1.3	2.6	2.9	7.9	9.5	38.3	28.0	56.7	81.5	92.1	8.7							
	P	0.0	0.0	0.0	0.3	0.0	0.0	1.0	1.7	3.6	8.0	13.4	19.1	44.2	45.0	71.5	94.9	89.9	10.5							
Mortality	M	0	0	0	0	0	0	0	2	2	11	13	19	28	35	41	42	36	15	244	5.5	1.3	76	7.2	6.4	8.2
	F	0	0	0	0	0	0	1	2	4	2	11	14	20	24	24	28	35	165	5.3	0.7	145	4.0	3.4	4.7	
	P	0	0	0	0	0	0	1	4	2	15	30	42	55	65	66	64	50	409	5.4	1.0	101	5.6	5.1	6.2	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.3	7.4	9.6	14.8	25.8	43.8	69.2	90.3	116.2	71.4	11.7							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	2.6	1.5	8.7	13.2	25.5	39.5	45.4	67.1	87.1	7.9							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	5.0	5.5	11.8	19.6	34.8	54.1	66.4	88.0	81.7	9.8							

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE_Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate (1 in x)	ASR (World)/100,000	Lower Limit	Upper Limit		
<b>C30-C37 NASAL CAVITY &amp; MIDDLE EAR AND ACCESSORY SINUSES</b>																										
Incidence	M	0	0	0	0	0	0	0	0	1	0	3	2	0	1	0	0	0	1	11	0.1	0.0	2345	0.4	0.2	0.7
	F	0	0	0	0	0	1	1	0	1	1	0	0	2	2	1	0	0	0	9	0.1	0.1	1915	0.3	0.1	0.6
	P	0	0	0	0	0	1	1	0	2	1	3	2	2	3	1	0	0	1	20	0.1	0.0	2090	0.4	0.2	0.5
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	2.3	1.8	0.0	1.7	0.0	0.0	0.0	4.8	0.5						
	F	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	0.7	0.7	0.0	2.6	3.3	1.9	0.0	0.0	0.0	0.4	0.4						
	P	0.0	0.0	0.0	0.0	0.4	0.3	1.0	0.0	0.7	0.4	1.2	0.9	1.3	2.5	1.0	0.0	1.6	0.5							
Mortality	M	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	2	4	0.1	0.0	12798	0.1	0.0	0.3
	F	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	2	0.1	0.0	25286	0.0	0.0	0.2
	P	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	1	2	6	6	0.1	0.0	16961	0.1	0.0	0.2
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	9.5	0.2						
	F	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2						
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	1.4	3.3	0.1							
<b>C32 LARYNX</b>																										
Incidence	M	0	0	0	0	0	0	1	1	4	7	15	21	16	19	9	11	4	108	0.9	0.6	180	3.4	2.8	4.2	
	F	0	0	0	0	0	0	0	0	1	0	2	2	3	2	1	2	1	14	0.2	0.1	1522	0.4	0.2	0.7	
	P	0	0	0	0	0	1	1	1	5	7	17	23	19	21	10	13	5	122	0.6	0.3	324	1.9	1.6	2.3	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.7	2.7	5.1	11.7	19.3	20.0	32.1	19.4	35.5	19.1	5.2							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.6	1.9	3.8	3.3	1.9	4.8	2.5	0.7							
	P	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.3	1.7	2.6	6.7	10.7	12.0	17.5	10.1	17.9	8.2	2.9							
Mortality	M	0	0	0	0	0	0	0	0	0	2	2	0	8	7	6	8	5	39	0.9	0.2	521	1.1	0.8	1.5	
	F	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0	1	2	5	0.2	0.0	10574	0.1	0.0	0.3	
	P	0	0	0	0	0	0	0	0	0	2	2	2	8	7	6	9	7	44	0.6	0.1	1015	0.6	0.4	0.8	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.5	1.6	0.0	10.0	11.8	12.9	25.8	23.8	1.9							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	2.4	5.0	0.2							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.7	0.8	0.9	5.1	5.8	6.0	12.4	11.4	1.1							
<b>C33-C34 TRACHEA AND BRONCHUS &amp; LUNG</b>																										
Incidence	M	0	0	0	0	0	0	5	14	31	53	91	166	208	229	184	159	75	1216	9.6	6.7	15	36.8	34.8	38.9	
	F	0	0	0	0	0	1	4	10	28	38	72	115	110	110	87	80	51	685	7.4	3.4	30	20.0	18.5	21.5	
	P	0	0	0	0	0	1	9	24	59	91	163	255	323	339	271	239	126	1901	8.7	5.0	20	28.0	26.8	29.3	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	3.2	9.4	20.8	38.9	71.1	152.7	260.2	386.5	395.7	513.4	357.2	58.2							
	F	0.0	0.0	0.0	0.0	0.0	0.7	2.6	6.6	18.3	27.7	56.9	84.2	146.9	181.0	164.6	191.6	127.0	32.7							
	P	0.0	0.0	0.0	0.0	0.0	0.4	2.9	7.9	19.6	33.3	64.1	118.9	204.1	282.4	272.7	328.7	206.0	45.5							
Mortality	M	0	0	0	0	0	0	2	10	22	44	74	135	180	172	171	142	79	1034	23.4	5.6	18	30.8	29.0	32.7	
	F	0	0	0	0	0	1	2	8	17	37	52	71	76	87	72	71	59	555	17.8	2.7	38	15.6	14.3	17.0	
	P	0	0	0	0	0	1	4	18	39	81	126	206	256	259	243	213	138	1589	21.1	4.1	25	22.9	21.7	24.0	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.7	1.4	1.3	6.7	14.8	32.3	57.8	124.2	225.2	290.3	367.7	376.3	49.5							
	F	0.0	0.0	0.0	0.0	0.0	0.7	1.4	1.3	5.2	11.1	26.9	41.1	67.2	97.1	143.1	136.2	170.1	146.9	26.5						
	P	0.0	0.0	0.0	0.0	0.0	0.3	1.4	1.3	6.0	12.9	29.6	49.5	96.1	161.8	215.8	244.6	225.6	38.0							
<b>C37, C38 THYMUS, HEART, MEDIASTINUM &amp; PLEURA</b>																										
Incidence	M	1	0	0	0	0	0	0	0	0	1	0	2	1	0	1	2	1	10	0.1	0.0	2711	0.4	0.2	0.7	
	F	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	4	0.0	0.0	5180	0.2	0.1	0.5	
	P	2	0	0	0	0	0	0	0	0	1	1	2	1	1	1	2	1	14	0.1	0.0	3586	0.3	0.2	0.5	
Rate Per 100,000	M	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.8	1.3	0.0	2.2	6.5	4.8	0.5							
	F	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.6	0.0	0.0	0.0	0.2							
	P	0.7	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.4	0.4	0.9	0.6	0.8	1.0	2.8	1.6	0.3							
Mortality	M	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	1	1	8	0.2	0.0	2832	0.3	0.1	0.5	
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.0	0.0	21147	0.0	0.0	0.2	
	P	0	0	0	0	0	0	0	0	0	1	0	2	0	1	1	1	1	9	0.1	0.0	5260	0.1	0.1	0.3	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.0	0.9	0.0	1.7	2.2	3.2	4.8	0.4							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.8	1.0	1.4	1.6	0.2							

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (World)/100,000	ASR	Lower Limit	Upper Limit	
<b>C40.C41 BONES, JOINTS &amp; ARTICULAR CARTILAGES</b>																										
Incidence	M	1	2	1	4	1	1	2	4	2	0	1	2	2	2	0	1	3	3	31	0.2	0.1	910	1.4	0.9	1.9
	F	2	0	2	0	0	0	0	2	0	1	0	1	0	1	2	1	1	1	14	0.2	0.1	1662	0.6	0.3	1.0
	P	3	2	3	4	1	2	2	6	2	1	1	3	2	3	2	2	4	4	45	0.2	0.1	1166	1.0	0.7	1.3
Rate Per 100,000	M	0.7	1.4	0.7	2.7	0.7	1.4	1.3	2.7	1.3	0.0	0.8	1.8	2.5	3.4	0.0	3.2	14.3	1.5							
	F	1.5	0.0	1.4	0.0	0.0	0.7	0.0	1.3	0.0	0.7	0.0	0.9	0.0	1.6	3.8	2.4	2.5	0.7							
	P	1.1	0.7	1.0	1.4	0.3	0.7	0.6	2.0	0.7	0.4	0.4	1.4	1.3	2.5	2.0	2.8	6.5	1.1							
Mortality	M	0	0	1	3	2	3	1	0	0	1	0	2	1	2	0	0	2	18	0.4	0.1	1433	0.8	0.5	1.3	
	F	0	0	1	1	2	1	1	0	0	0	1	0	1	0	0	1	1	11	0.4	0.0	2927	0.5	0.2	0.8	
	P	0	0	2	4	4	4	2	0	0	1	1	4	1	2	0	1	3	29	0.4	0.1	1924	0.6	0.4	0.9	
Rate Per 100,000	M	0.0	0.0	0.7	2.0	1.3	2.1	0.7	0.0	0.0	0.7	0.0	1.8	1.3	3.4	0.0	0.0	9.5	0.9							
	F	0.0	0.0	0.7	0.7	1.3	0.7	0.0	0.0	0.0	0.0	0.8	1.9	0.0	0.0	0.0	2.4	2.5	0.5							
	P	0.0	0.0	0.7	1.4	1.3	1.4	0.7	0.0	0.0	0.4	0.4	1.9	0.6	1.7	0.0	1.4	4.9	0.7							
<b>C44. M872-M879 MELANOMA</b>																										
Incidence	M	0	0	2	6	17	23	50	68	116	144	171	205	192	166	142	123	84	1558	12.3	7.4	14	52.1	49.5	54.7	
	F	0	0	2	6	29	39	46	90	108	109	110	95	94	76	76	79	56	1110	12.0	4.6	22	37.8	35.6	40.1	
	P	0	0	4	12	46	62	96	158	224	253	281	300	286	242	218	202	140	2668	12.2	6.0	17	44.6	43.0	46.4	
Rate Per 100,000	M	0.0	0.0	1.3	4.0	11.2	15.9	34.5	31.7	45.6	77.9	105.8	188.6	240.2	280.2	305.4	397.2	400.1	74.6							
	F	0.0	0.0	1.4	4.2	19.5	27.8	31.6	60.6	59.0	70.7	79.4	87.0	89.8	120.1	125.0	143.8	139.4	53.0							
	P	0.0	0.0	1.4	4.1	15.3	21.8	33.0	46.3	52.3	92.5	110.5	139.9	180.8	201.6	219.4	277.8	228.9	63.8							
Mortality	M	0	0	0	0	1	3	0	4	10	9	16	17	16	20	30	33	28	196	4.4	0.9	117	5.7	4.9	6.6	
	F	0	0	0	1	1	4	2	2	3	5	11	8	9	10	11	15	15	89	2.9	0.4	279	2.6	2.1	3.2	
	P	0	0	1	1	2	7	2	6	13	14	22	28	24	29	40	44	43	285	3.8	0.6	167	4.0	3.6	4.5	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.7	2.1	0.0	2.6	6.7	6.0	12.5	15.6	20.0	33.8	64.5	106.6	133.4	9.4							
	F	0.0	0.0	0.7	0.7	2.8	2.8	1.4	1.3	2.0	3.3	4.7	10.4	10.2	14.8	18.9	26.4	37.3	4.3							
	P	0.0	0.0	0.0	0.3	0.7	2.5	0.7	1.9	4.3	4.6	8.6	13.1	15.2	24.2	40.3	60.5	70.3	6.8							
<b>C44 OTHER SKIN (EXCL BCC/SCC)</b>																										
Incidence	M	0	0	0	1	1	1	1	2	6	6	7	8	8	12	13	23	18	106	0.8	0.4	242	3.0	2.4	3.6	
	F	0	0	0	1	0	1	3	2	2	4	4	2	5	5	4	6	13	54	0.6	0.2	534	1.5	1.1	1.9	
	P	0	0	1	1	1	2	4	2	4	8	10	11	13	17	17	29	31	160	0.7	0.3	337	2.2	1.8	2.5	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.7	0.7	0.7	1.3	4.0	4.4	5.5	7.4	10.0	20.3	28.0	74.3	85.7	5.1							
	F	0.0	0.0	0.0	0.7	0.0	0.7	2.1	1.3	1.3	2.9	3.2	1.9	6.4	8.2	7.6	14.4	32.4	2.6							
	P	0.0	0.0	0.0	0.3	0.3	0.7	1.4	0.6	1.3	2.7	4.3	4.7	8.2	14.2	17.1	39.9	50.7	3.8							
Mortality	M	0	0	0	0	0	0	0	0	0	0	0	3	1	7	4	5	5	25	0.6	0.1	819	0.7	0.4	1.0	
	F	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	0	3	7	0.2	0.0	3216	0.1	0.1	0.3	
	P	0	0	0	0	0	0	0	0	0	0	1	3	1	8	6	5	8	32	0.4	0.1	1323	0.4	0.3	0.5	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	1.3	11.8	8.6	16.1	23.8	1.2							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.6	3.8	0.0	7.5	0.3							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.4	0.6	6.7	6.0	6.9	13.1	0.8							
<b>M905 MESOTHELIOMA</b>																										
Incidence	M	0	0	0	0	0	0	0	1	0	5	16	14	15	25	10	17	8	111	0.9	0.6	179	3.3	2.7	4.0	
	F	0	0	0	0	0	0	0	0	2	0	3	3	3	2	1	3	0	17	0.2	0.1	1288	0.5	0.3	0.8	
	P	0	0	0	0	0	0	0	1	2	5	19	17	18	27	11	20	8	128	0.6	0.3	317	1.9	1.6	2.2	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	3.7	12.5	12.9	18.8	42.2	21.5	54.9	38.1	5.3							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	3.8	3.3	3.3	1.9	7.2	0.0	0.8	0.8							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	1.8	7.5	7.9	11.4	22.5	11.1	27.5	13.1	3.1							
Mortality	M	0	0	0	0	0	1	0	0	2	3	8	14	12	19	23	22	7	111	2.5	0.6	167	3.1	2.6	3.8	
	F	0	0	0	0	0	0	0	0	0	2	1	4	3	2	0	2	3	17	0.5	0.1	1521	0.5	0.3	0.8	
	P	0	0	0	0	0	1	0	0	2	5	9	18	15	21	23	24	10	128	1.7	0.3	309	1.7	1.5	2.1	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.3	2.2	6.3	12.9	15.0	32.1	49.5	71.0	33.3	5.3							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.8	3.8	3.8	3.3	0.0	4.8	7.5	0.8							
	P	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.7	1.8	3.5	8.4	9.5	17.5	23.1	33.0	16.3	3.1							

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE_Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (1 in x) 100,000	ASR (World)/ 100,000	Lower Limit	Upper Limit	
<b>M914 KAPOSI SARCOMA</b>																										
Incidence	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mortality	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVES</b>																										
Incidence	M	0	0	1	1	2	1	0	4	5	6	4	2	3	4	4	5	1	43	0.3	0.2	530	1.5	1.1	2.0	
	F	3	1	2	0	0	1	2	0	2	2	5	3	4	7	2	2	1	38	0.4	0.2	540	1.5	1.1	2.1	
	P	3	1	3	1	2	2	4	1	7	8	9	5	7	11	6	7	2	81	0.4	0.2	538	1.5	1.2	1.9	
Rate Per 100,000	M	0.0	0.0	0.7	0.7	1.3	0.7	0.0	2.6	0.0	4.4	3.1	1.8	3.8	6.8	8.6	16.1	4.8	2.1							
	F	2.3	0.7	1.4	0.0	0.0	0.7	1.4	0.0	1.3	1.5	4.0	2.8	5.1	11.5	3.8	4.8	2.5	1.8							
	P	1.1	0.4	1.0	0.3	0.7	0.7	1.3	0.3	2.3	2.9	3.5	2.3	4.4	9.2	6.0	9.6	3.3	1.9							
Mortality	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	F	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	P	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1915	0.4	0.2	0.7	
	F	0.8	0.0	0.0	0.7	0.0	0.7	0.0	0.0	0.0	0.7	2.3	0.9	1.3	1.7	2.2	0.0	4.8	0.5	0.1	0.1	1403	0.5	0.3	0.9	
	P	0.4	0.0	0.0	0.3	0.0	0.4	0.3	0.0	0.0	0.7	2.0	1.9	1.3	0.8	4.0	1.4	3.3	0.6	0.3	0.1	1611	0.5	0.3	0.7	
<b>C48 RETROPERITONEUM &amp; PERITONEUM</b>																										
Incidence	M	0	0	0	0	0	0	0	0	3	4	0	2	1	0	2	1	1	15	0.1	0.1	1572	0.5	0.3	0.8	
	F	0	0	0	0	0	0	0	1	3	1	6	6	5	11	8	2	4	47	0.5	0.3	375	1.4	1.0	1.8	
	P	0	0	0	0	0	0	0	4	7	1	8	7	6	11	10	3	5	62	0.3	0.2	599	1.0	0.7	1.2	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	1.6	0.9	1.3	0.0	4.3	3.2	4.8	0.7							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.0	0.7	4.7	5.7	6.4	18.1	15.1	4.8	10.0	2.2							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	2.3	0.4	3.1	3.3	3.8	9.2	10.1	4.1	8.2	1.5							
Mortality	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	P	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.0	0.0	0.0	1.3	1.7	0.0	0.0	9.5	0.3							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.3	2.8	7.7	9.9	13.2	7.2	12.4	1.5							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.4	0.0	1.4	4.4	5.8	7.0	4.1	11.4	0.9							
<b>C50 BREAST</b>																										
Incidence	M	0	0	0	0	0	0	0	0	0	1	0	4	3	3	8	1	4	24	0.2	0.2	658	0.7	0.4	1.0	
	F	0	0	0	0	2	8	41	204	266	323	337	343	264	212	150	125	124	2469	26.8	10.9	10	81.8	78.6	85.1	
	P	0	0	0	0	2	8	41	70	204	324	337	347	267	215	158	126	128	2493	11.4	5.6	18	41.7	40.0	43.3	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	3.7	3.8	5.1	17.2	3.2	19.1	1.1							
	F	0.0	0.0	0.0	0.0	1.3	5.7	28.2	133.7	174.2	235.2	266.6	324.4	337.2	348.8	283.7	299.5	308.7	117.9							
	P	0.0	0.0	0.0	0.0	0.7	2.8	14.1	67.6	88.2	118.5	132.5	161.8	168.7	179.1	159.0	173.3	209.3	59.6							
Mortality	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	P	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (World)/ 100,000	ASR	Lower Limit	Upper Limit	
<b>C51 VULVA</b>																										
Incidence M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
F	0	0	0	0	0	0	1	1	3	2	6	3	3	4	4	6	9	5	5	50	0.5	514	1.4	1.0	1.9	
P	0	0	0	0	0	0	1	1	3	2	6	3	3	4	4	6	9	5	5	50	0.2	n.a	n.a	n.a	n.a	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	n.a	
F	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	1.9	1.3	3.9	2.2	2.4	2.8	5.1	6.6	11.3	21.6	12.4	2.4	0.2	n.a	n.a	n.a	n.a	
P	0.0	0.0	0.0	0.0	0.0	0.4	0.3	1.0	0.7	2.0	1.1	1.2	1.4	2.5	3.3	6.0	12.4	8.2	1.2	0.2	n.a	n.a	n.a	n.a	n.a	
Mortality M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
F	0	0	0	0	0	0	0	0	0	0	1	0	2	2	2	0	1	5	13	0.4	0.0	2363	0.3	0.2	0.6	
P	0	0	0	0	0	0	0	0	0	0	1	0	2	2	2	0	1	5	13	0.2	0.0	n.a	n.a	n.a	n.a	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	n.a	
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.9	2.6	3.3	0.0	2.4	12.4	0.6	0.2	n.a	n.a	n.a	n.a	n.a	
P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.9	1.3	1.7	0.0	1.4	8.2	0.3	0.2	n.a	n.a	n.a	n.a	n.a	
<b>C53 CERVIX UTERI</b>																										
Incidence M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
F	0	0	0	0	1	9	14	14	14	13	12	18	13	9	4	8	5	3	143	1.6	0.6	173	5.2	4.4	6.1	
P	0	0	0	0	1	9	14	14	20	13	12	18	13	9	4	8	5	3	143	0.7	n.a	n.a	n.a	n.a	n.a	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	n.a	
F	0.0	0.0	0.0	0.0	0.7	6.4	9.6	8.9	13.1	8.5	8.7	14.2	12.3	11.5	6.6	15.1	12.0	7.5	6.8	0.8	0.2	n.a	n.a	n.a	n.a	
P	0.0	0.0	0.0	0.0	0.3	3.2	4.8	4.5	6.6	4.3	4.4	7.1	6.1	5.7	3.3	8.1	6.9	4.9	3.4	0.3	0.2	n.a	n.a	n.a	n.a	
Mortality M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
F	0	0	0	0	0	0	2	0	4	3	4	1	6	5	0	5	3	3	36	1.2	0.2	642	1.1	0.8	1.6	
P	0	0	0	0	0	0	2	0	4	3	4	1	6	5	0	5	3	3	36	0.5	n.a	n.a	n.a	n.a	n.a	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	n.a	
F	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	2.6	2.0	2.9	0.8	5.7	6.4	0.0	9.5	7.2	7.5	1.7	0.5	n.a	n.a	n.a	n.a	n.a	
P	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.3	1.0	1.5	0.4	2.8	3.2	0.0	5.0	4.1	4.9	0.9	0.2	n.a	n.a	n.a	n.a	n.a	
<b>C54 CORPUS UTERI</b>																										
Incidence M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
F	0	0	0	0	0	0	6	6	8	9	42	59	70	60	42	34	19	19	368	4.0	1.8	55	11.7	10.6	13.0	
P	0	0	0	0	0	0	6	6	8	9	42	59	70	60	42	34	19	19	368	1.7	n.a	n.a	n.a	n.a	n.a	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	n.a	
F	0.0	0.0	0.0	0.0	0.0	0.0	3.8	3.8	5.2	5.9	30.6	46.7	66.2	76.6	69.1	64.3	45.5	47.3	17.6	0.8	0.2	n.a	n.a	n.a	n.a	
P	0.0	0.0	0.0	0.0	0.0	0.0	3.0	3.0	2.6	3.0	15.4	23.2	32.6	37.9	35.0	34.2	26.1	31.1	8.8	0.3	0.2	n.a	n.a	n.a	n.a	
Mortality M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
F	0	0	0	0	0	0	1	1	1	1	3	7	12	8	14	8	8	9	72	2.3	0.3	289	2.0	1.6	2.6	
P	0	0	0	0	0	0	1	1	0	1	3	7	12	8	14	8	8	9	72	1.0	n.a	n.a	n.a	n.a	n.a	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	n.a	
F	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	0.7	2.2	5.5	11.3	10.2	23.0	15.1	19.2	22.4	3.4	0.5	n.a	n.a	n.a	n.a	n.a	
P	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.3	1.1	2.8	5.6	5.1	11.7	8.1	11.0	14.7	1.7	0.2	n.a	n.a	n.a	n.a	n.a	
<b>C56 OVARY</b>																										
Incidence M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
F	0	1	2	2	2	3	3	5	9	16	19	25	29	21	18	22	19	16	212	2.3	0.9	107	6.7	5.8	7.7	
P	0	1	2	2	2	3	3	5	9	16	19	25	29	21	18	22	19	16	212	1.0	n.a	n.a	n.a	n.a	n.a	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	n.a	
F	0.0	0.7	1.4	1.3	2.1	2.1	3.2	5.9	10.5	13.8	19.8	27.4	26.8	29.6	41.6	45.5	39.8	10.1	0.8	0.3	0.2	n.a	n.a	n.a	n.a	
P	0.0	0.4	0.7	0.7	1.1	1.0	1.6	3.0	5.3	6.9	9.8	13.5	13.3	15.0	22.1	26.1	26.2	5.1	0.3	0.2	n.a	n.a	n.a	n.a	n.a	
Mortality M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
F	0	0	0	0	0	0	0	2	3	9	7	13	20	18	15	13	20	16	136	4.4	0.6	173	3.8	3.2	4.5	
P	0	0	0	0	0	0	0	2	3	9	7	13	20	18	15	13	20	16	136	1.8	n.a	n.a	n.a	n.a	n.a	
Rate Per 100,000 M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	n.a	
F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	2.0	5.9	5.1	10.3	18.9	23.0	24.7	24.6	47.9	39.8	6.5	0.5	0.2	0.2	0.2	0.2	0.6	
P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.0	3.0	2.6	5.1	9.3	11.4	12.5	13.1	27.5	26.2	3.3	0.3	0.2	0.2	0.2	0.2	0.6	

Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007

ICD-O3/SITE_Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate (1 in x)	ASR (World)/100,000	Lower Limit	Upper Limit	
<b>C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANS</b>																									
Incidence	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
	F	0	0	0	0	2	1	0	3	3	2	7	5	8	5	4	7	8	8	55	0.6	0.2	457	1.6	2.1
	P	0	0	0	0	2	1	0	3	3	2	7	5	8	5	4	7	8	55	0.3	n.a	n.a	n.a	n.a	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	
	F	0.0	0.0	0.0	0.0	1.4	0.7	0.0	2.0	2.0	1.5	5.5	4.7	10.2	8.2	7.6	16.8	19.9	2.6	2.6	16.8	19.9	1.6	2.1	
	P	0.0	0.0	0.0	0.0	0.7	0.3	0.0	1.0	1.0	0.7	2.8	2.3	5.1	4.2	4.0	9.6	13.1	1.3	1.3	16.8	19.9	1.6	2.1	
Mortality	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
	F	0	0	0	0	0	0	1	0	1	0	1	1	1	1	1	1	5	6	18	0.6	0.0	2550	0.4	0.6
	P	0	0	0	0	0	0	1	0	1	0	1	1	1	1	1	5	6	18	0.2	n.a	n.a	n.a	n.a	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	
	F	0.0	0.0	0.0	0.0	0.8	0.4	0.6	1.6	1.6	1.3	8.8	7.6	16.8	14.9	13.2	28.8	40.9	0.9	0.9	16.8	19.9	1.6	2.1	
	P	0.0	0.0	0.0	0.0	0.4	0.3	0.3	0.3	0.3	0.4	1.4	1.1	2.8	2.3	2.1	6.9	9.8	0.4	0.4	16.8	19.9	1.6	2.1	
<b>C61 PROSTATE GLAND</b>																									
Incidence	M	0	0	0	0	0	0	1	14	80	225	517	683	760	534	447	235	184	3680	29.1	20.4	5	117.7	113.9	121.6
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
	P	0	0	0	0	0	0	1	14	80	225	517	683	760	534	447	235	184	3680	16.8	n.a	n.a	n.a	n.a	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.6	9.4	53.7	165.4	404.0	628.2	950.7	901.3	961.3	758.8	876.4	176.3	176.3	13.6	2.4	42	14.9	16.2
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.3	4.6	26.5	82.3	203.2	318.5	480.3	444.9	449.9	323.2	300.8	88.0	88.0	13.6	2.4	42	14.9	16.2
Mortality	M	0	0	0	0	0	0	0	2	1	3	14	36	49	65	123	136	171	600	600	8.0	n.a	n.a	n.a	n.a
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	
	P	0	0	0	0	0	0	0	2	1	3	14	36	49	65	123	136	171	600	8.0	n.a	n.a	n.a	n.a	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.7	2.2	10.9	33.1	61.3	109.7	264.5	439.1	814.5	28.7	28.7	8.0	n.a	n.a	n.a	n.a
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a	n.a	n.a	
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.3	1.1	5.5	16.8	31.0	54.1	123.8	187.0	279.6	14.3	14.3	8.0	n.a	n.a	n.a	
<b>C62 TESTIS</b>																									
Incidence	M	2	0	0	5	11	13	22	18	22	11	7	1	1	1	0	1	0	116	0.9	0.4	251	5.1	4.2	6.1
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
	P	2	0	0	5	11	13	22	18	22	11	7	1	1	1	0	1	0	116	0.5	n.a	n.a	n.a	n.a	
Rate Per 100,000	M	1.4	0.0	0.0	3.3	7.2	9.0	15.2	11.7	14.7	7.4	5.1	0.8	0.9	1.3	1.7	0.0	3.2	5.6	5.6	1.4	0.0	0.0	0.0	
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	P	0.7	0.0	0.0	1.7	3.7	4.6	7.6	5.8	7.3	3.6	2.6	0.4	0.5	0.6	0.8	0.0	1.4	2.8	2.8	0.0	0.0	0.0	0.0	
Mortality	M	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	4	4	0.1	0.0	7439	0.2	0.5
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	
	P	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	4	4	0.1	n.a	n.a	n.a	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.7	0.7	0.7	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	P	0.0	0.0	0.0	0.0	0.3	0.4	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	
<b>C60,C63 PENIS AND OTHER &amp; UNSPECIFIED MALE GENITAL ORGANS</b>																									
Incidence	M	0	0	0	0	0	0	0	2	0	2	1	0	5	3	4	5	2	24	0.2	0.1	851	0.7	0.4	1.0
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	n.a	
	P	0	0	0	0	0	0	0	2	0	2	1	0	5	3	4	5	2	24	0.1	n.a	n.a	n.a	n.a	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	1.5	0.8	0.0	6.3	5.1	8.6	16.1	9.5	1.1	1.1	0.0	0.0	0.0	0.0	
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.7	0.4	0.0	3.2	2.5	4.0	6.9	3.3	0.6	0.6	0.0	0.0	0.0	0.0	
Mortality	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	3	0.1	0.0	9300	0.1	0.2	
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	n.a	n.a	n.a	
	P	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	3	0.0	0.0	0.0	0.0	0.0	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (World)/ 100,000	ASR	Lower Limit	Upper Limit	
<b>C64-C66, C68 KIDNEY AND OTHER RENAL TRACT</b>																										
Incidence	M	2	0	0	0	0	0	10	11	25	28	41	57	54	42	59	39	25	395	3.1	2.0	50	12.5	11.3	13.8	
	F	0	1	2	0	1	3	7	10	10	19	17	19	30	18	21	20	28	207	2.2	0.9	114	6.2	5.4	7.1	
	P	2	1	2	0	1	3	17	21	35	47	58	76	84	60	80	59	53	602	2.8	1.4	70	9.2	8.5	10.0	
Rate Per 100,000	M	1.4	0.0	0.0	0.0	0.0	1.4	6.5	7.4	16.8	20.6	32.0	52.4	67.6	70.9	126.9	125.9	119.1	18.9							
	F	0.0	0.7	1.4	0.0	0.7	2.1	4.5	6.6	6.5	13.8	13.4	18.0	38.3	29.6	39.7	47.9	69.7	9.9							
	P	0.7	0.4	0.7	0.0	0.3	1.1	11.0	11.6	17.2	22.8	35.4	53.1	50.0	80.5	81.1	86.6	14.4								
Mortality	M	1	0	0	0	0	0	2	3	1	6	13	12	10	13	27	21	13	122	2.8	0.6	163	3.4	2.9	4.1	
	F	0	0	0	0	0	0	0	0	1	1	1	3	8	11	11	8	14	58	1.9	0.3	370	1.4	1.0	1.8	
	P	1	0	0	0	0	0	2	3	2	7	14	15	18	24	38	29	27	180	2.4	0.4	230	2.4	2.0	2.7	
Rate Per 100,000	M	0.7	0.0	0.0	0.0	0.0	0.0	1.3	2.0	0.7	4.4	10.2	11.0	12.5	21.9	58.1	67.8	61.9	5.8							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.8	2.8	10.2	18.1	20.8	19.2	34.9	2.8							
	P	0.4	0.0	0.0	0.0	0.0	0.0	0.6	1.0	0.7	2.6	5.5	7.0	11.4	20.0	38.2	39.9	44.1	4.3							
<b>C67 BLADDER</b>																										
Incidence	M	0	1	0	0	1	1	2	3	9	16	22	40	40	66	70	48	44	364	2.9	1.9	52	10.6	9.5	11.7	
	F	0	0	0	0	0	0	0	4	8	2	3	11	13	17	18	33	27	136	1.5	0.5	199	3.2	2.7	3.8	
	P	0	1	0	0	1	1	2	7	17	18	25	51	53	83	88	81	71	500	2.3	1.2	83	6.7	6.1	7.3	
Rate Per 100,000	M	0.0	0.7	0.0	0.0	0.7	0.7	1.3	2.0	6.0	11.8	17.2	36.8	50.0	111.4	150.5	155.0	209.6	17.4							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	5.2	1.5	2.4	10.4	16.6	28.0	34.0	79.1	67.2	6.5							
	P	0.0	0.4	0.0	0.0	0.3	0.4	0.6	2.3	5.6	6.6	9.8	23.8	33.5	69.1	88.6	111.4	116.1	12.0							
Mortality	M	0	0	0	0	0	0	0	0	1	4	11	4	15	15	31	27	23	131	3.0	0.6	158	3.4	2.8	4.0	
	F	0	0	0	0	0	0	0	1	1	1	2	2	2	9	9	7	15	48	1.5	0.2	513	1.0	0.8	1.4	
	P	0	0	0	0	0	0	1	1	2	4	12	6	17	24	40	34	38	179	2.4	0.4	247	2.1	1.8	2.5	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.9	8.6	3.7	18.8	25.3	66.7	87.2	109.5	6.3							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.7	0.0	0.8	1.9	2.6	14.8	17.0	16.8	37.3	2.3							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.7	1.5	4.7	2.8	10.7	20.0	40.3	46.8	62.1	4.3							
<b>C69 EYE &amp; ADNEXA</b>																										
Incidence	M	5	0	0	0	0	0	0	1	0	5	2	6	2	2	0	0	3	26	0.2	0.1	959	1.1	0.7	1.7	
	F	2	0	0	0	0	2	0	0	2	3	3	4	4	2	3	1	1	26	0.3	0.1	780	1.0	0.6	1.4	
	P	7	0	0	0	0	2	0	1	2	8	5	9	6	4	3	1	4	52	0.2	0.1	853	1.1	0.8	1.4	
Rate Per 100,000	M	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	3.7	1.6	5.5	2.5	3.4	0.0	0.0	14.3	1.2							
	F	1.5	0.0	0.0	0.0	0.0	1.4	0.0	0.0	1.3	2.2	2.4	2.8	5.1	3.3	5.7	2.4	2.5	1.2							
	P	2.6	0.0	0.0	0.0	0.0	0.7	0.0	0.3	0.7	2.9	2.0	4.2	3.8	3.3	3.0	1.4	6.5	1.2							
Mortality	M	0	0	0	0	0	0	0	0	0	0	1	1	1	2	2	0	1	8	0.2	0.1	1882	0.2	0.1	0.5	
	F	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	1	0	4	0.1	0.0	6162	0.1	0.0	0.3	
	P	0	0	0	0	0	0	0	0	1	0	1	2	1	3	2	1	1	12	0.2	0.0	2941	0.2	0.1	0.3	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.9	1.3	3.4	4.3	0.0	4.8	0.4							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.9	0.0	1.6	0.0	2.4	0.0	0.2							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.9	0.6	2.5	2.0	1.4	1.6	0.3							
<b>C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM</b>																										
Incidence	M	4	3	7	2	2	7	8	7	15	8	18	17	21	23	9	8	4	170	1.3	0.8	124	6.5	5.6	7.6	
	F	5	2	2	0	3	4	4	4	5	12	10	9	11	11	7	10	3	109	1.2	0.5	211	4.1	3.3	4.9	
	P	9	5	9	4	2	10	12	11	20	20	28	26	32	34	16	18	7	279	1.3	0.6	156	5.3	4.7	5.9	
Rate Per 100,000	M	2.8	2.1	4.7	1.3	1.3	4.9	5.5	4.5	10.1	5.9	14.1	15.6	26.3	38.8	19.4	25.8	19.1	8.1							
	F	3.8	1.5	1.4	0.0	2.1	2.7	2.6	5.9	3.3	8.7	7.9	8.5	14.1	18.1	13.2	24.0	7.5	5.2							
	P	3.3	1.8	3.1	1.4	0.7	3.5	4.1	3.5	6.6	7.3	11.0	12.1	20.2	28.3	16.1	24.8	11.4	6.7							
Mortality	M	1	2	0	0	0	3	2	3	3	16	7	13	17	24	7	10	0	125	2.8	0.6	157	4.4	3.7	5.2	
	F	0	4	0	0	3	0	1	2	1	6	12	9	7	14	4	5	7	82	2.6	0.4	270	2.8	2.2	3.5	
	P	1	6	0	3	0	4	4	4	23	13	25	26	24	38	11	15	7	207	2.7	0.5	199	3.6	3.1	4.1	
Rate Per 100,000	M	0.7	1.4	0.0	0.0	0.0	2.1	1.4	1.9	2.0	10.7	5.1	10.2	15.6	21.3	40.5	15.1	32.3	6.0							
	F	0.0	2.9	0.0	2.1	0.0	0.7	1.4	0.6	4.6	4.4	9.5	8.5	8.9	23.0	7.6	12.0	17.4	3.9							
	P	0.4	2.1	0.0	1.0	0.0	1.4	1.3	1.0	7.6	4.8	9.8	12.1	15.2	31.7	11.1	20.6	11.4	5.0							

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE_Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (1 in x)	ASR (World)/100,000	Lower Limit	Upper Limit	
<b>C73 THYROID GLAND</b>																										
Incidence	M	0	0	0	0	3	1	4	5	10	18	11	14	10	11	7	7	2	1	112	0.9	0.5	189	4.0	3.3	4.9
	F	0	0	0	7	13	25	33	32	37	46	45	39	21	20	14	10	5	3	350	3.8	1.4	72	13.6	12.2	15.1
	P	0	0	0	7	16	26	37	37	47	64	56	54	30	25	17	7	4	462	2.1	1.0	104	8.8	8.0	9.7	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	2.0	0.7	2.8	3.2	6.7	12.1	8.1	11.7	12.9	18.6	15.1	6.5	4.8	5.4							
	F	0.0	0.0	0.0	4.9	8.8	17.8	22.7	20.4	24.2	30.1	32.8	30.8	19.9	25.5	23.0	18.9	12.0	7.5	16.7						
	P	0.0	0.0	0.0	2.4	5.3	9.1	12.7	11.9	15.6	21.2	20.5	16.3	19.0	20.8	17.1	9.6	6.5	11.0							
Mortality	M	0	0	0	0	0	0	0	0	1	0	1	0	0	2	1	1	2	1	9	0.2	0.0	2583	0.3	0.1	0.5
	F	0	0	0	0	0	0	0	1	0	1	0	0	0	2	2	1	1	1	8	0.3	0.0	2391	0.2	0.1	0.4
	P	0	0	0	0	0	0	0	1	1	1	0	0	2	3	3	3	2	17	0.2	0.0	2460	0.2	0.1	0.4	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.7	0.0	0.0	2.5	1.7	2.2	6.5	4.8	0.4						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.0	0.0	0.0	0.0	3.3	3.8	2.4	2.5	0.4							
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.3	0.4	0.0	1.3	2.5	3.0	4.1	3.3	0.4							
<b>C74-C75 ADRENAL AND OTHER ENDOCRINE GLANDS</b>																										
Incidence	M	2	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	6	0.0	0.0	4075	0.3	0.1	0.7
	F	1	0	0	0	0	0	0	1	1	0	0	0	2	0	0	0	0	1	6	0.1	0.0	5515	0.2	0.1	0.5
	P	3	0	0	1	0	0	2	2	1	1	0	1	1	1	0	0	1	12	0.1	0.0	4656	0.3	0.2	0.5	
Rate Per 100,000	M	1.4	0.0	0.0	0.7	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.9	1.3	0.0	0.0	0.0	0.0	0.3							
	F	0.8	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	2.5	0.3						
	P	1.1	0.0	0.0	0.3	0.0	0.0	0.6	0.3	0.0	0.0	0.8	0.5	0.6	0.0	0.0	0.0	1.6	0.3							
Mortality	M	2	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	6	0.1	0.0	3944	0.3	0.1	0.8
	F	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0.1	0.0	12158	0.1	0.0	0.2
	P	2	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	2	9	0.1	0.0	5860	0.2	0.1	0.4
Rate Per 100,000	M	1.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.9	1.3	0.0	0.0	0.0	0.0	0.3							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	5.0	0.1						
	P	0.7	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.6	0.8	0.0	0.0	0.0	3.3	0.2						
<b>C26-C39,C76,C77,C80 OTHER &amp; ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE</b>																										
Incidence	M	0	0	0	0	0	1	5	1	18	26	29	41	42	49	44	52	42	351	2.8	1.6	62	10.4	9.4	11.6	
	F	2	0	0	0	1	2	1	8	10	18	11	21	34	36	42	52	87	325	3.5	1.2	84	7.8	7.0	8.7	
	P	2	0	0	0	1	3	6	9	28	44	40	62	76	85	86	104	129	676	3.1	1.4	71	9.1	8.5	9.9	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.7	3.2	0.7	12.1	19.1	22.7	37.7	52.5	82.7	94.6	167.9	200.0	16.8							
	F	1.5	0.0	0.0	0.0	0.7	1.4	0.6	5.2	6.5	13.1	8.7	19.9	43.4	59.2	79.4	124.6	216.6	15.5							
	P	0.7	0.0	0.0	0.0	0.3	0.4	1.0	1.9	3.0	9.3	16.1	15.7	28.9	48.0	70.8	86.6	143.0	16.2							
Mortality	M	0	0	0	0	0	0	0	0	0	0	9	17	25	33	27	37	34	209	4.7	0.9	107	5.9	5.1	6.8	
	F	0	1	0	0	0	0	1	2	4	3	8	15	13	23	20	43	74	207	6.6	0.6	167	4.3	3.8	5.0	
	P	0	1	0	0	0	1	0	4	10	12	25	34	38	56	47	80	108	416	5.5	0.8	131	5.1	4.7	5.7	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	13.3	17.5	31.3	55.7	58.1	119.5	161.9	10.0							
	F	0.0	0.7	0.0	0.0	0.0	0.7	0.0	1.3	2.6	2.2	6.3	14.2	16.6	37.8	37.8	103.0	184.2	9.9							
	P	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.0	1.3	3.3	4.4	9.8	15.9	24.0	46.7	47.3	110.0	176.6	9.9						
<b>M959-M972 ALL LYMPHOMAS</b>																										
Incidence	M	2	2	8	2	6	8	16	13	14	40	35	50	54	49	54	37	27	462	3.7	2.2	45	15.6	14.2	17.1	
	F	0	0	4	5	7	3	9	7	14	14	26	49	49	40	34	45	40	27	373	4.0	1.7	60	11.5	10.4	12.8
	P	2	2	12	7	13	11	25	20	28	54	61	94	94	83	99	77	54	835	3.8	2.0	52	13.5	12.6	14.5	
Rate Per 100,000	M	1.4	1.4	5.3	1.3	4.0	5.5	11.0	8.4	9.4	26.9	25.7	35.2	46.0	67.6	82.7	116.1	119.5	128.6	22.1						
	F	0.0	0.0	2.8	3.5	4.7	2.1	6.2	4.5	9.2	9.2	18.9	38.8	46.3	51.1	55.9	85.1	95.8	67.2	17.8						
	P	0.7	0.7	4.1	4.1	4.3	3.9	8.6	6.4	9.3	17.9	22.3	36.9	46.2	59.4	69.1	99.6	105.9	88.3	20.0						
Mortality	M	0	0	0	0	2	2	2	0	1	9	3	5	13	10	16	14	14	21	112	2.5	0.5	204	3.4	2.8	4.1
	F	0	0	0	0	1	0	0	0	1	5	3	4	5	7	11	20	16	23	97	3.1	0.4	250	2.3	1.8	3.2
	P	0	0	0	0	1	2	2	0	2	14	6	9	18	17	27	34	30	44	209	2.8	0.4	224	2.8	2.4	3.2
Rate Per 100,000	M	0.0	0.0	0.0	0.0	1.3	1.4	1.4	0.0	0.7	6.0	2.2	3.9	12.0	12.5	27.0	30.1	45.2	100.0	5.4						
	F	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.7	3.3	2.2	3.2	4.7	8.9	18.1	37.8	38.3	57.3	4.6						
	P	0.0	0.0	0.0	0.0	0.3	0.7	1.1	0.0	0.7	4.6	2.2	3.5	8.4	10.7	22.5	34.2	41.3	71.9	5.0						

**Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007**

ICD-O3/SITE Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (World)/ 100,000	ASR	Lower Limit	Upper Limit	
<b>M965-M966 HODGKIN LYMPHOMA</b>																										
Incidence	M	0	0	3	5	7	1	6	2	8	2	3	4	4	1	0	0	0	48	0.4	0.2	539	2.1	1.5	2.8	
	F	0	0	2	3	5	1	3	2	3	1	4	2	2	3	2	1	0	39	0.4	0.2	595	1.7	1.2	2.3	
	P	0	0	5	4	11	6	9	4	11	3	7	6	4	4	2	1	0	87	0.4	0.2	563	1.9	1.5	2.3	
Rate Per 100,000	M	0.0	0.0	2.0	0.7	3.3	0.6	4.0	1.3	5.9	1.6	2.8	5.0	1.7	0.0	0.0	0.0	0.0	2.3							
	F	0.0	0.0	1.4	2.1	4.0	0.7	3.4	2.2	2.2	3.8	2.6	4.9	3.8	2.4	0.0	0.0	0.0	1.9							
	P	0.0	0.0	1.7	1.4	3.7	2.1	4.1	0.6	3.0	4.0	1.2	3.3	3.8	3.3	2.0	1.4	0.0	2.1							
Mortality	M	0	0	0	0	2	1	1	0	2	0	0	1	0	1	0	0	2	11	0.2	0.0	2733	0.4	0.2	0.8	
	F	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	2	0.1	0.0	15270	0.1	0.0	0.3	
	P	0	0	0	0	2	1	1	0	4	0	0	1	0	1	0	0	2	13	0.2	0.0	4632	0.3	0.1	0.4	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	1.3	0.7	0.7	0.0	1.3	0.0	0.0	0.9	0.0	1.7	0.0	0.0	0.0	0.5							
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1							
	P	0.0	0.0	0.0	0.0	0.7	0.4	0.3	0.0	0.3	0.0	0.0	0.5	0.0	0.8	0.0	0.0	0.0	0.3							
<b>M959-M967-M972 NON-HODGKIN LYMPHOMA</b>																										
Incidence	M	2	5	1	1	3	9	12	8	38	27	43	47	50	48	54	37	27	414	3.3	2.1	49	13.5	12.3	14.9	
	F	0	2	2	2	1	2	4	6	11	12	23	48	38	31	43	39	27	334	3.6	1.5	66	9.9	8.8	11.0	
	P	2	7	3	3	5	13	18	19	50	50	91	92	88	79	97	76	54	748	3.4	1.8	57	11.6	10.8	12.5	
Rate Per 100,000	M	1.4	1.4	3.3	0.7	2.1	6.2	7.8	5.4	25.5	19.8	33.6	43.2	62.5	81.0	116.1	119.5	128.6	19.8							
	F	0.0	0.0	1.4	1.4	0.7	1.4	2.7	3.8	7.2	7.9	16.7	38.0	42.6	48.5	51.0	81.3	93.4	67.2	16.0						
	P	0.7	0.7	2.4	1.0	0.7	1.8	4.5	6.3	16.6	18.3	35.8	42.9	55.6	65.8	97.6	104.5	88.3	17.9							
Mortality	M	0	0	0	0	0	1	1	0	7	3	5	12	10	15	14	14	19	101	2.3	0.5	220	2.9	2.4	3.6	
	F	0	0	0	0	1	0	0	1	3	3	4	5	7	11	20	16	23	95	3.0	0.4	254	2.2	1.8	2.7	
	P	0	0	0	1	0	2	1	0	10	6	9	17	17	26	34	30	42	196	2.6	0.4	235	2.5	2.2	2.9	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.7	0.7	0.0	0.0	4.7	2.2	3.9	11.0	12.5	25.3	30.1	45.2	90.5	4.8							
	F	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.7	2.0	2.2	3.2	4.7	8.9	18.1	37.8	38.3	57.3	4.5							
	P	0.0	0.0	0.0	0.3	0.0	0.7	0.3	0.0	3.3	2.2	3.5	7.9	10.7	21.7	34.2	41.3	68.7	4.7							
<b>M980-M994 ALL LEUKAEMIAS</b>																										
Incidence	M	19	8	2	8	3	4	5	10	9	25	30	49	32	31	42	32	23	342	2.7	1.6	62	12.4	11.1	13.8	
	F	9	1	4	1	2	7	2	7	9	13	15	18	20	22	15	23	26	208	2.3	0.8	120	7.0	6.1	8.0	
	P	28	9	6	9	5	11	7	17	19	38	45	67	52	53	57	55	49	550	2.5	1.2	83	9.6	8.8	10.5	
Rate Per 100,000	M	13.5	5.6	1.3	5.3	2.0	2.8	3.4	6.5	6.7	18.4	23.4	45.1	40.0	52.3	90.3	103.3	109.5	16.4							
	F	6.8	0.7	2.8	0.7	1.3	5.0	1.4	4.5	5.9	9.2	11.9	17.0	25.5	36.2	28.4	55.1	64.7	9.9							
	P	10.2	3.2	2.1	3.1	1.7	3.9	2.4	5.5	6.3	13.9	17.7	31.2	32.9	44.2	57.4	75.6	80.1	13.2							
Mortality	M	0	0	0	0	0	2	1	1	2	6	6	20	13	16	36	22	20	150	3.4	0.8	129	4.3	3.7	5.1	
	F	1	1	1	1	3	0	2	2	3	6	2	5	9	9	11	16	18	91	2.9	0.3	294	2.6	2.1	3.1	
	P	1	1	1	1	7	0	5	3	4	12	8	25	22	25	47	38	38	241	3.2	0.6	182	3.4	3.0	3.8	
Rate Per 100,000	M	0.0	0.0	0.0	0.0	1.4	0.7	0.6	1.3	0.7	4.4	4.7	18.4	16.3	27.0	77.4	71.0	95.3	7.2							
	F	0.8	0.7	0.7	2.1	0.0	2.1	0.0	1.3	0.7	2.0	4.4	1.6	4.7	11.5	14.8	20.8	38.3	44.8	4.3						
	P	0.4	0.4	0.3	2.4	0.0	1.8	0.3	1.0	1.3	4.4	3.1	11.7	13.9	20.8	47.3	52.3	62.1	5.8							
<b>M982-M983 LYMPHOID LEUKAEMIA</b>																										
Incidence	M	14	6	2	6	0	1	2	2	1	5	12	19	26	14	12	18	9	8	157	1.2	0.8	133	6.2	5.3	7.2
	F	8	0	3	0	1	2	0	3	3	3	7	9	10	11	5	4	8	86	0.9	0.4	260	3.3	2.6	4.1	
	P	22	6	5	6	1	3	2	5	4	8	19	28	35	24	23	13	16	243	1.1	0.6	177	4.7	4.2	5.4	
Rate Per 100,000	M	9.9	4.2	1.3	4.0	0.0	0.7	1.4	1.3	0.7	3.4	8.8	14.8	23.9	17.5	20.3	38.7	29.1	38.1	7.5						
	F	6.0	0.0	2.1	0.0	0.7	1.4	0.0	1.9	2.0	5.1	7.1	8.5	12.8	18.1	9.5	9.6	19.9	4.1							
	P	8.0	2.1	1.7	2.1	0.3	1.1	0.7	1.6	1.3	2.7	6.9	11.0	16.3	15.2	19.2	23.1	17.9	26.2	5.8						
Mortality	M	0	0	0	0	2	0	2	1	0	0	1	4	2	5	14	4	5	42	1.0	0.3	398	1.3	0.9	1.7	
	F	1	1	1	0	1	0	0	0	1	2	0	0	1	5	4	5	6	27	0.9	0.1	937	0.8	0.5	1.1	
	P	1	1	1	0	3	0	2	1	0	2	1	4	3	10	18	9	11	69	0.9	0.2	570	1.0	0.8	1.3	
Rate Per 100,000	M	0.0	0.0	0.0	1.3	0.0	1.4	0.7	0.0	0.0	0.0	0.8	3.7	2.5	8.4	30.1	12.9	23.8	2.0							
	F	0.8	0.7	0.0	0.7	0.0	0.0	0.0	0.7	1.5	0.0	0.0	1.3	8.2	7.6	12.0	14.9	1.3	1.3							
	P	0.4	0.4	0.0	1.0	0.0	0.7	0.3	0.0	0.7	0.3	0.7	0.4	1.9	1.9	8.3	18.1	12.4	18.0	1.7						

Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007

ICD-O3/SITE Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	Cum Risk (World)/ 100,000	Lower Limit	Upper Limit	
<b>M964-M993 MYELOID LEUKAEMIA</b>																									
Incidence	M	4	1	1	1	2	3	3	5	2	9	7	21	13	11	12	14	10	125	1.0	0.6	181	4.4	3.6	5.2
	F	1	1	1	1	5	2	4	6	8	5	7	5	7	8	8	12	10	92	1.0	0.4	280	3.0	2.4	3.6
	P	5	3	2	2	8	5	10	11	10	14	12	28	20	19	20	26	20	217	1.0	0.5	220	3.6	3.2	4.2
Rate Per 100,000	M	2.8	1.4	0.0	0.7	1.3	2.1	3.9	3.3	1.3	6.6	5.5	19.3	16.3	18.6	25.8	45.2	47.6	6.0						
	F	0.8	0.7	0.7	0.7	3.6	1.4	2.6	3.9	5.2	3.6	4.0	6.6	8.9	13.2	15.1	28.7	24.9	4.4						
	P	1.8	1.1	0.3	0.7	1.0	2.8	1.7	3.2	3.3	5.1	4.7	13.1	12.6	15.8	20.1	35.8	32.7	5.2						
Mortality	M	0	0	0	0	0	0	1	0	1	5	4	16	11	9	17	14	11	91	2.1	0.4	224	2.7	2.1	3.3
	F	0	0	1	1	0	3	0	2	1	4	2	5	7	6	9	9	8	54	1.7	0.2	474	1.6	1.2	2.1
	P	0	0	1	3	0	3	0	3	1	2	6	21	18	13	23	23	19	145	1.9	0.3	307	2.1	1.8	2.4
Rate Per 100,000	M	0.0	0.0	0.0	1.3	0.0	0.0	0.6	0.0	0.7	3.7	3.1	14.7	13.8	15.2	36.6	45.2	52.4	4.4						
	F	0.0	0.0	0.7	0.7	0.0	2.1	0.0	1.3	0.7	2.9	1.6	4.7	6.6	11.3	21.6	19.9	2.6	2.6						
	P	0.0	0.0	0.3	1.0	0.0	1.1	0.0	1.0	0.3	0.7	2.4	9.8	11.4	10.8	23.1	31.6	31.1	3.5						
<b>M994 OTHER SPECIFIED LEUKAEMIA</b>																									
Incidence	M	1	0	0	0	0	0	2	2	2	4	3	2	5	8	11	8	3	51	0.4	0.3	363	1.5	1.1	2.0
	F	0	0	0	0	0	0	0	0	3	1	1	1	2	3	2	6	6	25	0.3	0.1	1274	0.6	0.4	0.9
	P	1	0	0	0	0	0	2	2	5	5	4	3	7	11	13	14	9	76	0.3	0.2	575	1.0	0.8	1.3
Rate Per 100,000	M	0.7	0.0	0.0	0.0	0.0	0.0	1.3	1.3	1.3	2.9	2.3	1.8	6.3	13.5	23.7	25.8	14.3	2.4						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.7	0.8	0.9	2.6	4.9	3.8	14.4	14.9	1.2						
	P	0.4	0.0	0.0	0.0	0.0	0.0	0.6	0.7	1.7	1.8	1.6	1.4	4.4	9.2	13.1	19.3	14.7	1.8						
Mortality	M	0	0	0	0	0	0	0	0	0	1	0	0	0	2	4	3	2	12	0.3	0.1	1574	0.3	0.1	0.5
	F	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	3	6	0.2	0.0	7854	0.1	0.0	0.2
	P	0	0	0	0	0	0	0	0	1	1	0	0	0	2	5	4	5	18	0.2	0.0	2705	0.2	0.1	0.3
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	3.4	8.6	9.7	9.5	0.6						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	1.9	2.4	7.5	0.3						
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	1.7	5.0	5.5	8.2	0.4						
<b>M980 UNSPECIFIED LEUKAEMIA</b>																									
Incidence	M	0	0	0	1	0	0	0	2	0	0	1	0	0	0	1	1	2	9	0.1	0.0	3673	0.3	0.1	0.6
	F	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	2	5	0.1	0.0	8997	0.1	0.0	0.3
	P	0	0	0	1	0	0	0	2	0	0	1	1	1	0	1	2	4	14	0.1	0.0	5215	0.2	0.1	0.3
Rate Per 100,000	M	0.0	0.0	0.0	0.7	0.0	0.0	0.0	1.3	0.0	0.0	0.8	0.0	0.0	0.0	2.2	3.2	9.5	0.4						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.3	0.0	0.0	2.4	5.0	0.2						
	P	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.7	0.0	0.0	0.4	0.5	0.6	0.0	1.0	2.8	6.5	0.3						
Mortality	M	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	2	5	0.1	0.0	6822	0.1	0.0	0.3
	F	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	1	1	4	0.1	0.0	10114	0.1	0.0	0.3
	P	0	0	0	1	0	0	0	0	0	0	1	0	1	0	1	2	3	9	0.1	0.0	8427	0.1	0.1	0.2
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	2.2	3.2	9.5	0.2						
	F	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	2.4	2.5	0.2						
	P	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.6	0.0	1.0	2.8	4.9	0.2						
<b>M973 MYELOPLASMA CELL TUMOURS</b>																									
Incidence	M	0	0	0	0	0	0	1	1	4	11	13	19	22	15	14	17	15	132	1.0	0.6	164	4.0	3.4	4.8
	F	0	0	0	0	1	0	0	3	2	6	15	10	9	13	15	8	6	88	1.0	0.5	221	2.5	2.0	3.1
	P	0	0	0	0	1	0	1	4	6	17	28	29	31	28	29	25	21	220	1.0	0.5	188	3.2	2.8	3.7
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.7	2.7	8.1	10.2	17.5	27.5	25.3	30.1	54.9	71.4	6.3						
	F	0.0	0.0	0.0	0.0	0.7	0.0	0.0	2.0	1.3	4.4	11.9	9.5	11.5	21.4	28.4	19.2	14.9	4.2						
	P	0.0	0.0	0.0	0.0	0.3	0.0	0.3	1.3	2.0	6.2	11.0	13.5	19.6	23.3	29.2	34.4	34.3	5.3						
Mortality	M	0	0	0	0	0	0	0	0	0	1	6	8	8	9	14	12	12	70	1.6	0.3	294	1.9	1.5	2.4
	F	0	0	0	0	0	0	0	1	0	1	5	6	6	4	15	5	10	53	1.7	0.3	373	1.3	1.0	1.7
	P	0	0	0	0	0	0	0	1	0	2	11	14	14	13	29	17	22	123	1.6	0.3	330	1.6	1.3	1.9
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	4.7	7.4	10.0	15.2	30.1	38.7	57.2	3.4						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	4.0	5.7	7.7	6.6	28.4	12.0	24.9	2.5						
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.7	4.3	6.5	8.8	10.8	29.2	23.4	36.0	2.9						

Table 5: Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2007

ICD-O3/SITE_Sex	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	Percent	Cum Rate	ASR (World)/100,000	Lower Limit	Upper Limit	
<b>M998 MYELODYSPLASTIC DISEASES</b>																									
Incidence	M	1	0	0	0	0	0	0	2	2	3	5	6	20	20	20	25	28	134	1.1	0.6	169	3.7	3.1	4.4
	F	0	0	0	0	0	1	1	0	2	3	7	5	2	9	9	17	17	21	86	0.9	0.3	293	1.9	2.3
	P	1	0	0	0	0	1	2	2	4	6	12	8	29	29	37	42	49	220	1.0	0.5	215	2.7	2.4	3.1
Rate Per 100,000	M	0.7	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.3	2.2	5.5	5.5	25.0	33.8	43.0	80.7	133.4	6.4						
	F	0.0	0.0	0.0	0.0	0.0	0.3	0.6	0.7	1.3	2.2	4.0	1.9	11.5	14.8	32.2	40.7	52.3	4.1						
	P	0.4	0.0	0.0	0.0	0.0	0.3	0.7	1.3	2.2	4.7	3.7	18.3	24.2	37.2	57.8	80.1	5.3							
Mortality	M	0	0	0	0	0	0	0	0	1	0	2	2	4	4	10	18	14	55	1.2	0.2	536	1.3	1.0	1.7
	F	0	0	0	0	0	0	0	0	0	0	4	4	0	2	5	4	15	32	1.0	0.1	1084	0.6	0.4	0.8
	P	0	0	0	0	0	0	0	0	1	0	6	2	6	6	15	22	29	87	1.2	0.1	728	0.9	0.7	1.1
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.6	1.8	5.0	6.8	21.5	58.1	66.7	2.6						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	2.6	3.3	9.5	9.6	37.3	1.5						
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.0	2.4	0.9	3.8	5.0	15.1	30.3	47.4	2.1						
<b>M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASES</b>																									
Incidence	M	0	0	0	0	0	3	2	4	3	6	11	4	8	16	9	10	9	88	0.7	0.4	241	2.8	2.2	3.4
	F	1	0	0	1	0	1	1	3	6	6	10	8	6	1	9	7	5	65	0.7	0.3	365	2.0	1.5	2.6
	P	1	0	0	1	0	3	4	7	9	12	21	12	14	17	18	17	14	153	0.7	0.3	291	2.4	2.0	2.8
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	2.1	1.4	1.9	2.7	4.4	8.6	3.7	10.0	27.0	19.4	32.3	42.9	4.2						
	F	0.8	0.0	0.0	0.0	0.0	0.7	0.6	2.0	3.9	4.4	7.9	7.6	7.7	1.6	17.0	16.8	12.4	3.1						
	P	0.4	0.0	0.0	0.3	0.0	1.1	1.0	1.3	2.3	3.0	4.4	8.3	5.6	8.8	14.2	18.1	23.4	22.9	3.7					
Mortality	M	0	0	0	0	0	0	0	1	0	0	2	5	2	3	1	5	2	21	0.5	0.1	1209	0.6	0.4	0.9
	F	0	0	0	0	0	0	0	0	0	0	2	0	0	2	3	3	10	10	0.3	0.0	3525	0.2	0.1	0.3
	P	0	0	0	0	0	0	0	1	0	0	2	7	2	3	3	8	5	31	0.4	0.1	1792	0.4	0.3	0.6
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.6	4.6	2.5	5.1	2.2	16.1	9.5	1.0						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	3.8	7.2	7.5	0.5						
	P	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.8	3.3	1.3	2.5	3.0	11.0	8.2	0.7						
<b>M974-M976 OTHER NEOPLASMS OF LYMPHATIC &amp; HAEMATOPOIETIC TISSUE</b>																									
Incidence	M	0	0	0	0	0	0	0	0	0	0	0	3	2	3	1	2	0	12	0.1	0.1	1522	0.4	0.2	0.7
	F	0	0	0	1	0	0	1	0	0	1	0	0	1	0	0	0	0	4	0.0	0.0	5983	0.2	0.0	0.5
	P	0	0	0	1	0	0	1	0	1	1	0	3	3	3	1	2	0	16	0.1	0.0	2451	0.3	0.2	0.4
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	2.5	5.1	2.2	6.5	0.0	0.6						
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.7	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.2						
	P	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.3	0.4	0.0	1.4	1.9	2.5	1.0	2.8	0.0	0.4						
Mortality	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0.0	0.0	5211	0.1	0.0	0.2
	F	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.0	0.0	28559	0.1	0.0	0.4
	P	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	3	0.0	0.0	9169	0.1	0.0	0.2
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	2.2	0.0	0.1						
	F	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						
	P	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.0	0.0	0.1						
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>																									
Incidence	M	39	16	22	30	51	84	131	254	539	853	1409	1835	2025	1727	1516	1120	816	12638	100.0	65.1	2	406.2	399.2	413.4
	F	27	6	21	30	66	110	181	501	657	826	999	1033	1058	922	875	842	776	9217	100.0	40.7	3	287.8	282.0	293.7
	P	66	22	43	60	117	194	312	458	755	1196	2408	2868	3083	2649	2391	1962	1592	21855	100.0	52.7	2	344.7	340.2	349.3
Rate Per 100,000	M	27.7	11.2	14.7	20.0	33.6	58.2	90.3	110.8	170.1	262.9	453.2	533.2	553.2	473.2	416.5	326.3	236.6	3886.6	605.4					
	F	20.3	4.4	14.8	21.0	44.5	78.4	124.4	328.3	430.3	601.4	790.2	831.4	851.4	741.4	665.2	617.1	544.2	7852.2	440.2					
	P	24.1	7.9	14.7	20.5	39.0	68.2	107.4	147.2	250.1	396.5	614.1	666.6	684.6	587.8	520.8	430.3	326.8	4602.8	522.7					
Mortality	M	4	3	1	7	11	17	11	20	53	130	171	337	471	615	728	703	573	4416	100.0	21.5	5	127.8	124.0	131.6
	F	2	6	2	11	3	14	19	37	48	111	146	226	322	333	409	382	561	3115	100.0	12.9	8	81.3	78.5	84.2
	P	6	9	3	18	14	31	30	57	101	241	317	563	793	894	1137	1186	1134	7531	100.0	17.1	6	102.9	100.6	105.2
Rate Per 100,000	M	2.8	2.1	0.7	4.7	7.2	11.8	7.6	13.0	35.5	87.3	125.7	178.8	201.8	263.3	301.8	272.0	211.5	1488.8	211.5					
	F	1.5	4.4	1.4	7.7	2.0	10.0	13.1	23.6	31.5	72.7	106.3	139.6	178.8	178.8	211.5	211.5	148.8	1000.0	148.8					
	P	2.2	3.2	1.0	6.2	4.7	10.9	10.3	18.3	33.5	79.9	115.9	221.3	263.3	301.8	330.6	330.6	330.6	1854.0	180.1					

**Table 6: Limited duration (5-year and 25-year) cancer prevalence by Site, Sex and Age Group, Queensland, 2007**

5 year prevalence							25 year prevalence				
ICD-O3/SITE	Sex	0-29 years	30-49 years	50-69 years	70 years plus	All ages	0-29 years	30-49 years	50-69 years	70 years plus	All ages
<b>C00 LIP</b>											
Counts	M	19	190	322	198	729	28	599	1174	911	2712
	F	1	33	86	100	220	3	101	302	389	795
	P	20	223	408	298	949	31	700	1476	1300	3507
Rate Per 100,000	M	2.2	31.5	70.6	126.2	35.6	3.3	99.2	256.6	584.1	134.1
	F	0.1	5.3	19.0	50.5	9.9	0.4	16.1	66.8	192.2	35.5
	P	1.2	18.3	45.0	84.1	22.4	1.8	57.3	162.3	364.2	82.6
<b>C01,C02 TONGUE</b>											
Counts	M	3	41	173	52	269	5	65	323	164	557
	F	2	24	74	32	132	3	42	143	106	294
	P	5	65	247	84	401	8	107	466	270	851
Rate Per 100,000	M	0.3	6.7	37.6	32.6	12.5	0.6	10.6	70.2	104.3	26.6
	F	0.2	3.8	16.3	16.6	5.9	0.4	6.8	31.6	53.5	13.2
	P	0.3	5.3	27.0	24.2	9.2	0.5	8.7	51.0	76.9	19.8
<b>C03 GUM</b>											
Counts	M	0	2	16	12	30	1	3	34	22	60
	F	0	5	12	14	31	1	8	23	29	61
	P	0	7	28	26	61	2	11	57	51	121
Rate Per 100,000	M	0.0	0.3	3.5	7.6	1.5	0.1	0.5	7.4	13.9	2.9
	F	0.0	0.8	2.6	6.4	1.3	0.1	1.3	5.0	14.2	2.7
	P	0.0	0.6	3.1	7.2	1.4	0.1	0.9	6.2	14.2	2.8
<b>C04 FLOOR OF MOUTH</b>											
Counts	M	0	7	51	18	76	0	14	109	57	180
	F	0	5	24	10	39	0	7	42	37	86
	P	0	12	75	28	115	0	21	151	94	266
Rate Per 100,000	M	0.0	1.1	11.0	11.3	3.5	0.0	2.2	23.5	36.1	8.5
	F	0.0	0.8	5.3	5.2	1.7	0.0	1.1	9.3	19.5	3.9
	P	0.0	0.9	8.2	8.1	2.6	0.0	1.6	16.4	27.2	6.2
<b>C05,C06 PALATE AND OTHER &amp; UNSPECIFIED PARTS OF MOUTH</b>											
Counts	M	2	21	66	27	116	2	27	132	74	235
	F	4	5	35	25	69	5	17	70	75	167
	P	6	26	101	52	185	7	44	202	149	402
Rate Per 100,000	M	0.2	3.4	14.1	17.1	5.4	0.2	4.4	28.1	46.8	11.2
	F	0.5	0.8	7.7	12.8	3.1	0.6	2.8	15.5	37.5	7.5
	P	0.3	2.1	11.0	14.7	4.3	0.4	3.6	21.9	42.1	9.3
<b>C07,C08 PAROTID AND OTHER &amp; UNSPECIFIED MAJOR SALIVARY GLANDS</b>											
Counts	M	5	17	57	69	148	12	36	127	138	313
	F	11	25	30	28	94	18	60	79	77	234
	P	16	42	87	97	242	30	96	206	215	547
Rate Per 100,000	M	0.6	2.8	12.5	44.1	7.5	1.4	5.9	27.6	88.2	15.7
	F	1.3	4.1	6.6	13.6	4.3	2.1	9.8	17.5	37.2	10.6
	P	0.9	3.4	9.6	26.6	5.7	1.7	7.8	22.6	59.5	12.9
<b>C09,C10 TONSIL AND OROPHARYNX</b>											
Counts	M	0	49	151	37	237	0	63	256	80	399
	F	0	11	34	10	55	0	13	55	28	96
	P	0	60	185	47	292	0	76	311	108	495
Rate Per 100,000	M	0.0	7.9	33.5	23.2	11.0	0.0	10.2	56.2	49.9	18.6
	F	0.0	1.7	7.6	5.2	2.5	0.0	2.0	12.2	14.4	4.3
	P	0.0	4.8	20.6	13.8	6.7	0.0	6.0	34.3	31.1	11.4
<b>C11 NASOPHARYNX</b>											
Counts	M	2	13	20	4	39	6	26	52	13	97
	F	3	5	9	3	20	4	10	21	10	45
	P	5	18	29	7	59	10	36	73	23	142
Rate Per 100,000	M	0.2	2.1	4.5	2.5	1.8	0.7	4.3	11.3	8.2	4.5
	F	0.4	0.8	2.0	1.7	0.9	0.5	1.6	4.6	5.5	2.1
	P	0.3	1.5	3.2	2.1	1.4	0.6	2.9	7.9	6.7	3.3
<b>C12,C13 PYRIFORM SINUS AND HYPOPHARYNX</b>											
Counts	M	0	3	46	24	73	0	3	82	54	139
	F	0	1	7	3	11	0	4	11	9	24
	P	0	4	53	27	84	0	7	93	63	163
Rate Per 100,000	M	0.0	0.5	10.1	15.4	3.5	0.0	0.5	17.9	34.3	6.8
	F	0.0	0.2	1.5	1.8	0.5	0.0	0.6	2.4	4.9	1.1
	P	0.0	0.3	5.8	7.8	1.9	0.0	0.6	10.2	18.1	3.8
<b>C14 OTHER &amp; ILL-DEFINED SITES IN LIP, ORAL CAVITY &amp; PHARYNX</b>											
Counts	M	0	5	30	14	49	0	10	48	21	79
	F	0	3	4	0	7	0	4	6	6	16
	P	0	8	34	14	56	0	14	54	27	95
Rate Per 100,000	M	0.0	0.8	6.6	8.7	2.3	0.0	1.6	10.5	13.1	3.7
	F	0.0	0.5	0.9	0.0	0.3	0.0	0.6	1.3	3.0	0.7
	P	0.0	0.6	3.8	4.1	1.3	0.0	1.1	5.9	7.9	2.2
<b>C15 OESOPHAGUS</b>											
Counts	M	0	9	140	94	243	0	14	216	174	404
	F	0	5	49	60	114	0	5	69	118	192
	P	0	14	189	154	357	0	19	285	292	596
Rate Per 100,000	M	0.0	1.5	30.1	60.1	11.8	0.0	2.3	46.5	110.8	19.8
	F	0.0	0.8	10.9	30.7	5.1	0.0	0.8	15.2	59.5	8.6
	P	0.0	1.1	20.5	43.4	8.3	0.0	1.5	31.0	82.5	14.0
<b>C16 STOMACH</b>											
Counts	M	2	27	182	221	432	3	38	314	480	835
	F	1	24	67	117	209	1	48	160	265	474
	P	3	51	249	338	641	4	86	474	745	1309
Rate Per 100,000	M	0.2	4.4	39.3	140.6	21.8	0.3	6.2	67.3	308.5	43.1
	F	0.1	3.9	14.5	59.0	9.4	0.1	7.7	35.0	130.6	21.0
	P	0.2	4.1	27.0	95.1	15.2	0.2	7.0	51.3	206.9	30.9

**Table 6: Limited duration (5-year and 25-year) cancer prevalence by Site, Sex and Age Group, Queensland, 2007**

		5 year prevalence					25 year prevalence				
ICD-O3/SITE	Sex	0-29 years	30-49 years	50-69 years	70 years plus	All ages	0-29 years	30-49 years	50-69 years	70 years plus	All ages
<b>C17 SMALL INTESTINE</b>											
Counts	M	1	22	69	44	136	1	35	125	113	274
	F	3	16	51	50	120	3	22	81	102	208
	P	4	38	120	94	256	4	57	206	215	482
Rate Per 100,000	M	0.1	3.7	14.8	27.7	6.5	0.1	5.8	27.0	72.3	13.6
	F	0.4	2.6	11.4	26.6	5.6	0.4	3.6	17.9	53.9	9.6
	P	0.2	3.1	13.1	27.1	6.0	0.2	4.6	22.5	61.2	11.4
<b>C18-C20,C218 COLORECTAL</b>											
Counts	M	25	290	2287	2389	4991	31	445	4235	6149	10860
	F	27	312	1609	2103	4051	35	501	3222	5803	9561
	P	52	602	3896	4492	9042	66	946	7457	11952	20421
Rate Per 100,000	M	2.9	47.2	494.6	1513.3	249.1	3.6	72.5	914.1	3922.9	557.0
	F	3.1	50.0	354.6	1071.3	182.6	4.1	80.3	708.8	2868.4	423.9
	P	3.0	48.6	425.3	1271.3	214.1	3.8	76.4	812.5	3340.1	485.6
<b>C18 COLON</b>											
Counts	M	15	155	1270	1684	3124	20	247	2416	4150	6833
	F	20	181	1036	1643	2880	26	304	2099	4474	6903
	P	35	336	2306	3327	6004	46	551	4515	8624	13736
Rate Per 100,000	M	1.8	25.3	274.4	1068.1	158.6	2.3	40.4	521.3	2650.9	354.8
	F	2.3	28.9	228.3	833.9	129.8	3.1	48.6	461.9	2206.4	305.8
	P	2.0	27.1	251.6	938.9	143.2	2.7	44.6	491.9	2404.4	328.2
<b>C19,C20 RECTOSIGMOID JUNCTION AND RECTUM</b>											
Counts	M	9	135	1035	751	1930	10	198	1842	2071	4121
	F	6	126	563	472	1167	8	194	1110	1364	2676
	P	15	261	1598	1223	3097	18	392	2952	3435	6797
Rate Per 100,000	M	1.0	22.0	224.0	473.9	93.8	1.1	32.1	397.8	1317.3	207.2
	F	0.7	20.3	124.1	243.4	52.7	0.9	31.2	244.0	679.3	119.0
	P	0.9	21.1	174.5	349.1	72.5	1.0	31.6	321.6	965.9	160.3
<b>C21 ANUS &amp; ANAL CANAL</b>											
Counts	M	1	15	39	32	87	1	23	99	82	205
	F	1	23	77	53	154	1	27	132	131	291
	P	2	38	116	85	241	2	50	231	213	496
Rate Per 100,000	M	0.1	2.4	8.6	20.8	4.4	0.1	3.8	21.7	52.8	10.2
	F	0.1	3.7	17.1	27.4	7.0	0.1	4.4	29.3	65.1	13.0
	P	0.1	3.1	12.8	24.0	5.7	0.1	4.1	25.4	59.5	11.6
<b>C22 LIVER &amp; INTRAHEPATIC BILE DUCTS</b>											
Counts	M	2	28	117	58	205	16	37	154	78	285
	F	5	9	28	26	68	18	12	42	38	110
	P	7	37	145	84	273	34	49	196	116	395
Rate Per 100,000	M	0.2	4.5	25.3	36.5	9.7	1.8	6.0	33.3	49.1	13.5
	F	0.6	1.5	6.1	13.5	3.1	2.1	2.0	9.2	19.6	5.0
	P	0.4	3.0	15.7	23.7	6.3	2.0	4.0	21.3	32.6	9.1
<b>C23,C24 GALLBLADDER AND OTHER &amp; UNSPECIFIED PARTS OF BILIARY TRACT</b>											
Counts	M	0	4	49	48	101	0	7	90	82	179
	F	1	1	37	41	80	1	5	56	92	154
	P	1	5	86	89	181	1	12	146	174	333
Rate Per 100,000	M	0.0	0.6	10.4	30.6	5.0	0.0	1.1	19.2	52.9	8.9
	F	0.1	0.2	8.3	20.5	3.6	0.1	0.8	12.5	45.9	6.9
	P	0.1	0.4	9.4	24.7	4.2	0.1	1.0	15.9	48.3	7.8
<b>C25 PANCREAS</b>											
Counts	M	1	11	100	77	189	1	17	132	114	264
	F	2	10	72	64	148	2	21	102	107	232
	P	3	21	172	141	337	3	38	234	221	496
Rate Per 100,000	M	0.1	1.8	21.7	48.7	9.2	0.1	2.8	28.5	72.5	13.0
	F	0.2	1.6	16.0	31.2	6.5	0.2	3.4	22.5	52.2	10.2
	P	0.2	1.7	18.8	39.4	7.8	0.2	3.1	25.5	61.7	11.6
<b>C30,C31 NASAL CAVITY &amp; MIDDLE EAR AND ACCESSORY SINUSES</b>											
Counts	M	4	10	25	18	57	9	17	47	46	119
	F	1	9	12	8	30	3	17	30	24	74
	P	5	19	37	26	87	12	34	77	70	193
Rate Per 100,000	M	0.5	1.7	5.4	11.4	2.8	1.0	2.8	10.2	29.2	5.9
	F	0.1	1.5	2.7	3.9	1.4	0.4	2.8	6.8	11.5	3.3
	P	0.3	1.6	4.1	7.4	2.1	0.7	2.8	8.5	19.7	4.6
<b>C32 LARYNX</b>											
Counts	M	0	25	219	152	396	0	31	461	481	973
	F	0	4	24	17	45	0	8	47	52	107
	P	0	29	243	169	441	0	39	508	533	1080
Rate Per 100,000	M	0.0	4.0	47.0	95.3	19.0	0.0	5.0	98.7	304.2	48.4
	F	0.0	0.7	5.3	8.8	2.0	0.0	1.3	10.4	26.4	4.8
	P	0.0	2.3	26.3	48.2	10.2	0.0	3.1	54.9	150.9	25.4
<b>C33,C34 TRACHEA AND BRONCHUS &amp; LUNG</b>											
Counts	M	5	63	686	711	1465	11	98	992	1183	2284
	F	4	55	494	393	946	8	92	709	681	1490
	P	9	118	1180	1104	2411	19	190	1701	1864	3774
Rate Per 100,000	M	0.6	10.2	147.2	448.2	72.7	1.3	16.0	213.1	749.4	114.8
	F	0.5	8.8	108.0	208.6	42.9	1.0	14.6	155.5	352.2	67.1
	P	0.5	9.5	127.8	317.1	56.8	1.1	15.3	184.6	529.9	89.2
<b>C37, C38 THYMUS, HEART, MEDIASTINUM &amp; PLEURA</b>											
Counts	M	5	7	9	2	23	15	25	31	17	88
	F	7	3	8	4	22	9	9	17	11	46
	P	12	10	17	6	45	24	34	48	28	134
Rate Per 100,000	M	0.6	1.2	1.9	1.2	1.1	1.7	4.2	6.7	10.6	4.2
	F	0.8	0.5	1.8	2.2	1.0	1.0	1.5	3.7	5.8	2.1
	P	0.7	0.8	1.8	1.7	1.0	1.4	2.8	5.2	8.0	3.2

**Table 6: Limited duration (5-year and 25-year) cancer prevalence by Site, Sex and Age Group, Queensland, 2007**

5 year prevalence							25 year prevalence				
ICD-O3/SITE	Sex	0-29 years	30-49 years	50-69 years	70 years plus	All ages	0-29 years	30-49 years	50-69 years	70 years plus	All ages
<b>C40,C41 BONES, JOINTS &amp; ARTICULAR CARTILAGES</b>											
Counts	M	37	26	15	10	88	71	94	73	31	269
	F	26	9	13	11	59	56	59	48	37	200
	P	63	35	28	21	147	127	153	121	68	469
Rate Per 100,000	M	4.2	4.4	3.2	6.4	4.2	8.0	15.9	16.0	19.6	13.0
	F	3.1	1.5	3.0	5.5	2.8	6.7	9.7	10.8	19.5	9.6
	P	3.6	2.9	3.1	5.8	3.5	7.3	12.8	13.5	19.3	11.3
<b>C44, M872-M879 MELANOMA</b>											
Counts	M	236	1246	2882	2221	6585	431	3567	8094	6146	18238
	F	315	1389	1950	1297	4951	542	4253	6715	4484	15994
	P	551	2635	4832	3518	11536	973	7820	14809	10630	34232
Rate Per 100,000	M	27.3	206.5	626.9	1412.2	323.7	50.1	589.9	1760.5	3917.7	896.6
	F	37.5	226.2	434.6	659.4	228.0	65.1	690.2	1492.4	2261.3	730.5
	P	32.3	216.4	531.7	992.6	272.1	57.5	640.5	1628.0	2984.0	804.4
<b>C44 OTHER SKIN (EXCL BCC/SCC)</b>											
Counts	M	8	30	77	142	257	17	77	181	276	551
	F	8	35	50	73	166	12	76	115	161	364
	P	16	65	127	215	423	29	153	296	437	915
Rate Per 100,000	M	0.9	4.9	16.8	91.3	13.4	1.9	12.8	39.8	177.6	28.5
	F	0.9	5.8	11.1	34.8	7.4	1.4	12.4	25.5	77.9	16.3
	P	0.9	5.4	14.0	59.2	10.1	1.7	12.6	32.7	120.6	21.8
<b>M905 MESOTHELIOMA</b>											
Counts	M	0	2	67	56	125	0	3	73	68	144
	F	0	7	17	7	31	0	8	23	11	42
	P	0	9	84	63	156	0	11	96	79	186
Rate Per 100,000	M	0.0	0.3	14.2	35.1	6.1	0.0	0.5	15.5	42.7	7.0
	F	0.0	1.1	3.7	3.7	1.4	0.0	1.3	5.0	5.7	1.9
	P	0.0	0.7	9.0	18.2	3.6	0.0	0.9	10.3	22.8	4.3
<b>M914 KAPOSI SARCOMA</b>											
Counts	M	1	12	6	0	19	1	22	19	9	51
	F	0	1	1	1	3	0	1	2	5	8
	P	1	13	7	1	22	1	23	21	14	59
Rate Per 100,000	M	0.1	2.0	1.3	0.0	0.9	0.1	3.7	4.2	5.7	2.5
	F	0.0	0.2	0.2	0.5	0.1	0.0	0.2	0.4	2.4	0.3
	P	0.1	1.1	0.8	0.3	0.5	0.1	1.9	2.3	3.9	1.4
<b>C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVES</b>											
Counts	M	21	32	73	47	173	60	106	209	142	517
	F	32	43	44	39	158	70	92	133	111	406
	P	53	75	117	86	331	130	198	342	253	923
Rate Per 100,000	M	2.4	5.3	16.1	29.8	8.4	6.8	17.6	45.7	90.4	25.2
	F	3.8	7.0	9.7	20.1	7.4	8.3	15.0	29.2	56.3	18.7
	P	3.1	6.1	12.9	24.2	7.8	7.5	16.3	37.5	71.1	21.8
<b>C48 RETROPERITONEUM &amp; PERITONEUM</b>											
Counts	M	3	7	12	12	34	4	13	23	16	56
	F	2	12	55	41	110	5	19	78	57	159
	P	5	19	67	53	144	9	32	101	73	215
Rate Per 100,000	M	0.3	1.1	2.6	7.4	1.7	0.5	2.2	4.8	9.9	2.7
	F	0.2	1.9	12.0	22.2	5.0	0.6	3.0	17.0	30.9	7.3
	P	0.3	1.5	7.2	15.3	3.4	0.5	2.6	10.9	21.2	5.0
<b>C50 BREAST</b>											
Counts	M	0	5	46	43	94	0	10	82	94	186
	F	29	2286	5782	2665	10762	33	3582	14662	9408	27685
	P	29	2291	5828	2708	10856	33	3592	14744	9502	27871
Rate Per 100,000	M	0.0	0.8	9.8	27.4	4.7	0.0	1.6	17.7	60.8	9.5
	F	3.6	365.9	1282.6	1399.1	489.1	4.1	571.0	3232.2	4832.7	1243.6
	P	1.8	185.3	642.5	770.5	251.9	2.0	289.4	1613.9	2675.0	645.9
<b>C51 VULVA</b>											
Counts	M	0	0	0	0	0	0	0	0	0	0
	F	2	29	62	68	161	2	72	165	185	424
	P	2	29	62	68	161	2	72	165	185	424
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	0.2	4.6	13.7	33.4	7.2	0.2	11.5	36.5	88.3	18.7
	P	0.1	2.3	6.8	18.7	3.8	0.1	5.8	18.1	50.3	9.9
<b>C53 CERVIX UTERI</b>											
Counts	M	0	0	0	0	0	0	0	0	0	0
	F	41	337	201	76	655	49	1020	1310	421	2800
	P	41	337	201	76	655	49	1020	1310	421	2800
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	5.1	55.5	44.9	39.2	31.0	6.0	165.1	292.8	218.2	129.0
	P	2.5	28.0	22.3	21.4	15.7	3.0	83.3	145.7	119.1	65.5
<b>C54 CORPUS UTERI</b>											
Counts	M	0	0	0	0	0	0	0	0	0	0
	F	2	115	857	449	1423	2	195	1769	1743	3709
	P	2	115	857	449	1423	2	195	1769	1743	3709
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	0.2	18.5	187.2	237.6	63.8	0.2	31.2	386.4	894.1	166.1
	P	0.1	9.3	92.9	128.2	32.7	0.1	15.8	191.6	490.2	86.7
<b>C56 OVARY</b>											
Counts	M	0	0	0	0	0	0	0	0	0	0
	F	34	105	334	163	636	59	311	808	511	1689
	P	34	105	334	163	636	59	311	808	511	1689
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	4.0	17.0	74.0	86.6	29.1	6.9	50.4	177.5	263.8	76.6
	P	2.0	8.6	36.8	46.7	14.8	3.4	25.4	88.1	144.3	39.4

**Table 6: Limited duration (5-year and 25-year) cancer prevalence by Site, Sex and Age Group, Queensland, 2007**

5 year prevalence							25 year prevalence				
ICD-O3/SITE	Sex	0-29 years	30-49 years	50-69 years	70 years plus	All ages	0-29 years	30-49 years	50-69 years	70 years plus	All ages
<b>C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANS</b>											
Counts	M	0	0	0	0	0	0	0	0	0	0
	F	6	29	60	46	141	7	65	126	112	310
	P	6	29	60	46	141	7	65	126	112	310
Rate Per 100,000	M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F	0.7	4.7	13.3	23.8	6.5	0.8	10.6	27.9	56.2	14.1
	P	0.4	2.4	6.6	13.0	3.3	0.4	5.3	13.9	31.2	7.3
<b>C61 PROSTATE GLAND</b>											
Counts	M	0	191	7373	6053	13617	1	197	9435	13351	22984
	F	0	0	0	0	0	0	0	0	0	0
	P	0	191	7373	6053	13617	1	197	9435	13351	22984
Rate Per 100,000	M	0.0	30.4	1579.1	3824.8	664.7	0.1	31.4	2021.5	8512.1	1175.2
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.0	15.0	796.8	1741.7	318.3	0.1	15.5	1020.3	3768.8	545.4
<b>C62 TESTIS</b>											
Counts	M	143	380	72	6	601	232	1239	541	54	2066
	F	0	0	0	0	0	0	0	0	0	0
	P	143	380	72	6	601	232	1239	541	54	2066
Rate Per 100,000	M	16.4	64.1	16.4	3.8	29.5	26.9	206.8	120.8	34.1	99.7
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	8.3	31.8	8.2	1.7	14.7	13.6	102.5	60.6	15.5	49.6
<b>C60,C63 PENIS AND OTHER &amp; UNSPECIFIED MALE GENITAL ORGANS</b>											
Counts	M	2	7	29	30	68	3	17	81	90	191
	F	0	0	0	0	0	0	0	0	0	0
	P	2	7	29	30	68	3	17	81	90	191
Rate Per 100,000	M	0.2	1.2	6.4	19.3	3.4	0.3	2.8	17.6	58.0	9.7
	F	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	P	0.1	0.6	3.2	8.3	1.6	0.2	1.4	8.9	25.0	4.5
<b>C64-C66,C68 KIDNEY AND OTHER RENAL TRACT</b>											
Counts	M	16	147	625	470	1258	58	215	1260	1095	2628
	F	17	94	281	291	683	64	145	597	760	1566
	P	33	241	906	761	1941	122	360	1857	1855	4194
Rate Per 100,000	M	1.9	24.1	135.1	297.4	61.4	6.6	35.1	271.5	697.1	129.5
	F	2.1	15.2	62.2	148.3	31.0	7.6	23.3	131.9	383.5	70.6
	P	2.0	19.6	98.9	215.7	45.6	7.1	29.1	202.3	522.5	98.6
<b>C67 BLADDER</b>											
Counts	M	6	78	690	1064	1838	12	176	1484	2982	4654
	F	2	36	177	323	538	7	73	420	1016	1516
	P	8	114	867	1387	2376	19	249	1904	3998	6170
Rate Per 100,000	M	0.7	12.7	148.6	676.8	94.4	1.4	28.8	319.7	1910.4	244.5
	F	0.2	5.8	39.0	160.4	24.0	0.9	11.8	92.4	496.8	66.9
	P	0.5	9.2	94.3	388.6	56.6	1.1	20.2	207.1	1111.0	147.5
<b>C69 EYE &amp; ADNEXA</b>											
Counts	M	16	21	66	46	149	48	61	186	145	440
	F	8	23	39	44	114	39	60	108	105	312
	P	24	44	105	90	263	87	121	294	250	752
Rate Per 100,000	M	1.8	3.4	14.2	29.6	7.2	5.5	10.0	40.5	93.4	21.7
	F	1.0	3.8	8.6	23.4	5.3	4.6	9.8	23.8	53.8	14.4
	P	1.4	3.6	11.4	25.7	6.2	5.1	9.9	32.2	70.5	17.7
<b>C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM</b>											
Counts	M	73	110	99	29	311	154	240	192	55	641
	F	37	71	69	24	201	104	178	145	46	473
	P	110	181	168	53	512	258	418	337	101	1114
Rate Per 100,000	M	8.3	18.3	21.8	18.3	14.9	17.6	40.0	42.2	35.0	30.7
	F	4.4	11.7	15.4	12.5	9.5	12.4	29.3	32.4	23.1	22.4
	P	6.4	15.0	18.6	15.4	12.2	15.1	34.6	37.4	28.8	26.5
<b>C73 THYROID GLAND</b>											
Counts	M	14	134	183	81	412	21	292	399	175	887
	F	124	547	514	131	1316	159	1175	1348	388	3070
	P	138	681	697	212	1728	180	1467	1747	563	3957
Rate Per 100,000	M	1.6	22.1	40.0	51.1	19.7	2.4	48.4	86.8	111.1	42.5
	F	14.7	89.2	115.6	71.5	61.9	18.9	191.3	301.4	203.7	142.6
	P	8.0	56.0	77.7	61.6	40.9	10.5	120.5	193.7	160.5	92.9
<b>C74,C75 ADRENAL AND OTHER ENDOCRINE GLANDS</b>											
Counts	M	12	3	4	2	21	35	20	16	7	78
	F	5	7	9	7	28	20	14	16	15	65
	P	17	10	13	9	49	55	34	32	22	143
Rate Per 100,000	M	1.4	0.5	0.9	1.3	4.0	4.0	3.4	3.4	4.4	3.7
	F	0.6	1.1	2.0	3.9	1.3	2.4	2.3	3.5	7.8	3.1
	P	1.0	0.8	1.4	2.6	1.2	3.2	2.8	3.5	6.3	3.4
<b>C26,C39,C76,C77,C80 OTHER &amp; ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE</b>											
Counts	M	4	60	241	219	524	7	107	419	485	1018
	F	10	37	155	189	391	15	74	284	368	741
	P	14	97	396	408	915	22	181	703	853	1759
Rate Per 100,000	M	0.5	9.8	52.5	139.0	26.0	0.8	17.5	91.3	309.9	51.5
	F	1.1	6.0	34.5	93.9	17.5	1.7	11.9	63.1	180.7	33.0
	P	0.8	7.9	43.5	114.3	21.6	1.3	14.7	77.3	237.7	41.6
<b>M959-M972 ALL LYMPHOMAS</b>											
Counts	M	146	268	712	503	1629	291	711	1430	1068	3500
	F	102	187	565	471	1325	181	566	1228	1042	3017
	P	248	455	1277	974	2954	472	1277	2658	2110	6517
Rate Per 100,000	M	16.6	44.4	154.0	317.7	79.1	33.1	117.9	310.3	680.0	171.3
	F	11.9	30.5	123.9	242.3	60.3	21.3	92.5	269.7	524.5	136.8
	P	14.3	37.4	139.0	276.5	69.4	27.3	105.1	290.1	592.7	153.2

**Table 6: Limited duration (5-year and 25-year) cancer prevalence by Site, Sex and Age Group, Queensland, 2007**

5 year prevalence						25 year prevalence					
ICD-O3/SITE	Sex	0-29 years	30-49 years	50-69 years	70 years plus	All ages	0-29 years	30-49 years	50-69 years	70 years plus	All ages
<b>M965-M966 HODGKIN LYMPHOMA</b>											
Counts	M	65	62	46	13	186	131	268	141	44	584
	F	67	54	37	17	175	122	264	119	35	540
	P	132	116	83	30	361	253	532	260	79	1124
Rate Per 100,000	M	7.4	10.5	10.2	8.1	8.9	14.9	44.9	31.2	27.8	28.2
	F	7.8	9.1	8.2	9.0	8.4	14.3	43.7	26.3	18.2	25.8
	P	7.6	9.8	9.2	8.7	8.7	14.6	44.3	28.7	22.5	27.0
<b>M959,M967-M972 NON-HODGKIN LYMPHOMA</b>											
Counts	M	81	206	666	490	1443	160	443	1289	1024	2916
	F	35	133	528	454	1150	59	302	1110	1007	2478
	P	116	339	1194	944	2593	219	745	2399	2031	5394
Rate Per 100,000	M	9.2	33.9	143.8	309.6	70.1	18.2	73.0	279.2	652.2	143.1
	F	4.1	21.4	115.6	233.2	51.9	7.0	48.8	243.6	506.3	111.0
	P	6.7	27.6	129.8	267.8	60.7	12.7	60.8	261.5	570.1	126.3
<b>M980-M994 ALL LEUKAEMIAS</b>											
Counts	M	147	105	433	316	1001	400	261	837	719	2217
	F	120	92	247	211	670	339	213	495	579	1626
	P	267	197	680	527	1671	739	474	1332	1298	3843
Rate Per 100,000	M	16.8	17.4	93.3	199.8	48.5	45.3	43.5	180.6	456.8	108.5
	F	14.3	14.9	54.4	108.8	30.9	40.1	34.7	109.0	291.5	74.7
	P	15.6	16.2	74.0	149.9	39.3	42.7	39.0	145.1	364.8	90.8
<b>M982-M983 LYMPHOID LEUKAEMIA</b>											
Counts	M	104	29	286	196	615	311	90	522	489	1412
	F	81	25	157	127	390	262	55	305	420	1042
	P	185	54	443	323	1005	573	145	827	909	2454
Rate Per 100,000	M	11.9	4.7	61.6	123.9	29.6	35.2	14.9	112.7	310.6	69.2
	F	9.7	4.0	34.5	66.2	18.0	31.0	9.0	66.7	210.1	47.6
	P	10.8	4.4	48.2	92.4	23.6	33.1	11.9	89.9	255.3	58.0
<b>M984-M993 MYELOID LEUKAEMIA</b>											
Counts	M	38	62	99	56	255	80	150	204	107	541
	F	39	57	77	43	216	76	143	164	97	480
	P	77	119	176	99	471	156	293	368	204	1021
Rate Per 100,000	M	4.3	10.4	21.2	35.6	12.3	9.1	25.0	43.9	67.9	26.0
	F	4.6	9.3	17.0	22.5	10.1	9.0	23.3	36.6	50.7	22.5
	P	4.5	9.8	19.1	28.2	11.1	9.0	24.2	40.4	57.8	24.1
<b>M994 OTHER SPECIFIED LEUKAEMIA</b>											
Counts	M	1	12	48	64	125	3	16	110	119	248
	F	0	8	12	40	60	0	11	23	59	93
	P	1	20	60	104	185	3	27	133	178	341
Rate Per 100,000	M	0.1	2.0	10.5	40.3	6.3	0.3	2.6	23.7	75.8	12.4
	F	0.0	1.3	2.7	19.5	2.7	0.0	1.7	5.1	28.9	4.1
	P	0.1	1.6	6.6	29.0	4.4	0.2	2.2	14.4	49.6	8.0
<b>M980 UNSPECIFIED LEUKAEMIA</b>											
Counts	M	4	2	0	1	7	6	5	1	5	17
	F	0	2	1	1	4	1	4	3	3	11
	P	4	4	1	2	11	7	9	4	8	28
Rate Per 100,000	M	0.4	0.3	0.0	0.6	0.3	0.7	0.9	0.3	3.1	0.9
	F	0.0	0.3	0.2	0.6	0.2	0.1	0.6	0.6	1.7	0.5
	P	0.2	0.3	0.1	0.6	0.3	0.4	0.7	0.4	2.3	0.7
<b>M973 MYELOMA/PLASMA CELL TUMOURS</b>											
Counts	M	0	22	182	166	370	0	37	288	257	582
	F	1	18	134	127	280	1	27	220	226	474
	P	1	40	316	293	650	1	64	508	483	1056
Rate Per 100,000	M	0.0	3.6	39.1	105.6	18.3	0.0	6.0	61.9	163.7	28.7
	F	0.1	2.9	29.3	65.5	12.6	0.1	4.3	48.2	115.8	21.3
	P	0.1	3.2	34.3	82.5	15.2	0.1	5.2	55.1	136.2	24.7
<b>M998 MYELOYDYSPLASTIC DISEASES</b>											
Counts	M	5	6	87	229	327	9	13	135	328	485
	F	2	15	65	167	249	4	23	107	254	388
	P	7	21	152	396	576	13	36	242	582	873
Rate Per 100,000	M	0.6	1.0	18.9	148.5	17.7	1.0	2.1	29.3	212.8	26.0
	F	0.2	2.4	14.5	79.1	10.8	0.5	3.7	23.8	121.4	16.9
	P	0.4	1.7	16.7	108.3	13.7	0.7	2.9	26.6	159.5	20.8
<b>M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASES</b>											
Counts	M	9	48	140	132	329	17	90	346	326	779
	F	4	42	108	99	253	12	98	254	289	653
	P	13	90	248	231	582	29	188	600	615	1432
Rate Per 100,000	M	1.0	7.9	30.2	84.2	16.3	2.0	14.8	74.6	209.1	38.8
	F	0.5	6.8	23.8	49.6	11.4	1.4	15.8	56.5	139.8	29.1
	P	0.8	7.3	27.0	64.8	13.7	1.7	15.3	65.7	170.9	33.6
<b>M974-M976 OTHER NEOPLASMS OF LYMPHATIC &amp; HAEMATOPOIETIC TISSUE</b>											
Counts	M	1	3	14	24	42	3	5	31	47	86
	F	1	2	12	14	29	3	5	25	26	59
	P	2	5	26	38	71	6	10	56	73	145
Rate Per 100,000	M	0.1	0.5	3.0	15.0	2.1	0.3	0.8	6.6	29.6	4.3
	F	0.1	0.3	2.6	7.0	1.3	0.4	0.8	5.5	12.6	2.6
	P	0.1	0.4	2.8	10.7	1.7	0.3	0.8	6.0	20.5	3.4
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>											
Counts	M	967	3684	17484	13345	35480	2003	9041	33061	33907	78012
	F	995	5973	13568	8838	29374	1891	13172	34859	28045	77967
	P	1962	9657	31052	22183	64854	3894	22213	67920	61952	155979
Rate Per 100,000	M	110.8	608.0	3773.0	8444.5	1731.3	229.5	1494.3	7147.2	21618	3897.6
	F	118.5	965.4	3005.1	4556.7	1339.3	225.3	2126.3	7700.8	14180	3521.8
	P	114.6	788.6	3394.7	6312.5	1519.9	227.4	1813.7	7426.2	17413	3667.3

**Table 7: Relative Survival by Site, Sex and Years after Diagnosis, Queensland, 2003-2007**

Relative survival by years after diagnosis, ages 0-89 years								
ICD-O3/SITE	Sex	N	1 year	5 years	10 years	15 years	20 years	25 years
<b>C00 LIP</b>								
Percent [95% CI]	M	818	99.3 [98.1, 100]	93.8 [91.2,96.2]	89.0 [85.5,92.2]	84.7 [80.5,88.7]	76.3 [70.9,81.6]	71.6 [64.2,79.1]
	F	277	98.6 [95.9, 100]	87.3 [82.0,91.7]	81.7 [75.2,87.6]	78.0 [69.8,85.7]	78.1 [68.4,87.5]	76.3 [58.4,94.0]
	P	1095	99.1 [98.1,99.9]	92.1 [89.7,94.2]	87.0 [83.9,89.9]	82.9 [79.1,86.5]	76.3 [71.6,81.0]	72.2 [65.4,78.9]
<b>C01,C02 TONGUE</b>								
Percent [95% CI]	M	350	81.6 [77.2,85.3]	56.8 [51.2,62.0]	47.3 [41.1,53.4]	42.6 [35.5,49.8]	38.5 [30.3,47.4]	34.0 [22.5,47.7]
	F	150	76.9 [69.4,82.8]	60.8 [52.5,68.3]	53.6 [44.7,62.1]	39.8 [30.3,49.6]	27.8 [17.9,39.5]	**
	P	500	80.2 [76.5,83.4]	58.0 [53.5,62.4]	49.5 [44.4,54.4]	41.4 [35.7,47.2]	35.3 [28.7,42.3]	31.0 [22.3,41.2]
<b>C03 GUM</b>								
Percent [95% CI]	M	45	69.4 [53.8,81.0]	42.0 [27.2,56.8]	35.8 [20.4,52.8]	**	**	**
	F	40	85.5 [70.5,93.7]	68.7 [50.6,82.5]	64.3 [42.3,82.6]	63.9 [33.1,91.7]	**	**
	P	85	76.8 [66.4,84.6]	54.8 [43.0,65.6]	48.7 [35.4,61.7]	44.1 [28.7,60.4]	**	**
<b>C04 FLOOR OF MOUTH</b>								
Percent [95% CI]	M	108	78.4 [69.5,85.0]	51.4 [42.2,60.1]	36.9 [28.1,46.1]	28.0 [18.9,38.3]	**	**
	F	50	92.8 [81.1,97.9]	54.5 [40.1,67.3]	36.8 [23.3,51.3]	30.9 [18.1,45.7]	**	**
	P	158	83.0 [76.2,88.1]	52.9 [45.2,60.1]	37.5 [30.0,45.2]	29.8 [22.2,38.2]	19.7 [12.9,27.9]	**
<b>C05,C06 PALATE AND OTHER &amp; UNSPECIFIED PARTS OF MOUTH</b>								
Percent [95% CI]	M	159	84.8 [78.4,89.6]	53.4 [44.9,61.4]	34.7 [26.5,43.4]	28.2 [19.9,37.5]	28.0 [19.1,38.4]	32.1 [21.9,43.8]
	F	91	84.3 [74.9,90.6]	63.9 [51.9,74.3]	45.8 [34.0,57.5]	37.1 [26.1,48.9]	38.6 [26.0,52.4]	46.1 [31.1,62.7]
	P	250	84.6 [79.6,88.6]	57.0 [50.1,63.5]	38.7 [31.9,45.7]	31.5 [24.8,38.6]	32.4 [25.0,40.5]	37.8 [29.2,47.2]
<b>C07,C08 PAROTID AND OTHER &amp; UNSPECIFIED MAJOR SALIVARY GLANDS</b>								
Percent [95% CI]	M	181	90.8 [85.1,94.8]	68.1 [59.4,76.0]	60.7 [50.7,70.4]	55.3 [43.6,67.0]	55.6 [41.6,70.2]	**
	F	92	93.2 [85.7,97.2]	83.0 [72.4,90.9]	80.2 [67.8,90.3]	71.6 [56.6,85.0]	51.4 [34.4,68.8]	49.5 [30.6,70.2]
	P	273	91.6 [87.3,94.8]	73.3 [66.5,79.3]	67.7 [59.9,75.0]	61.1 [51.9,70.1]	52.5 [41.6,63.8]	43.9 [29.1,60.7]
<b>C09,C10 TONSIL AND OROPHARYNX</b>								
Percent [95% CI]	M	287	83.0 [78.2,86.8]	56.1 [50.0,61.8]	39.9 [33.0,46.9]	36.3 [28.3,44.7]	27.2 [17.7,38.5]	**
	F	73	78.4 [67.6,86.1]	57.4 [45.1,68.3]	43.8 [29.3,58.3]	**	**	**
	P	360	82.0 [77.8,85.6]	56.3 [50.9,61.5]	40.6 [34.4,46.9]	35.9 [28.7,43.4]	27.0 [18.8,36.5]	**
<b>C11 NASOPHARYNX</b>								
Percent [95% CI]	M	54	80.1 [67.6,88.3]	59.2 [45.6,70.7]	49.1 [35.1,62.3]	48.4 [32.4,64.0]	**	**
	F	22	91.1 [69.1,98.0]	76.2 [52.2,90.1]	54.0 [27.0,75.9]	**	**	**
	P	76	83.4 [73.4,90.0]	63.1 [51.4,73.0]	51.6 [39.6,62.8]	48.3 [34.3,61.8]	43.2 [28.2,58.6]	42.0 [23.9,62.1]
<b>C12,C13 PYRIFORM SINUS AND HYPOPHARYNX</b>								
Percent [95% CI]	M	129	63.7 [55.0,71.3]	30.7 [23.6,38.1]	19.4 [13.3,26.6]	**	**	**
	F	27	53.4 [34.2,69.4]	**	**	**	**	**
	P	156	61.9 [54.0,68.9]	30.9 [24.4,37.8]	20.1 [14.3,26.8]	11.6 [7.1,17.5]	**	**
<b>C14 OTHER &amp; ILL-DEFINED SITES IN LIP, ORAL CAVITY &amp; PHARYNX</b>								
Percent [95% CI]	M	84	60.4 [49.6,69.7]	27.7 [18.7,37.7]	**	**	**	**
	F	15	59.0 [31.9,78.9]	**	**	**	**	**
	P	99	60.2 [50.2,68.9]	29.1 [20.6,38.4]	17.1 [10.4,25.3]	**	**	**
<b>C15 OESOPHAGUS</b>								
Percent [95% CI]	M	669	42.2 [38.6,45.8]	17.4 [14.8,20.2]	12.7 [10.2,15.6]	11.4 [8.4,14.9]	11.0 [7.2,16.0]	**
	F	284	52.0 [46.2,57.6]	16.8 [12.9,21.1]	10.3 [7.3,14.1]	9.9 [6.5,14.3]	**	**
	P	953	45.1 [42.1,48.2]	17.3 [15.1,19.7]	11.9 [9.9,14.2]	11.0 [8.7,13.7]	10.2 [7.3,13.7]	**
<b>C16 STOMACH</b>								
Percent [95% CI]	M	1028	52.3 [49.4,55.2]	27.6 [24.9,30.5]	23.7 [20.6,27.0]	23.1 [19.5,27.0]	21.1 [16.9,25.9]	**
	F	458	53.0 [48.6,57.1]	28.0 [24.3,32.0]	24.4 [20.5,28.6]	22.1 [17.9,26.7]	19.2 [14.6,24.6]	20.9 [15.5,27.2]
	P	1486	52.5 [50.1,54.9]	27.8 [25.6,30.1]	24.0 [21.5,26.5]	22.7 [20.0,25.7]	20.7 [17.5,24.2]	19.3 [14.7,24.7]
<b>C17 SMALL INTESTINE</b>								
Percent [95% CI]	M	173	78.3 [71.5,83.7]	62.9 [54.5,70.6]	59.0 [49.0,68.6]	50.5 [37.0,64.5]	51.9 [35.7,69.6]	**
	F	145	81.8 [74.5,87.4]	60.8 [51.3,69.3]	54.5 [43.6,65.0]	49.3 [35.2,63.7]	44.1 [26.2,64.2]	**
	P	318	79.9 [75.1,84.0]	62.0 [55.8,67.8]	57.1 [49.7,64.2]	50.6 [40.6,60.7]	49.2 [36.9,62.3]	**
<b>C18-C20, C218 COLORECTAL</b>								
Percent [95% CI]	M	6604	84.8 [83.9,85.7]	65.5 [64.2,66.8]	60.0 [58.4,61.7]	57.8 [55.6,59.9]	54.7 [51.8,57.7]	53.9 [48.9,59.2]
	F	5273	83.1 [82.0,84.1]	66.9 [65.4,68.3]	61.5 [59.7,63.2]	58.6 [56.5,60.8]	56.0 [53.3,58.8]	53.5 [49.5,57.6]
	P	11877	84.0 [83.3,84.7]	66.1 [65.1,67.1]	60.7 [59.5,61.9]	58.1 [56.6,59.6]	55.3 [53.4,57.3]	53.6 [50.4,56.8]
<b>C18 COLON</b>								
Percent [95% CI]	M	4051	83.4 [82.2,84.6]	65.1 [63.4,66.8]	59.2 [57.1,61.4]	57.4 [54.7,60.2]	54.8 [51.3,58.5]	54.6 [48.7,60.7]
	F	3714	82.0 [80.7,83.2]	67.3 [65.6,69.0]	62.1 [60.0,64.2]	58.8 [56.2,61.3]	57.2 [54.0,60.5]	55.1 [50.5,59.8]
	P	7765	82.8 [81.9,83.6]	66.2 [65.0,67.4]	60.6 [59.1,62.1]	58.1 [56.2,59.9]	56.0 [53.6,58.4]	54.7 [51.0,58.4]
<b>C19,C20 RECTOSIGMOID JUNCTION AND RECTUM</b>								
Percent [95% CI]	M	2515	86.9 [85.5,88.2]	66.2 [64.1,68.3]	61.6 [59.0,64.2]	58.5 [54.9,62.0]	54.2 [49.1,59.5]	51.9 [42.3,62.4]
	F	1494	85.5 [83.6,87.2]	65.7 [63.0,68.2]	59.8 [56.6,62.9]	58.2 [54.3,62.0]	52.8 [47.8,57.8]	49.1 [41.1,57.7]
	P	4009	86.4 [85.3,87.4]	66.0 [64.4,67.6]	60.9 [58.9,62.9]	58.4 [55.8,61.0]	53.6 [50.0,57.2]	50.5 [44.2,57.2]

**Table 7: Relative Survival by Site, Sex and Years after Diagnosis, Queensland, 2003-2007**

Relative survival by years after diagnosis, ages 0-89 years								
ICD-O3/SITE	Sex	N	1 year	5 years	10 years	15 years	20 years	25 years
<b>C21 ANUS &amp; ANAL CANAL</b>								
Percent [95% CI]	M	133	84.0 [76.7,89.5]	57.7 [48.6,66.2]	50.1 [40.1,60.0]	45.9 [34.0,58.3]	49.4 [34.7,65.0]	51.5 [32.1,73.2]
	F	186	89.5 [84.2,93.3]	72.4 [64.3,79.3]	62.3 [51.7,72.1]	59.0 [46.6,71.1]	45.1 [29.3,62.4]	**
	P	319	87.2 [83.0,90.5]	65.9 [59.9,71.5]	56.8 [49.5,63.9]	53.1 [44.4,61.8]	45.0 [33.2,57.6]	47.0 [32.0,63.8]
<b>C22 LIVER &amp; INTRAHEPATIC BILE DUCTS</b>								
Percent [95% CI]	M	499	40.3 [36.3,44.3]	14.6 [11.6,18.0]	11.2 [ 8.3,14.6]	10.0 [ 7.1,13.7]	10.4 [ 7.3,14.1]	**
	F	189	31.4 [25.7,37.2]	11.8 [ 8.0,16.3]	9.3 [ 5.9,13.8]	8.0 [ 4.7,12.5]	**	**
	P	688	37.8 [34.6,41.1]	13.9 [11.4,16.6]	10.8 [ 8.4,13.4]	9.5 [ 7.2,12.3]	8.2 [ 5.1,12.5]	8.6 [ 5.3,13.0]
<b>C23,C24 GALLBLADDER AND OTHER &amp; UNSPECIFIED PARTS OF BILIARY TRACT</b>								
Percent [95% CI]	M	214	55.1 [48.6,61.1]	24.5 [19.3,30.1]	17.4 [12.5,23.2]	15.3 [10.2,21.8]	**	**
	F	254	36.3 [31.0,41.6]	16.6 [12.7,21.1]	11.4 [ 7.8,15.7]	11.6 [ 7.6,16.7]	12.2 [ 7.5,18.4]	**
	P	468	44.7 [40.5,48.8]	20.1 [16.8,23.6]	13.9 [10.9,17.4]	13.1 [ 9.8,17.0]	11.6 [ 7.8,16.5]	**
<b>C25 PANCREAS</b>								
Percent [95% CI]	M	852	23.1 [20.6,25.7]	4.6 [ 3.4, 6.0]	3.8 [ 2.7, 5.2]	3.1 [ 2.0, 4.6]	3.8 [ 2.4, 5.7]	**
	F	736	20.8 [18.3,23.4]	6.0 [ 4.6, 7.6]	4.0 [ 2.8, 5.5]	4.2 [ 2.9, 5.8]	**	**
	P	1588	22.0 [20.2,23.9]	5.3 [ 4.4, 6.3]	4.0 [ 3.1, 5.0]	3.8 [ 2.9, 4.8]	3.9 [ 2.7, 5.3]	**
<b>C30,C31 NASAL CAVITY &amp; MIDDLE EAR AND ACCESSORY SINUSES</b>								
Percent [95% CI]	M	72	86.7 [76.5,93.0]	66.4 [53.3,77.3]	51.4 [37.1,65.4]	46.2 [30.5,62.8]	**	**
	F	34	85.2 [68.8,93.8]	64.4 [46.3,78.6]	52.6 [34.8,69.0]	47.9 [29.3,66.8]	**	**
	P	106	86.2 [78.1,91.7]	66.0 [55.7,74.9]	52.3 [41.2,63.1]	47.3 [35.1,59.7]	**	**
<b>C32 LARYNX</b>								
Percent [95% CI]	M	519	87.7 [84.5,90.3]	67.2 [62.7,71.5]	51.3 [46.1,56.4]	40.2 [34.9,45.6]	29.8 [24.4,35.7]	27.7 [20.8,35.7]
	F	57	86.2 [74.5,93.2]	54.2 [39.7,67.2]	44.9 [30.8,59.1]	35.9 [22.9,50.4]	28.3 [16.2,43.1]	**
	P	576	87.5 [84.5,90.1]	66.0 [61.7,70.1]	50.6 [45.8,55.5]	39.8 [34.9,44.9]	29.7 [24.7,35.2]	27.0 [20.4,34.5]
<b>C33,C34 TRACHEA AND BRONCHUS &amp; LUNG</b>								
Percent [95% CI]	M	5024	35.8 [34.6,37.0]	11.0 [10.2,11.9]	7.6 [ 6.9, 8.4]	6.1 [ 5.4, 6.9]	5.0 [ 4.1, 5.9]	4.6 [ 3.6, 5.7]
	F	2723	43.3 [41.6,45.0]	15.3 [14.0,16.6]	10.8 [ 9.6,12.1]	8.9 [ 7.6,10.2]	6.6 [ 5.3, 8.0]	6.0 [ 4.4, 7.9]
	P	7747	38.4 [37.4,39.4]	12.5 [11.8,13.2]	8.7 [ 8.1, 9.4]	7.1 [ 6.4, 7.8]	5.5 [ 4.8, 6.3]	5.1 [ 4.2, 6.1]
<b>C37, C38 THYMUS, HEART, MEDIASTINUM &amp; PLEURA</b>								
Percent [95% CI]	M	41	76.0 [62.3,85.5]	64.7 [49.8,76.8]	60.6 [44.5,74.4]	59.5 [42.6,74.4]	50.9 [29.3,71.2]	54.1 [31.2,75.7]
	F	32	76.1 [58.8,87.1]	59.2 [40.4,74.2]	49.8 [30.0,67.7]	59.6 [35.9,81.1]	66.8 [40.2,90.9]	**
	P	73	76.1 [65.8,83.7]	62.8 [51.3,72.6]	56.5 [44.2,67.6]	56.7 [43.3,68.9]	52.1 [35.5,67.8]	49.6 [31.2,67.7]
<b>C40,C41 BONES, JOINTS &amp; ARTICULAR CARTILAGES</b>								
Percent [95% CI]	M	109	87.8 [80.3,92.7]	65.2 [55.5,73.6]	61.9 [51.7,71.0]	60.0 [49.3,69.7]	59.0 [47.8,69.2]	56.4 [44.5,67.7]
	F	87	88.2 [79.7,93.5]	66.8 [56.7,75.4]	61.7 [50.7,71.4]	58.2 [46.4,68.9]	57.7 [45.5,68.8]	59.0 [46.5,70.3]
	P	196	88.0 [82.7,91.8]	66.0 [59.1,72.1]	61.8 [54.5,68.5]	59.2 [51.4,66.5]	58.4 [50.3,66.0]	57.2 [48.5,65.5]
<b>C44, M872-M879 MELANOMA</b>								
Percent [95% CI]	M	7095	97.9 [97.5,98.3]	92.5 [91.5,93.4]	87.9 [86.6,89.2]	85.3 [83.5,87.0]	83.9 [81.8,86.1]	82.2 [78.7,85.6]
	F	5146	98.6 [98.2,99.0]	95.2 [94.4,96.0]	93.5 [92.4,94.6]	91.8 [90.3,93.2]	90.9 [89.1,92.7]	88.4 [85.6,91.1]
	P	12241	98.2 [97.9,98.5]	93.7 [93.0,94.3]	90.4 [89.5,91.3]	88.1 [87.0,89.3]	87.0 [85.6,88.4]	84.8 [82.7,87.0]
<b>C44 OTHER SKIN (EXCL BCC/SCC)</b>								
Percent [95% CI]	M	327	83.8 [79.1,87.6]	58.4 [52.3,64.3]	48.7 [41.6,55.9]	47.4 [39.7,55.5]	47.0 [37.8,56.9]	**
	F	189	87.4 [81.8,91.6]	74.4 [66.7,81.2]	65.3 [55.6,74.4]	52.6 [41.7,63.4]	49.1 [36.6,62.1]	48.7 [35.4,62.8]
	P	516	85.1 [81.6,88.1]	64.2 [59.3,68.8]	54.7 [48.9,60.4]	49.7 [43.3,56.2]	48.1 [40.6,55.9]	43.3 [31.5,56.5]
<b>M905 MESOTHELIOMA</b>								
Percent [95% CI]	M	436	44.5 [39.9,49.1]	4.8 [ 3.0, 7.2]	**	**	**	**
	F	91	53.3 [43.2,62.5]	**	**	**	**	**
	P	527	46.0 [41.8,50.1]	5.9 [ 4.1, 8.1]	**	**	**	**
<b>M914 KAPOSI SARCOMA</b>								
Percent [95% CI]	M	21	77.0 [56.3,88.9]	61.7 [39.8,78.5]	50.3 [29.1,70.0]	**	**	**
	F	3	**	**	**	**	**	**
	P	24	75.5 [55.9,87.4]	61.9 [41.4,77.9]	53.0 [32.5,71.6]	40.3 [21.9,60.1]	46.3 [25.2,69.1]	**
<b>C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVES</b>								
Percent [95% CI]	M	255	82.5 [77.4,86.6]	62.8 [56.7,68.5]	61.0 [54.2,67.5]	62.1 [54.0,69.9]	66.9 [57.6,75.8]	70.6 [59.2,81.6]
	F	210	85.5 [80.1,89.6]	62.7 [55.6,69.2]	55.0 [47.4,62.2]	48.6 [40.4,56.7]	39.0 [30.1,48.3]	31.2 [18.6,46.2]
	P	465	83.8 [80.2,86.9]	63.0 [58.4,67.3]	58.5 [53.4,63.3]	55.4 [49.5,61.1]	52.5 [45.8,59.3]	49.9 [40.4,59.7]
<b>C48 RETROPERITONEUM &amp; PERITONEUM</b>								
Percent [95% CI]	M	39	82.5 [66.9,91.8]	59.0 [40.6,74.5]	49.2 [28.8,68.3]	**	**	**
	F	149	84.2 [77.3,89.3]	38.8 [30.9,46.7]	22.5 [14.6,31.6]	**	**	**
	P	188	83.9 [77.8,88.6]	42.5 [35.2,49.7]	27.6 [19.9,36.1]	21.4 [13.6,30.8]	21.9 [13.9,31.6]	**
<b>C50 BREAST</b>								
Percent [95% CI]	M	98	98.0 [91.7, 101]	78.8 [67.7,87.9]	64.6 [50.8,77.5]	50.0 [31.3,70.4]	62.8 [38.7,89.5]	**
	F	11410	97.9 [97.6,98.2]	88.7 [88.0,89.4]	81.4 [80.4,82.3]	75.5 [74.2,76.8]	71.4 [69.7,73.1]	68.5 [65.5,71.4]
	P	11508	97.9 [97.6,98.2]	88.6 [87.9,89.3]	81.3 [80.3,82.2]	75.3 [74.0,76.6]	71.4 [69.7,73.1]	68.5 [65.6,71.4]

**Table 7: Relative Survival by Site, Sex and Years after Diagnosis, Queensland, 2003-2007**

Relative survival by years after diagnosis, ages 0-89 years										
ICD-O3/SITE	Sex	N	1 year	5 years	10 years	15 years	20 years	25 years		
<b>C51 VULVA</b>										
Percent [95% CI]	M	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	F	191	89.1 [83.7,93.0]	74.9 [67.5,81.2]	65.0 [56.4,73.1]	64.7 [54.7,74.4]	49.2 [37.7,61.3]	45.7 [32.8,60.0]		
	P	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<b>C53 CERVIX UTERI</b>										
Percent [95% CI]	M	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	F	784	89.6 [87.3,91.5]	75.6 [72.5,78.5]	69.3 [66.0,72.4]	67.1 [63.6,70.4]	64.9 [61.2,68.4]	64.3 [60.3,68.1]		
	P	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<b>C54 CORPUS UTERI</b>										
Percent [95% CI]	M	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	F	1600	94.4 [93.1,95.5]	82.1 [79.9,84.1]	79.1 [76.3,81.8]	76.6 [72.9,80.2]	74.3 [69.6,78.9]	70.4 [62.9,78.0]		
	P	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<b>C56 OVARY</b>										
Percent [95% CI]	M	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	F	1017	77.8 [75.3,80.2]	45.2 [42.3,48.1]	37.8 [34.8,40.8]	35.5 [32.4,38.7]	34.0 [30.6,37.5]	33.3 [29.1,37.6]		
	P	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<b>C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANS</b>										
Percent [95% CI]	M	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	F	191	73.6 [67.1,79.2]	54.3 [46.8,61.4]	47.4 [39.1,55.7]	48.4 [39.2,57.5]	47.3 [36.7,58.2]	46.9 [34.8,59.8]		
	P	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<b>C61 PROSTATE GLAND</b>										
Percent [95% CI]	M	13775	97.5 [97.1,97.8]	87.5 [86.6,88.3]	75.7 [74.3,77.2]	64.0 [61.7,66.2]	57.6 [53.7,61.7]	55.9 [47.7,64.9]		
	F	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
	P	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<b>C62 TESTIS</b>										
Percent [95% CI]	M	629	99.2 [98.1,99.7]	96.6 [94.8,98.0]	96.6 [94.4,98.2]	96.5 [93.9,98.5]	96.5 [93.1,99.2]	98.3 [94.4, 101]		
	F	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
	P	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<b>C60,C63 PENIS AND OTHER &amp; UNSPECIFIED MALE GENITAL ORGANS</b>										
Percent [95% CI]	M	76	87.4 [77.9,93.6]	82.6 [70.8,91.8]	71.2 [56.8,84.3]	58.7 [43.1,74.5]	53.7 [35.8,73.3]	63.5 [41.1,88.5]		
	F	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
	P	.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<b>C64-C66,C68 KIDNEY AND OTHER RENAL TRACT</b>										
Percent [95% CI]	M	1515	82.8 [80.7,84.6]	68.4 [65.7,71.0]	60.0 [56.7,63.3]	55.9 [51.7,60.1]	52.7 [47.3,58.2]	48.8 [40.3,57.8]		
	F	901	81.0 [78.3,83.4]	65.4 [62.0,68.7]	55.7 [51.8,59.6]	49.5 [44.7,54.2]	45.4 [39.7,51.2]	41.8 [34.6,49.4]		
	P	2416	82.1 [80.5,83.6]	67.3 [65.2,69.4]	58.4 [55.9,60.9]	53.3 [50.2,56.5]	49.7 [45.7,53.7]	45.6 [39.4,52.1]		
<b>C67 BLADDER</b>										
Percent [95% CI]	M	2510	90.5 [89.2,91.8]	75.8 [73.7,77.9]	68.2 [65.4,70.9]	61.8 [58.3,65.3]	57.5 [53.0,62.1]	58.4 [51.4,65.7]		
	F	732	82.4 [79.5,85.0]	70.1 [66.4,73.7]	65.1 [60.6,69.5]	57.0 [51.6,62.3]	55.2 [48.8,61.7]	46.2 [36.6,56.7]		
	P	3242	88.7 [87.5,89.8]	74.6 [72.7,76.4]	67.5 [65.2,69.9]	60.7 [57.7,63.6]	57.1 [53.4,60.9]	54.4 [48.6,60.5]		
<b>C69 EYE &amp; ADNEXA</b>										
Percent [95% CI]	M	172	97.9 [93.7, 100]	85.6 [78.3,91.4]	75.1 [66.1,83.3]	75.7 [65.0,85.8]	73.7 [60.9,86.1]	**		
	F	117	98.0 [92.6, 100]	92.7 [85.1,97.9]	79.0 [68.3,87.8]	72.8 [60.4,83.7]	68.1 [53.3,81.8]	65.0 [48.8,80.3]		
	P	289	97.9 [95.0,99.7]	88.6 [83.4,92.8]	76.7 [69.9,82.9]	74.5 [66.5,82.0]	71.4 [61.8,80.7]	59.3 [43.4,75.3]		
<b>C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM</b>										
Percent [95% CI]	M	730	45.8 [42.4,49.2]	22.7 [20.0,25.6]	22.3 [19.8,24.9]	14.8 [12.2,17.5]	14.1 [11.5,16.9]	13.5 [10.7,16.5]		
	F	473	46.1 [42.0,50.2]	24.6 [21.2,28.2]	20.6 [17.4,24.1]	17.7 [14.5,21.2]	14.2 [11.1,17.6]	11.5 [ 7.9,15.8]		
	P	1203	46.0 [43.3,48.6]	23.5 [21.4,25.7]	18.8 [16.8,20.9]	16.0 [14.0,18.1]	14.2 [12.2,16.4]	12.5 [10.1,15.2]		
<b>C73 THYROID GLAND</b>										
Percent [95% CI]	M	406	96.0 [93.5,97.7]	93.4 [89.7,96.4]	90.5 [85.0,95.2]	86.3 [77.8,93.6]	84.2 [73.4,93.8]	90.5 [77.6, 102]		
	F	1210	98.3 [97.3,98.9]	97.4 [96.0,98.6]	95.7 [93.5,97.5]	95.5 [92.6,98.0]	95.2 [91.2,98.7]	97.5 [92.7, 102]		
	P	1616	97.7 [96.8,98.4]	96.4 [95.1,97.6]	94.4 [92.3,96.2]	93.4 [90.5,96.0]	92.8 [88.9,96.3]	95.8 [91.2,99.9]		
<b>C74,C75 ADRENAL AND OTHER ENDOCRINE GLANDS</b>										
Percent [95% CI]	M	30	76.6 [57.5,88.3]	48.1 [32.3,62.7]	40.0 [25.6,54.3]	39.1 [24.7,53.7]	40.7 [25.8,55.9]	41.0 [25.9,56.3]		
	F	44	78.3 [63.8,87.6]	56.0 [39.9,69.8]	43.4 [27.5,59.1]	45.1 [28.6,61.4]	43.1 [25.1,61.7]	**		
	P	74	77.6 [66.7,85.4]	51.7 [40.6,62.0]	42.0 [31.5,52.5]	42.0 [31.2,52.8]	42.0 [30.5,53.6]	43.7 [31.7,55.7]		
<b>C26,C39,C76,C77,C80 OTHER &amp; ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE</b>										
Percent [95% CI]	M	1220	34.9 [32.6,37.2]	25.6 [23.3,28.0]	22.3 [19.8,24.9]	22.7 [19.8,25.8]	23.4 [19.8,27.4]	21.1 [15.3,28.2]		
	F	915	28.3 [25.9,30.7]	19.2 [17.0,21.5]	16.5 [14.2,19.0]	15.3 [12.8,18.0]	15.3 [12.6,18.3]	14.6 [11.1,18.7]		
	P	2135	32.0 [30.4,33.7]	22.8 [21.2,24.5]	19.8 [18.0,21.6]	19.3 [17.3,21.4]	19.6 [17.3,22.1]	18.1 [14.5,22.1]		
<b>M959-M972 ALL LYMPHOMAS</b>										
Percent [95% CI]	M	2008	84.9 [83.2,86.4]	69.6 [67.3,71.8]	61.7 [58.9,64.5]	55.3 [51.9,58.7]	51.0 [46.9,55.0]	44.8 [38.7,51.1]		
	F	1594	84.4 [82.5,86.1]	71.6 [69.1,74.0]	62.1 [59.1,65.0]	57.0 [53.5,60.4]	52.5 [48.4,56.7]	50.9 [45.1,56.7]		
	P	3602	84.7 [83.4,85.8]	70.5 [68.8,72.1]	61.9 [59.8,63.9]	56.0 [53.6,58.5]	51.7 [48.8,54.6]	47.8 [43.6,52.1]		

**Table 7: Relative Survival by Site, Sex and Years after Diagnosis, Queensland, 2003-2007**

Relative survival by years after diagnosis, ages 0-89 years								
ICD-O3/SITE	Sex	N	1 year	5 years	10 years	15 years	20 years	25 years
<b>M965-M966 HODGKIN LYMPHOMA</b>								
Percent [95% CI]	M	206	92.7 [88.3,95.6]	82.1 [76.0,87.0]	75.3 [68.2,81.3]	72.3 [64.6,79.1]	65.6 [57.0,73.4]	61.6 [51.8,70.7]
	F	184	94.0 [89.5,96.7]	88.3 [82.5,92.4]	84.9 [78.5,89.8]	83.4 [76.4,88.8]	78.9 [70.4,85.7]	76.3 [65.8,84.7]
	P	390	93.3 [90.4,95.4]	84.9 [80.9,88.3]	79.8 [75.1,83.9]	77.5 [72.3,82.0]	71.6 [65.5,77.0]	68.1 [60.9,74.6]
<b>M959,M967-M972 NON-HODGKIN LYMPHOMA</b>								
Percent [95% CI]	M	1802	84.0 [82.2,85.6]	68.1 [65.6,70.5]	60.0 [56.9,63.1]	52.5 [48.6,56.4]	48.8 [44.0,53.7]	41.1 [33.0,49.7]
	F	1410	83.1 [81.1,85.0]	69.4 [66.7,72.0]	58.8 [55.5,62.0]	52.8 [48.9,56.7]	48.2 [43.4,53.0]	46.8 [40.3,53.7]
	P	3212	83.6 [82.3,84.9]	68.7 [66.9,70.5]	59.4 [57.2,61.6]	52.6 [49.9,55.4]	48.5 [45.1,51.9]	44.4 [39.3,49.7]
<b>M980-M994 ALL LEUKAEMIAS</b>								
Percent [95% CI]	M	1446	78.5 [76.4,80.5]	58.0 [55.3,60.6]	46.0 [43.0,49.0]	37.1 [33.7,40.5]	35.1 [31.2,39.1]	36.6 [32.1,41.3]
	F	952	76.1 [73.4,78.6]	60.8 [57.6,63.8]	50.9 [47.3,54.4]	43.0 [38.9,47.0]	36.8 [32.0,41.8]	31.4 [24.2,39.4]
	P	2398	77.6 [75.9,79.2]	59.1 [57.1,61.1]	48.0 [45.7,50.3]	39.5 [36.9,42.2]	35.9 [32.9,39.0]	34.8 [30.8,39.0]
<b>M982-M983 LYMPHOID LEUKAEMIA</b>								
Percent [95% CI]	M	752	91.2 [88.8,93.1]	74.1 [70.5,77.5]	59.1 [54.6,63.5]	45.5 [40.3,50.8]	42.2 [36.4,48.3]	44.6 [37.7,51.9]
	F	482	93.3 [90.7,95.4]	79.8 [75.7,83.6]	67.6 [62.2,72.7]	58.2 [51.8,64.4]	49.7 [42.0,57.6]	43.6 [31.0,57.4]
	P	1234	92.0 [90.3,93.5]	76.4 [73.7,79.0]	62.5 [59.1,65.9]	50.7 [46.6,54.7]	45.5 [40.8,50.3]	44.7 [38.0,51.6]
<b>M984-M993 MYELOID LEUKAEMIA</b>								
Percent [95% CI]	M	506	59.7 [55.6,63.5]	36.6 [32.6,40.5]	28.6 [24.6,32.7]	25.3 [21.0,29.8]	25.9 [21.2,31.0]	25.5 [20.0,31.5]
	F	373	56.8 [52.0,61.3]	41.6 [36.9,46.2]	34.0 [29.2,38.8]	28.7 [23.6,34.0]	24.7 [18.7,31.3]	18.7 [11.1,28.3]
	P	879	58.4 [55.4,61.4]	38.6 [35.6,41.7]	30.9 [27.9,34.0]	26.6 [23.3,30.0]	25.3 [21.5,29.2]	22.7 [18.1,27.9]
<b>M994 OTHER SPECIFIED LEUKAEMIA</b>								
Percent [95% CI]	M	175	80.2 [73.5,85.6]	53.2 [44.9,61.1]	42.1 [33.3,51.2]	36.0 [25.8,47.4]	34.0 [22.1,48.1]	39.3 [25.5,55.6]
	F	84	72.7 [62.3,80.9]	43.0 [30.5,55.6]	40.0 [26.1,54.9]	**	**	**
	P	259	77.8 [72.3,82.5]	50.5 [43.6,57.2]	41.3 [33.8,49.0]	32.8 [24.3,42.2]	29.6 [20.2,40.6]	32.0 [21.4,44.6]
<b>M980 UNSPECIFIED LEUKAEMIA</b>								
Percent [95% CI]	M	13	**	**	**	**	**	**
	F	13	**	**	**	**	**	**
	P	26	44.6 [27.4,60.7]	**	**	**	**	**
<b>M973 MYELOMA/PLASMA CELL TUMOURS</b>								
Percent [95% CI]	M	551	80.5 [76.9,83.6]	43.3 [39.0,47.6]	24.4 [20.2,29.0]	20.1 [15.3,25.7]	14.8 [9.1,22.4]	**
	F	418	79.5 [75.4,83.1]	43.9 [39.2,48.6]	28.4 [23.8,33.3]	23.1 [16.8,30.2]	29.8 [21.8,39.1]	35.9 [23.3,51.3]
	P	969	80.1 [77.4,82.5]	43.6 [40.4,46.8]	26.3 [23.1,29.7]	22.0 [18.1,26.3]	20.9 [15.6,27.0]	23.2 [16.1,31.8]
<b>M998 MYELOYDPLASTIC DISEASES</b>								
Percent [95% CI]	M	588	75.1 [71.3,78.5]	41.8 [37.3,46.3]	23.3 [18.3,29.0]	19.1 [13.1,26.4]	**	**
	F	398	79.4 [75.1,83.1]	46.9 [41.4,52.4]	30.3 [23.9,37.2]	21.5 [13.3,31.8]	26.0 [16.0,38.5]	29.4 [18.1,43.6]
	P	986	76.8 [74.0,79.4]	43.9 [40.4,47.4]	26.1 [22.1,30.4]	20.4 [15.3,26.2]	16.9 [10.2,25.9]	**
<b>M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASES</b>								
Percent [95% CI]	M	406	93.3 [90.2,95.7]	78.5 [73.6,82.9]	67.9 [61.7,73.8]	57.3 [49.0,65.7]	43.8 [33.5,54.9]	38.2 [25.9,52.6]
	F	274	95.1 [91.6,97.5]	81.4 [75.8,86.3]	66.7 [59.9,73.2]	58.6 [50.5,66.7]	49.6 [39.4,60.2]	49.9 [36.6,64.5]
	P	680	94.1 [91.8,95.8]	79.6 [76.0,82.9]	67.0 [62.5,71.4]	57.9 [52.1,63.6]	46.7 [39.4,54.3]	43.5 [34.0,53.8]
<b>M974-M976 OTHER NEOPLASMS OF LYMPHATIC &amp; HAEMATOPOIETIC TISSUE</b>								
Percent [95% CI]	M	51	91.3 [79.8,97.3]	76.1 [60.9,88.3]	55.8 [33.3,77.3]	**	**	**
	F	42	91.8 [78.5,98.0]	69.9 [50.2,85.6]	59.9 [37.8,80.0]	62.5 [39.4,83.5]	63.7 [40.2,85.1]	**
	P	93	91.6 [83.7,96.3]	73.8 [62.1,83.8]	58.0 [42.5,72.8]	55.1 [37.6,72.6]	59.2 [40.4,78.0]	51.3 [31.1,73.0]
<b>TOTAL MALIGNANT NEOPLASMS (C00-C80)</b>								
Percent [95% CI]	M	52498	80.6 [80.3,80.9]	64.9 [64.4,65.3]	57.5 [56.9,58.1]	52.7 [51.9,53.4]	49.7 [48.8,50.6]	47.9 [46.5,49.3]
	F	40281	83.5 [83.1,83.8]	69.6 [69.2,70.1]	63.7 [63.1,64.2]	59.9 [59.2,60.5]	57.1 [56.3,57.9]	55.0 [53.9,56.1]
	P	92779	81.8 [81.6,82.1]	67.0 [66.6,67.3]	60.3 [59.9,60.7]	56.0 [55.5,56.5]	53.2 [52.6,53.8]	51.2 [50.3,52.1]

## APPENDIX 1: GUIDELINES FOR RELEASE OF INFORMATION QUEENSLAND CANCER REGISTRY

The *Public Health Act 2005*, provides the following:

### Division 4 Confidentiality

#### 237 Definitions for div 4

In this division *relevant person* means the following—

- (a) a person who is, or was, the chief executive;
- (b) a person who is, or was, involved in the administration of this part, including, for example, a health service employee or a public service employee, but not including a contractor or an employee of a contractor;
- (c) a person who was involved in the administration or enforcement of the repealed provisions.

#### 238 Confidentiality of information

- (1) A relevant person must not, whether directly or indirectly, disclose confidential information.
- (2) The *Health Services Act 1991*, section 62A, does not apply to a relevant person in relation to confidential information.

#### 239 Disclosure under an Act or another law

Section 238(1) does not apply if the disclosure of the confidential information by a relevant person is authorised under an Act or another law.

#### 244 Disclosure to Commonwealth, another State or Commonwealth or State entity

- (1) Section 238(1) does not apply to the disclosure of confidential information by the chief executive if—
  - (a) the disclosure is to the Commonwealth or another State, or an entity of the Commonwealth or another State and the disclosure—
    - (i) is required or allowed under an agreement—
      - (A) between Queensland and the Commonwealth, State or entity; and
      - (B) prescribed under a regulation for this paragraph; and
    - (ii) is considered by the chief executive to be in the public interest; or
  - (b) the disclosure is to an entity of the State and the disclosure—
    - (i) is required or allowed under an agreement—
      - (A) between the chief executive and the entity; and
      - (B) prescribed under a regulation for this paragraph; and
    - (ii) is considered by the chief executive to be in the public interest.
- (2) The Commonwealth, a State or entity that receives confidential information under an agreement under subsection (1)—
  - (a) must not give it to anyone else unless allowed to do so by the agreement or in writing by the chief executive; and
  - (b) must ensure the confidential information is used only for the purpose for which it was given under the agreement.

#### Disclosure by contractor

Section 248 does not apply to the disclosure of confidential information by the contractor or an employee of the contractor if the disclosure—

- (a) is made in the performance of functions under this part; or
- (b) is made in a form that does not identify any person; or
- (c) is made to the chief executive, at the written request of the chief executive stating the chief executive considers the disclosure is necessary for ensuring the proper administration of this part; or
- (d) is made to a person or entity to which the chief executive may make the disclosure under section 242, 243 or 244, if the chief executive authorises the contractor, in writing, to disclose the information; or
- (e) is for the purpose of giving information under chapter 6, part 4, division 2 for research, if the chief executive authorises the contractor, in writing, to disclose the information; or
- (f) is authorised under an Act or another law.

Statistical information in an aggregate form may be obtained by contacting the Queensland Cancer Registry.

Medical researchers wishing to obtain information on individual patients from the Cancer Registry should complete an application under the Public Health Act 2005 and forward to the Registrar of the Queensland Cancer Registry. The research proposal must also have received ethical approval and set out the aims and methods of the research. The application will be submitted to the Queensland Health Data Custodian for approval by the Director General of Queensland Health. If the application is approved then the researcher will be granted access to Cancer Registry data under the terms of the application approved under the Public Health Act 2005.

Before information concerning a live patient is released to any researcher, the latter must sign a declaration that any such information will not be used to contact patients, other than the researcher's own patients, without first obtaining permission from each patient's own medical practitioner.

The data set collected for each cancer includes:-

- patient name(s)
- usual residential address (at diagnosis and at last contact)
- date of birth/age
- occupation
- country of birth
- sex
- indigenous status
- marital status
- date of last contact
- institution of last contact
- treating doctor
- date of diagnosis
- site of cancer
- cancer histology
- differentiation
- basis of diagnosis
- laterality
- date of death
- cause of death

Further information is collected for: -

Breast cancer –

- tumour size
- size complete
- number of nodes
- number of positive nodes
- nodes complete

Melanoma –

- thickness
- ulceration
- Clark's level



### APPENDIX 3: CANCER REPORTING DEFINITIONS AND CALCULATION OF STATISTICS

Rates per 100,000 are calculated by dividing the number of cases in each five year age and sex stratum by the Australian Bureau of Statistics estimated resident population<sup>1</sup> for that stratum and multiplying the product by 100,000.

Age-standardised rates are calculated by summing the products of the age-specific rates with either the World Standard Population strata (1960) or the Australian age-specific population distribution in 2001 (see Appendix 4). They provide a rate that is independent of the age structure of the population of interest and are therefore useful in making comparisons between different populations, time periods etc.

Confidence intervals: All statistical estimates are calculated with some degree of imprecision. The level of accuracy is typically reported in terms of a confidence interval, which specifies a range of values in which the true data point is expected to occur with a given level of certainty. For example, a 5-year survival rate may be estimated as 88.5% with a 95% confidence interval of 87.9%-89.2%. This means that there is a 95% probability that the true survival rate will be somewhere between 87.9% and 89.2%.

Cumulative rates are calculated for ages 0-79 in this report. The cumulative rate is used as an estimate of the risk of developing or dying of cancer up to the age of 79, and is expressed as a percentage (i.e., rate per 100 population). *Note that previous publications have used 0-74 years to calculate cumulative risks, so direct comparisons between publications are not possible.*

Cumulative Rate (0-79) = 5 \* [sum of age-specific rates for ages 0-79]\*100/ 100,000

Cumulative risk is another measure of risk derived from the cumulative rate. It is more precise, as it takes into account the removal of persons from the population of interest who have already been diagnosed or died from cancer. Expressed as a '1 in n' proportion, it is calculated as follows:

$$n = 1/(1 - e^{-\text{cumulative rate}/100})$$

This report calculates the cumulative risk up to the age of 80 years as an approximation of lifetime risk (previous reports have used up to 75 years). The calculation assumes that the person experiences the current age-specific risk rates up to the age of 80, and is unable to factor in individual risk factors such as smoking etc.

Incidence is defined as the occurrence of new cancers in a defined population during a specified time period. For the purposes of this report, 2007 incidence, for example, is based on those cancers notified to the registry which were first diagnosed between 1 January 2007 and 31 December 2007 for residents of Queensland.

Limited duration prevalence reports the number of people still alive at a given point in time (ie. 31<sup>st</sup> December 2007) who were diagnosed within a specific time period. In this report limited duration prevalence estimates are presented for people diagnosed within 5 years and 25 years. Note that persons diagnosed with cancer before 1982 (when the Queensland Cancer Registry began operating) were excluded from these prevalence estimates.

In contrast to the previous publication,<sup>2</sup> these prevalence estimates exclude multiple cancers within the same person. For this reason prevalence estimates from the previous report<sup>2</sup> should not be compared to these latest estimates.

Mortality is based on those deaths notified to the registry for persons who died from cancer during a specified time period and who usually resided in Queensland at the time of diagnosis of cancer. This means that mortality information is not directly comparable with death data released from the Australian Bureau of Statistics (which is based on the state where the death was registered).

Multiple Primary Tumours: Incidence reflects the number of primary tumours rather than the number of individuals with cancer. The Queensland Cancer Registry records multiple primary cancers in the same person,

of which only the first instance in each topographic site is reported for incidence purposes according to the rules of the International Agency for Research on Cancer and International Association of Cancer Registries. In brief, these rules state that:-

- The recognition of the existence of one or more primary tumours does not depend on time. Hence synchronous and metachronous multiple lesions are not distinguished as the definitions are frequently arbitrary.
- A primary cancer is one that originates in a primary site or tissue and is thus not an extension, a recurrence, nor a metastasis of a pre-existing tumour.
- Only one tumour shall be recognised in an organ or pair of organs or tissue (as defined by the three-digit rubric of the ICD-O-3 topography) unless of 'different' histology. Some 3-digit topography codes are combined as single groups for this purpose, such as trachea (C33) and lung (C34).
- A 'different' cancer in the same organ is counted as a new tumour. There are twelve defined groups of malignant neoplasms considered to be histologically 'different' based on the first three digits of the ICDO morphology code, and incidence reporting of multiple tumours is based upon these groups. (ICDO 3<sup>rd</sup> edition. Ed Fritz A, Percy C, Jack A, Shanmugaratnum K, Sobin L, Parkin M and Whelan S. Geneva: WHO, 2000.)

Relative survival compares the survival of people who have a particular disease or condition against the expected survival of a comparable group from the general population, taking into account age, sex and year of diagnosis. The 5-year relative survival estimate can be interpreted as the proportion of cancer patients alive 5 years after diagnosis in the hypothetical situation where the cancer in question is the only possible cause of death.<sup>3</sup> For instance, a 5-year relative survival estimate of 75% indicates that 75% of people diagnosed with that cancer could expect to live for at least 5 years, ignoring the impact of other causes of death. This means that these cancer patients have a mortality outlook much lower than that of the general population (of comparable age and gender). The method does not require knowledge of the specific cause of death, only knowledge of whether the patient has died.

Relative survival estimates can be calculated using either period or cohort methods.<sup>4</sup> The period method has been used in this report, as it is recognised as providing more up-to-date survival estimates.<sup>5</sup> Under the period method, the group of cancer patients included in the survival calculations are selected based on whether they are living with a diagnosis of cancer in the "at risk" period, which for this report is 2003-2007. In contrast, the cohort method is defined by the time of diagnosis. We included all patients diagnosed up to 31st December 2006, with follow up to 31st December 2007 to ensure that each patient had at least 12 months of potential follow up. For 5-, 10-, 15-, 20- and 25- year estimates, cancer patients were diagnosed during 1998-2003, 1993-1998, 1988-1993, 1983-1988 and 1982-1983, respectively.

Patients who were still alive at 31st December 2007 were considered censored. Persons aged 90 years and over at time of diagnosis have been excluded from the calculation of survival estimates, as have those whose cancer diagnosis was based on death certificate or autopsy, or those with a survival time of zero days or less.

A suite of computer programs developed by Paul Dickman from the Karolinska Institutet in Sweden<sup>6</sup> were used to generate the relative survival estimates, using the actuarial method for calculating observed survival and the Ederer II method<sup>3</sup> for calculating expected survival. Expected survival was based on the total Queensland mortality data obtained from the Australian Bureau of Statistics,<sup>7</sup> incorporating three year moving averages to minimise the effects of year to year variation.

To interpret the relative survival tables:

N represents the initial number of 'at risk' cases.

\*\* means estimates were too unreliable to be included (the standard error was greater than 25% of the estimate).

## References:

1. ABS, 2008. *3201.0 Population by Age and Sex, Australian States and Territories*. Australian Bureau of Statistics (Catalogue number 3201.0) ([www.abs.gov.au](http://www.abs.gov.au)): Canberra.
2. Queensland Cancer Registry, 2009. *Cancer in Queensland: Incidence and Mortality, 1982 to 2006*. QCR, Cancer Council Queensland and Queensland Health: Brisbane.
3. Ederer F, Axtell LM, Cutler SJ, 1961. The relative survival rate: a statistical methodology. *NCI Monogr*, 6:101-121.
4. Brenner H, 2002. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. *Lancet*, 360(9340):1131-1135.
5. Brenner H, Gefeller O, Hakulinen T, 2004. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computation realisation and applications. *Eur J Cancer*, 40:326-335.
6. Dickman PW, 2004. *Estimating and modelling relative survival using SAS*. Retrieved 24 July 2007, from [http://www.pauldickman.com/rsmodel/sas\\_colon/](http://www.pauldickman.com/rsmodel/sas_colon/).
7. Australian Bureau of Statistics, 2009. *Unit record mortality data for Queensland by State of usual residence, 1982-2007*. (unpublished data). ABS: Canberra.

**APPENDIX 4: AGE DISTRIBUTION OF STANDARD POPULATIONS**

Age group	'Australia 2001'	Population structure – Total 100,000	
		'Aust 2001'	'World'
0-4	1,282,357	6600	12,000
5-9	1,351,664	7000	10,000
10-14	1,353,177	7000	9,000
15-19	1,352,745	7000	9,000
20-24	1,302,412	6700	8,000
25-29	1,407,081	7200	8,000
30-34	1,466,615	7500	6,000
35-39	1,492,204	7700	6,000
40-44	1,479,257	7600	6,000
45-49	1,358,594	7000	6,000
50-54	1,300,777	6700	5,000
55-59	1,008,799	5200	4,000
60-64	822,024	4200	4,000
65-69	682,513	3500	3,000
70-74	638,380	3300	2,000
75-79	519,356	2700	1,000
80-84	330,050	1700	500
85+	265,235	1400	500
All ages	19,413,240	100,000	100,000

## APPENDIX 5: INDICES OF DATA QUALITY, QUEENSLAND, 2006 AND 2007

Three commonly used indices of data quality are tabulated on the following page. These are defined in *Cancer Incidence in Five Continents Vol V*<sup>1</sup> as follows:

- Histological Verification (HV%) – the proportion of cases registered which had histological verification of diagnosis.
- Death Certificate Only (DCO%) – the proportion of cases registered for which no information was available other than a statement on the death certificate that the deceased died from or with cancer.
- Mortality to Incidence Ratio (M/I%) – the comparison of the number of deaths attributed to a specific cancer in a defined population with the number of cases of the same cancer registered during the same period in the same population.

<sup>1</sup> Muir C, Waterhouse J, Mack T, et al. *Cancer Incidence in Five Continents Vol V*, IARC Scientific Publication No 88. Lyon: International Agency for Research on Cancer, 1987 (p45).

**Indices of Data Quality by Selected Site and Sex, Queensland, 2006 and 2007**

ICD-O3/SITE	Incidence		Mortality		HV%		DCO%		M/%	
	2006	2007	2006	2007	2006	2007	2006	2007	2006	2007
<b>MALES</b>										
C00 Lip	190	140	1	2	98	100	0.0	0.0	1	1
C01,C02 Tongue	63	91	23	21	95	97	4.3	4.8	37	23
C09,C10 Tonsil and Oropharynx	73	85	25	24	95	99	0.0	4.2	34	28
C15 Oesophagus	166	173	125	130	90	94	0.8	3.1	75	75
C16 Stomach	241	198	147	151	95	96	1.4	1.3	61	76
C18 Colon	933	995	332	306	92	95	2.4	1.6	36	31
C19,C20 Rectosigmoid Junction and Rectum	552	558	182	210	95	97	0.0	0.5	33	38
C22 Liver & Intrahepatic Bile Ducts	141	159	105	106	42	35	1.0	4.7	74	67
C23,C24 Gallbladder and Other & Unspecified Parts of Biliary Tract	44	59	32	37	73	75	6.3	2.7	73	63
C25 Pancreas	235	255	177	244	58	56	1.1	2.0	75	96
C26, C39,C76,C77,C80 Other & Ill-defined Sites and Unknown Primary Site	318	351	215	209	68	74	3.7	5.7	68	60
C32 Larynx	118	108	34	39	96	95	2.9	2.6	29	36
C33,C34 Trachea and Bronchus & Lung	1283	1216	1005	1034	76	80	1.3	2.5	78	85
C44, M872-M879 Melanoma	1454	1558	154	196	100	99	0.0	0.0	10	13
C44 Other Skin (Excl BCC/SCC)	71	106	14	25	92	98	0.0	0.0	20	24
C61 Prostate Gland	3308	3680	556	600	94	95	1.3	1.3	17	16
C62 Testis	138	116	4	4	96	98	0.0	0.0	3	3
C64-C66,C68 Kidney and Other Renal Tract	397	395	106	122	83	84	0.9	2.5	27	31
C67 Bladder	543	364	125	131	89	88	1.6	1.5	23	36
C70-C72 Brain, Meninges and Other Central Nervous System	172	170	142	125	89	85	0.7	0.0	83	74
C73 Thyroid Gland	92	112	15	9	98	99	0.0	0.0	16	8
M905 Mesothelioma	109	111	84	111	89	97	1.2	0.9	77	100
M959,M967-M972 Non-Hodgkin Lymphoma	415	414	123	101	88	95	1.6	2.0	30	24
M973 Myeloma/Plasma Cell Tumours	134	132	57	70	75	87	0.0	0.0	43	53
M982-M983 Lymphoid Leukaemia	166	157	46	42	70	94	0.0	0.0	28	27
M984-M993 Myeloid Leukaemia	101	125	68	91	77	95	0.0	0.0	67	73
Total Malignant Neoplasms (C00-C80)	12219	12638	4132	4416	88	91	1.4	1.9	34	35
<b>FEMALES</b>										
C00 Lip	49	46	1	3	98	100	0.0	0.0	2	7
C01,C02 Tongue	31	51	11	12	94	96	0.0	0.0	35	24
C09,C10 Tonsil and Oropharynx	15	19	3	6	93	100	0.0	0.0	20	32
C15 Oesophagus	70	75	42	58	93	95	4.8	0.0	60	77
C16 Stomach	105	113	60	84	89	90	1.7	4.8	57	74
C18 Colon	898	884	277	325	91	93	2.9	3.1	31	37
C19,C20 Rectosigmoid Junction and Rectum	350	327	96	122	95	94	0.0	0.8	27	37
C22 Liver & Intrahepatic Bile Ducts	48	51	40	30	52	49	0.0	3.3	83	59
C23,C24 Gallbladder and Other & Unspecified Parts of Biliary Tract	69	56	38	55	67	70	5.3	1.8	55	98
C25 Pancreas	192	182	173	165	41	49	4.0	4.8	90	91
C26, C39,C76,C77,C80 Other & Ill-defined Sites and Unknown Primary Site	296	325	199	207	55	62	12.1	11.6	67	64
C32 Larynx	15	14	4	5	100	86	0.0	0.0	27	36
C33,C34 Trachea and Bronchus & Lung	669	685	530	555	79	86	2.3	3.1	79	81
C44, M872-M879 Melanoma	1011	1110	84	89	99	100	0.0	0.0	8	8
C44 Other Skin (Excl BCC/SCC)	46	54	7	7	96	100	0.0	0.0	15	13
C50 Breast	2511	2469	432	498	98	98	1.4	1.8	17	20
C53 Cervix Uteri	188	143	58	36	84	98	3.4	0.0	31	25
C54 Corpus Uteri	336	368	64	72	99	99	1.6	1.4	19	20
C56 Ovary	232	212	132	136	81	90	2.3	2.2	57	64
C64-C66,C68 Kidney and Other Renal Tract	229	207	71	58	79	86	2.8	3.4	31	28
C67 Bladder	157	136	51	48	85	88	0.0	8.3	32	35
C70-C72 Brain, Meninges and Other Central Nervous System	111	109	86	82	78	78	0.0	1.2	77	75
C73 Thyroid Gland	287	350	12	8	97	100	0.0	0.0	4	2
M905 Mesothelioma	23	17	18	17	91	100	0.0	0.0	78	100
M959,M967-M972 Non-Hodgkin Lymphoma	346	334	96	95	87	95	0.0	4.2	28	28
M973 Myeloma/Plasma Cell Tumours	98	88	45	53	71	86	0.0	0.0	46	60
M982-M983 Lymphoid Leukaemia	114	86	29	27	63	88	0.0	3.7	25	31
M984-M993 Myeloid Leukaemia	93	92	57	54	81	90	1.8	0.0	61	59
Total Malignant Neoplasms (C00-C80)	9256	9217	2949	3115	88	92	2.6	3.3	32	34



**Queensland  
Government**  
Queensland Health

Queensland Cancer Registry  
Cancer Council Queensland  
Locked Bag No 1450  
Spring Hill Qld 4004  
Telephone (07) 3634 5333  
Facsimile (07) 3259 8590  
email [qcr@cancerqld.org.au](mailto:qcr@cancerqld.org.au)  
[www.health.qld.gov.au/hic](http://www.health.qld.gov.au/hic)  
[www.cancerqld.org.au](http://www.cancerqld.org.au)

